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The nuclear receptor superfamily is a large group of related receptors that bind steroid 
hormones, signaling molecules, or xenobiotic chemicals and are expressed across many 
mammalian tissues. The impact of nuclear receptor activation using two different mouse 
model systems is explored in this thesis: (1) in utero exposure of the environmental 
xenoestrogen and proposed endocrine disruptor bisphenol A (BPA) and (2) short adult 
exposures to the mouse constitutive androstane receptor (CAR) specific agonist ligand 1,4-
bis-[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP). First, experiments involving the 
impact of in utero BPA exposure on the male mouse reproductive tract are described. 
Minimal changes to long-term mouse testis morphology and function were observed as 
mice treated with BPA in utero did not show significant changes in spermatozoa production 
or testis histopathology. Microarray analysis showed few persistently dysregulated genes, 
none of which were validated using qPCR due to high variability among biological 
 
replicates. Next, nuclear RNA-seq was used to characterize global changes in the mouse 
liver transcriptome following exposure to TCPOBOP, including changes in novel long 
non-coding RNAs that may contribute to xenobiotic-induced pathophysiology. 
Dysregulated protein coding genes were associated with a striking male-biased pro-tumor 
response, including activation of pro-tumor upstream regulators such as cyclin D1 and 
inhibition of tumor suppressors such as p21 and p53, consistent with the reported male-
biased susceptibility to CAR-dependent mouse liver tumorigenesis. Novel long non-coding 
RNAs were identified in livers of mice exposed to TCPOBOP, including lncRNAs 
proximal to the CAR target genes like Cyp2b10. Then, DNase-seq was used to identify 
DHS in male and female mouse liver that open or close following TCPOBOP treatment 
proximal to CAR responsive coding and non-coding genes. Finally, a series of ChIP-seq 
experiments targeting the activating histone modifications H3K4me1, H3K4me3 and 
H3K27ac, and the repressive chromatin modification H3K27me3 were performed in male 
mice to characterize the corresponding changes in local chromatin environment around 
DHS and responsive genes. Using a combination of DNase-seq and ChIP-seq, several 
classes of DNA regulatory elements have been identified, including active enhancers and 
promoter regions that may play a function role in regulating nearby CAR-responsive 
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Environmental chemicals define a broad class of molecules that are found in the soil, air, 
water supplies or food as a result of pollution or in consumer products as a result of the 
manufacturing process. Some chemicals, such as the heavy metals mercury, lead, cadmium 
and arsenic, are found at US Environmental Protection Agency Superfund cleanup sites 
due to pollution from oil spills, toxic waste dumps and natural disasters. Other chemicals, 
such as bisphenol A (BPA), are monomers used as a building block for generating hard 
polycarbonate plastics used in water bottles, baby bottles and toys, interior linings for 
canned foods, dental fillings, consumer electronics and various other applications. 
Additionally, chemicals such as dichlorodiphenyltrichloroethane (DDT) and methoxychlor 
were used as chemical pesticides and insecticides for commercial farming. Together, these 
environmental chemicals pose a health risk to humans and wildlife through their multitude 
of exposure routes, near ubiquitous presences and, for many chemicals, poorly understood 
impact and mechanism of action following exposure. One proposed mechanism of action 
for some of these chemicals in mammals is through the direct binding to nuclear receptors 
primarily found in liver, gonads and other endocrine tissues. The nuclear receptor 
superfamily contains several receptors, including constitutive androstane receptor (CAR) 
that act as a so-called xenobiotic sensor and steroid hormone receptors like estrogen 
2 
 
receptor (ER) which is involved in hormone and endocrine signaling. CAR binds a broad 
set of xenobiotic chemicals and induces several numbers of Phase I and Phase II drug 
metabolizing enzymes, especially the cytochrome P450 (Cyp) gene superfamily to rapidly 
metabolize and clear foreign compounds. ER is closely involved in hormone signaling and 
development of several tissues in utero, in particular the gonads. While most ER ligands 
are endogenous steroid hormones, it has been shown to bind exogenous estrogen-like 
compounds, known as xenoestrogens. 
 
In my thesis work, I have explored the potential impact of environmental chemical 
exposure using two separate and distinct models. In the first model, designed to assess the 
impact of a single environmental chemical, I exposed male mice in utero to doses of the 
proposed xenoestrogen and endocrine disruptor BPA that were designed to mimic the 
average human exposure and measured reproductive health in adulthood. The second 
model, in contrast, was designed to assess the impact of a broad set of chemicals by 
inducing CAR with its potent, receptor-specific ligand, TCPOBOP, in order to characterize 
the impact on the mouse liver transcriptome and epigenome. 
 
1.2 Endocrine disrupting compounds (EDC) 
The first section of my thesis (Chapter 2) focuses on the effects of exposure to a single 
environmental chemical, and proposed endocrine disruptor, on the developing male mouse 
reproductive system. The endocrine disruption field was established by Theo Colburn in 
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1991 when a group of 21 scientists met at the Wingspread Conference Center in Wisconsin 
to discuss the harmful side effects of exposure to industrial chemical in wildlife. Endocrine 
disrupting compounds (EDCs) are broadly defined as compounds that have the ability to 
interfere with endogenous hormone signaling. Furthermore these compounds can 
sometimes induce linear dose responses but often induce nonmonotonic dose responses 
(NMDR), giving U-shaped or inverted U-shaped plots typical of endogenous steroid 
hormones (Fig 1.1) (Vandenberg et al. 2009). A specific subclass of EDCs, xenoestrogens 
(XEs), have the capacity to bind to and activate the nuclear receptor estrogen receptor α 
(ERα) or ERβ or estrogen-related receptor γ (ERRγ) due to their structural similarities to 
endogenous estrogens, such as estradiol. Three of these compounds - methoxychlor 
(MXC), diethylstilbestrol (DES), and bisphenol A (BPA) - are the focus of this section 
(Fig. 1.2).  
 
1.2.1 Diethylstilbestrol (DES) and methoxychlor (MXC) 
Diethylstilbestrol (DES) and methoxychlor (MXC) are potent xenoestrogens. DES was 
actively prescribed in the US to pregnant women to help prevent miscarriages beginning 
in 1938 and ending in 1971, when it was finally banned. As a result, the CDC estimates 
that 5-10 million American children were exposed in utero to this potent XE, the effects of 
which are increased incidence of vaginal and cervical cancer in exposed daughters (Rubin 
2011). MXC is an insecticide developed as an alternative to DDT, which was banned in 
the US in 1971 when it was discovered to be an EDC capable of reducing the egg shell 
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strength of many bird species. The US EPA later banned MXC as well as it was found to 
lower fertility in both male and female rodents. MXC was still in use for thirty-two years, 
however, leaving countless exposed.   
 
1.2.2 Bisphenol A (BPA) 
BPA was first synthesized in 1936 as an alternative to natural estrogen for  hormone 
replacement (Umweltbundesamt 2010). While it was never prescribed and it was replaced 
by better hormone mimics, it was found to be useful as plasticizer and roughly 6-8 billion 
pounds of it are produced globally each year (Kang et al. 2011). Polycarbonate plastics 
synthesized from BPA polymers are ubiquitous and found in a wide range of products 
including CD/DVDs, eyeglasses, plastic water coolers and baby bottles 
(Umweltbundesamt 2010). BPA epoxy resins are used as dental sealants and also coat the 
interiors of canned food (Umweltbundesamt 2010). A lowest observed effect level (LOEL) 
of 50 mg/kg bw/day was established in 1988 based on rodent models (Rubin 2011).  The 
CDC set the human reference dose at 50 µg/kg body weight/day using and a uncertainty 
factor of 1000 based on an assumed linear dose response (Rubin 2011). While this method 
to determine a safe limit for human exposures is not ideal and may not reflect the toxicology 




1.2.2.1 Controversy surrounding BPA in literature 
The effects of exposure to XEs are controversial and are an active area of research. Initial 
studies performed by vom Saal et al. in 1998 identified bisphenol A as an endocrine 
disruptor in male and female mouse reproduction (vom Saal et al. 1998) and early work 
corroborated this conclusion. Several studies found either adult or developmental 
exposures to BPA altered testicular histology (Fisher et al. 1999, Atanassova 2000, Chitra 
et al. 2003, Takahashi and Oishi 2003, Naciff et al. 2005) or sperm physiology (vom Saal 
et al. 1998, Sakaue et al. 2001, Al-Hiyasat et al. 2002, Chitra et al. 2003, Takahashi and 
Oishi 2003, Toyama and Yuasa 2004) in rodents. Soon after the initial classification of 
BPA as an EDC, there was significant pushback from some groups that reported no clear 
evidence of endocrine disruption by bisphenol A.  Gray (Gray et al. 2010), Ryan (Ryan et 
al. 2010) and Tyl (Tyl et al. 2002, Tyl et al. 2008, Tyl 2009), reported no significant effects 
of BPA in rodents using both in utero and adult exposure models. However, vom Saal and 
others pointed out major flaws in their experiments which have led to a misinterpretation 
of their results (vom Saal et al. 2010).  These studies used the estrogen insensitive Long-
Evens rat strain which then lead them to use inappropriately low doses of both BPA and 
their positive control ethinylestradoil, due to their insensitivity to estrogens. Additionally, 
polycarbonate cages were used to house the rats, which themselves are made from BPA, 
and thus all rats in the experiment were exposed to an unknown level of BPA (vom Saal et 
al. 2010). Outside of these studies, there have been other reports in the literature that show 
little to no long term effects of early BPA exposure on the male mouse reproductive tract, 
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despite closely following the standard practices described by vom Saal and others. LaRocca 
(LaRocca et al. 2011) exposed C57/Bl6 mice, an estrogen sensitive mouse strain (Wadia 
et al. 2007), to 50 µg BPA/kg body weight/day and 1000 µg BPA/kg body weight/day and 
found little effects the male reproductive tract. Conversely, recent publications on BPA 
again suggest it is an EDC capable of altering meiosis and spermatogenesis in rodents 
(Vrooman et al. 2015, Wisniewski et al. 2015, Li et al. 2016, Xie et al. 2016, Ahbab et al. 
2017). Exposure to BPA has also been correlated with reduced sperm quality in men 
(Goldstone et al. 2015, Vitku et al. 2016) as well as obesity in elderly women (Lee et al. 
2015). Given the conflicting reports in the literature about the exact impact on BPA on 
overall male reproductive health, additional research is clearly needed. Absent in the 
literature is a consensus about mouse exposures to BPA at human relevant doses during 
specific windows of development to identify clear critical time points of vulnerability. The 
window we have chosen to study is embryonic days 9 through 18, which represents a 
critical period in testis organogenesis and establishment of cells required for proper 
spermatogenesis in adult animals. Doses chosen represents conditions at and around the 
human reference dose to avoid missing relevant findings due to known nonmonotonic dose 
responses observed with BPA (Fig. 1.1). To understand how perturbations in endocrine 
signaling during development through xenoestrogen exposure affects testicular function 
and morphology, however, we first need to understand how the mouse testis is developed 




1.2.3 Testis physiology 
Proper testis organogenesis and development is critical for androgen biosynthesis 
throughout life as well as post-pubertal spermatogenesis. In this section, I will review testis 
organogenesis in male mice in the context of the embryonic development timeline as a 
justification for our dosing window. Additionally, I will review the process of 
spermatogenesis in adult mice as a foundation for understanding testis pathophysiology 
and any subsequent perturbations in sperm count.  
 
1.2.3.1 Testis organogenesis and development 
Testis organogenesis in mice is initiated by the migration of primordial germ cells (PGCs) 
and somatic cells (Sertoli cell precursors in males) into the genital ridge of the embryo at 
E9.5 (Sekido and Lovell-Badge 2009). This early structure is known as the bipotential 
gonad as it is capable of differentiating into either a testis or an ovary given the correct 
internal and external cues. In both sexes at E10.5, the transcription factor Sox9 is expressed 
at a basal level in both sexes.  A second transcription factor, steroidogenic factor 1 (Sf1), 
is also expressed and has the potential to activate sex-determining region of Y (Sry) located 
on the Y-chromosome; thus Sf1 can only induce Sry in males as females lack this locus. In 
males, Sry and Sf1 work in concert to boost Sox9 expression until a critical threshold is 
reached when it can be maintained by auto-regulation (Wilhelm et al. 2007, Sekido and 
Lovell-Badge 2009). In the females, Sry is not expressed and β-catenin begins to 
accumulate in response to Wnt4 signaling (Sekido and Lovell-Badge 2009). This sets up a 
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system where gonads destined to be testes express high levels of Sox9 and low levels of β-
catenin whereas gonads destined to become ovaries express high levels of β-catenin and 
low levels of Sox9 (Fig. 1.3). Sox9 expression is entirely responsible for the development 
of the organ as a whole as well as differentiation of all of the associated cell types.  Sox9 
promotes the differentiation of Sertoli cells, Wolffian ducts (precursors of the epididymides 
and vas deferens), peritubular myloid (PM) cells and Leydig cells, the major androgen 
producing cell type in the male (Wilhelm et al. 2007).  During organogenesis, PM cells 
surround the Sertoli cells and PGCs to form sex cords which will eventually develop into 
seminiferous tubules.  By E14.5, clear construction of seminiferous tubules with PM cells 
encompassing Sertoli cells and germ cell masses are established with Leydig cells forming 
within the interstitial space (Wilhelm et al. 2007).  From E14.5 until birth, seminiferous 
tubules and interstitial Leydig cells continue to grow under the control of Sox9. Thus, the 
window between E9 and birth (~E20) represents a critical window where outside 
influences can cause permanent deleterious alterations in testis development. 
 
1.2.3.2 Spermatogenesis 
The adult mammalian testis is a heterogeneous organ and is the site of spermatogenesis as 
well as the major source of androgen biosynthesis. As discussed above, adult exposure to 
BPA disrupts both androgen biosynthesis and spermatogenesis in rodents (vom Saal et al. 
1998, Fisher et al. 1999, Atanassova 2000, Takahashi and Oishi 2000, Sakaue et al. 2001, 
Al-Hiyasat et al. 2002, Chitra et al. 2003, Takahashi and Oishi 2003, Naciff et al. 2005, 
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vom Saal and Hughes 2005, Salian et al. 2009, Nakamura et al. 2010, Salian et al. 2011, 
Xi et al. 2011). Spermatogenesis occurs in seminiferous tubules where a spermatogenic 
stem cell (SCC) divides and eventually gives rise to many differentiated spermatozoa.  
Broadly, the process is comprised of three major types of cells: spermatogonia, 
spermatocytes, and spermatids. Each of these groups can be further divided into many sub-
types.  
 
Type As spermatogonia (the SCC) lay on the basal lateral epithelium of seminiferous 
tubules.  Once stimulated to divide, they give rise to Apr (Apaired) spermatogonia followed 
by Aal (Aaligned) spermatogonia which are so-called as their orientation is parallel to the 
epithelium (de Rooij 2009, Godmann et al. 2009). Aal, also known as A1, spermatogonia 
can continue to divide and create chains up to 16 cells long (de Rooij 2009, Godmann et 
al. 2009). A1 spermatogonia progressively divide five times by mitosis and are known as 
A2, A3, A4, In, and type B spermatogonia after each division (de Rooij 2009, Godmann et 
al. 2009). A sixth round of mitosis then yields resting primary spermatocytes. A resting 
primary spermatocyte, also known as pre-leptotene spermatocytes, enters meiosis I and 
marks the beginning of the leptotene primary spermatocyte stage (Rousseaux et al. 2005, 
Godmann et al. 2009). These cells then differentiate through zygotene and pachytene 
primary spermatocyte stages where crossing over and recombination occurs before finally 
arriving in the diplotene primary spermatocyte stage. Once at this stage meiosis division I 
yields type II secondary spermatocytes.  These cells rapidly enter meiotic division II to 
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form haploid round spermatids (Rousseaux et al. 2005). The remaining process of a round 
spermatid (stage 1) maturing into a spermatozoon (stage 16) is known as spermiogenesis. 
The three major cell types (spermatogonia, spermatocytes, and spermatids) can be visually 
distinguished from each other by morphology and nuclei staining patterns in histological 
hematoxylin and eosin staining. The process of spermatogenesis is tightly controlled by 
Sertoli cells and Leydig cells in the SCC niche. The SSC niche is thought to be a unique 
milieu within the seminiferous tubule and also among other stem cell niches (de Rooij 
2009). This is because the topography of a testis cross-section reveals several different 
environments that lay adjacent to As spermatogonia and their surrounding Sertoli cells (Fig. 
1.4). The true niche is believed to be located where Sertoli cells are neighboring large, 
diverse, and complex interstitial spaces (de Rooij 2009). Any perturbations to the niche 
identified by histology can be attributed to stem cell loss and ultimately to sub- or 
infertility. In Chapter 2, I explored the potential impact on in utero BPA or DES exposure 
on proper testis organogenesis. To do this, I present data on anatomical structures present 
or absent in mice exposure to BPA or DES. I then measured sperm count as a metric for 
overall reproductive health of the animals exposed to BPA or DES. Lastly, I present global 
gene expression profiles of mice exposed to BPA or DES compared to unexposed animals. 
 
1.3 Nuclear receptors: xenobiotic sensing receptor CAR 
In contrast to the previous section which focused on a single chemical exposure and the 
impact on multiple endpoints through undefined, presumed multiple, receptors, the next 
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section of my thesis (Chapter 3 and 4) aims to establish coding and non-coding 
transcriptomic and epigenomic signatures when a single nuclear receptor is activated in 
mouse liver. To achieve this, we have chosen the nuclear receptor CAR (constitutive 
androstane receptor) and its potent and receptor-specific ligand TCPOBOP (Fig. 1.5). CAR 
is one of the so-called xenobiotic sensing receptors found in the mammalian genome. Once 
thought to be an orphan receptor with no known endogenous ligands or functions, it is now 
known to directly bind several steroid hormones (Kawamoto et al. 2000, Hernandez et al. 
2009) and regulate bile acid (Lickteig et al. 2016), glucose and lipid homeostasis (Kodama 
et al. 2004, Konno et al. 2008, Moreau et al. 2008, Wada et al. 2009, Gao and Xie 2010) in 
liver. The main function of CAR is thought to be clearance of xenobiotics though direct 
binding of the chemical in its large ligand binding pocket (Suino et al. 2004, Xu et al. 
2004), or indirect activation through EGFR signaling (Meyer and Jirtle 2013, Yang and 
Wang 2014, Kobayashi et al. 2015), and induction of genes involved in drug metabolism 
(Sueyoshi et al. 1999, Ueda et al. 2002, Chen et al. 2003, Kodama et al. 2004, Timsit and 
Negishi 2007). In addition to the positive physiological benefits to activated CAR (i.e. 
xenobiotic clearance and homeostasis), several negative effects have been associated with 
prolonged CAR activation. Recently, activated CAR has been linked to induction of liver 
steatosis (Mellor et al. 2016) and tumor promotion (Yamamoto et al. 2004). In this section, 
I will review the protein structure of CAR that allows both its constitutive activity in the 
absence of ligand and its ability to being a diverse set of compounds, the protein sequence 
conservation of CAR between mouse and human, the known physiological roles of CAR 
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in mouse and human liver, sex differences in the expression of CAR in mouse liver and the 
impact of steroid hormones on CAR activity.  
 
1.3.1 CAR protein structure 
CAR contains two domains essential to its function as a ligand activated transcription factor; 
a DNA binding domain (DBD) and a c-terminal ligand binding domain (LBD). 
Additionally, CAR has an activating function domain (AF2) at the c-terminus that is the 
site of co-activator or co-repressor binding in the nucleus. The crystal structure of mouse 
CAR bound to its potent, synthetic ligand TCPOBOP and in a heterodimer with RXR was 
resolved in 2004 (Suino et al. 2004) and the same year, human CAR bound to its specific 
ligand, CITCO, and complexed with RXR and other coactivators was published (Xu et al. 
2004), providing great insight into its structure and species similarities in mice and humans. 
In this section, I will describe the protein structure of CAR and how its physical properties 
lead to its known functions. 
 
1.3.1.1 DNA binding domain (DBD) 
The DBD of CAR is well conserved between mouse and humans with 88% homology 
between the two species (Timsit and Negishi 2007), thus allowing CAR to bind to 
homologous sequences in the mouse and human genome. Additionally, the DBD of NRs 
in a given species is highly homologous and as such, most NRs can recognize and bind to 
identical sequences in the genome. The core recognition sequence for NRs is a non-
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palindromic repeat of a half-site of 3’-AGGTAC-5’, found in either a direct repeat (DR), 
inverted repeat (IR) or everted repeat (ER) with a given number of spacer sequence in 
between the two half-sites (Waxman 1999, Claessens and Gewirth 2004). NRs can be 
classified by their preference for binding to specific repeat orientations, with CAR 
preferentially binding to DR containing 4 or 5 nucleotide spacers (DR4; DR5) or an ER6 
motif (Fig. 1.6).  
 
1.3.1.2 Ligand binding domain (LBD) 
In contrast to the DBD, the LBD in CAR is more variable across mammalian species and 
between NRs in a given species. The mouse CAR LBD is only 72% homologous to human 
CAR (Timsit and Negishi 2007) which leads to differences in ligand binding efficiency 
between the two species. For example, the potent mouse CAR direct agonist 1,4-Bis-[2-
(3,5-dichloropyridyloxy)]benzene (TCPOBOP) is specific for mouse CAR while 6-(4-
Chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime 
(CITCO) is a potent and specific ligand for human CAR (Fig. 1.5). X-Ray crystallography 
of the mouse CAR LBD followed by a sequence alignment of mouse CAR to human CAR 
shows that 10 out of 31 residues responsible for TCPOBOP docking in the mouse CAR 
LDB are different between species (Suino et al. 2004). 
 
Structurally, the LDB of most NRs, including CAR, contains 12 α-helixes which form a 
hydrophilic binding pocket suitable for binding small molecules (Huang et al. 2010). The 
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size of the binding pocket formed by these 12 helixes vary across NRs and can contribute 
to their function. For example, ER, while capable of binding xenoestrogens as discussed 
earlier, can only bind a narrow range of chemicals that have estrogen-like structures and 
derivatives due to its moderately sized ligand binding pocket (450 Å3) (Huang et al. 2010). 
In contrast, CAR and PXR have larger binding pockets that are capable of binding 
structurally diverse compounds. In addition to TCPOBOP, mouse CAR can bind steroid 
hormones such as androstanol and androstenol (Forman et al. 1998), environmental 
estrogens such as ethinyl estradiol (Repo et al. 2008) and nonylphenol (Hernandez et al. 
2007), phthalates such as DEHP (Eveillard et al. 2009) and statins such as cerivastatin 
(Kobayashi et al. 2005) due primarily to its 525 Å3 binding pocket (675 Å3 in human CAR) 
that can expand to accommodate larger molecules (Suino et al. 2004). A summary of 
known CAR agonists, antagonist and inverse agonists can be found in Table 1.1. The 
binding pocket of mouse PXR is 1200 Å3, allowing it to not only bind structurally diverse 
compounds such as the steroid hormone derivative pregnolone 16-α carbonitrile and the 
plant derived sulforaphane but also the extremely large, bacteria derived, antibiotic 
rifampicin (Timsit and Negishi 2007). The ability to bind such a broad class of molecules 
is what allows both CAR and PXR to function as xenobiotic sensors in the cell.  
 
1.3.1.3 Helix 12, AF2 domain 
Contained within the LDB of CAR and other NRs, at the c-terminal end, is helix 12 (H12), 
also known as the activating function 2 (AF2) domain. The AF2 domain is the site of 
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coactivator or corepressor binding through LXXLL motifs found in coactivator proteins or 
LXXXIXXXL found in corepressor proteins (Suino et al. 2004). Binding sites for either 
coactivators or corepressors can be revealed depending on the orientation of the AF2 
domain relative to the other helixes in the LDB, specifically H3 and H4 (Huang et al. 2010). 
For most NRs, the AF2 domain is fixed in an inactive state in the absence of bound ligand 
and does not contain a binding site for either coactivators or corepressors. When an agonist 
ligand binds to the LBD, the AF2 domain undergoes a conformational change which 
reveals a small binding site for coactivator LXXLL motifs. If the ligand is an antagonist, 
the conformation change the AF2 domain undergoes reveals a larger binding site that 
allows for corepressor binding though a LXXXIXXXL motif (Suino et al. 2004). In 
contrast to other NRs, the AF2 domain in the CAR protein is fixed in the active orientation, 
allowing for binding of coactivators in the absence of ligand and thus giving CAR its 
constitutive activity. The ligand-independent active orientation of AF2 is due to three 
distinct structural aspects unique to CAR among all NRs. First, the length of the linker 
sequence separating H11 (named Hx in CAR) and H12 is shorter than in other NRs, making 
the relative orientation between these two helixes less flexible. Second, the CAR H12 helix 
is itself truncated when compared to other NRs and the c-terminal carboxylate group forms 
a hydrogen bond with H4, stabilizing the H12 in the active orientation. Lastly, H2 is 
extended in CAR which stabilizes the H3 helix by shifting its position (Suino et al. 2004). 
Although beyond the scope of this thesis, CAR’s ability to bind a structurally diverse set 




1.3.1.4 Consequences of constitutive activity 
One of the defining characteristics of CAR among all NRs is its constitutive activity in the 
absence of ligand. A consequence of activity in the absence of direct binding is CAR is 
able to be activated by indirect mechanisms. Indeed, the classic CAR activator 
phenobarbital (PB) works through an indirect mechanism and is mediated by EGFR (Fig. 
1.7) (Meyer and Jirtle 2013, Yang and Wang 2014, Kobayashi et al. 2015). Due to its 
constitutive activity, the cell needs to sequester CAR in they cytoplasm to prevent 
persistent and aberrant activity and it achieves this sequestering by complexing CAR with 
heat shock proteins 90 (HSP90) and by a tetratricopeptide repeat protein termed the 
cytoplasmic CAR retention protein (CCRP) (Kobayashi et al. 2003, Timsit and Negishi 
2014) and by phosphorylating CAR at Thr-38 (Osabe and Negishi 2011). Direct binding 
of ligands causes conformational changes that free CAR from the protein complex with 
HSP90 and CCRP, leads to the dephosphorylation of Thr-38 by PP2a and exposes a nuclear 
localization signal (NLS) (Kanno et al. 2005). However, when an indirect activator like PB 
is present, CAR is dephosphorylated at Thr-38 by PP2A through RACK and MEK/ERK 
signaling (Yang and Wang 2014).  
 
In addition to the ability of CAR to be activated by direct and indirect ligands, the activity 
of CAR can also be reduced by an inverse agonist due to its constitutive activity in the 
absence of ligand (Hanania et al. 2010). Unlike a true antagonist, which prevents activation 
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of a receptor (i.e. the receptor is kept in its basal state), an inverse agonist reduces the 
activity of a receptor and lowers its constitutive activity below its basal state (Fig. 1.8). For 
example, if CAR was activated by an indirect activator like PB, the simultaneous presence 
of an antagonist would have no effect on the activated CAR’s activity (i.e. it will remain 
fully active). However, if CAR was activated by an indirect activator like PB, the 
simultaneous presence of an inverse agonist would reduce the activated CAR’s activity (i.e. 
it would be less active). Indeed, androstanol and androstenol, two of the few known 
endogenous ligands of CAR, are inverse agonists of the receptor (Forman et al. 1998, Suino 
et al. 2004).   
 
1.3.2 Regulation of gene expression 
Once activated by exogenous xenobiotics or endogenous steroid hormones in the 
cytoplasm, CAR translocates to the nucleus and regulates the transcription of protein 
coding genes involved in drug metabolism and excretion, thus playing a central role in 
xenobiotic sensing and clearance. In this section, I will review known direct gene targets 
of CAR as well as transcriptome wide gene regulation in mouse liver by CAR. 
 
1.3.3 CAR target genes 
1.3.3.1 Protein coding genes 
Cytochrome P450 genes are well known protein coding targets of CAR regulation in liver. 
Some of the earliest work on the effects of phenobarbital or TCPOBOP on liver as early as 
18 
 
1959 identified cytochrome P450s as being highly induced following drug treatment long 
before CAR was known to be the receptor and transcription factor intermediate (Remmer 
1959, Orrenius and Ericsson 1966, Poland et al. 1980, Poland et al. 1981, Waxman and 
Azaroff 1992, Waxman 1999). Since then, the Cyp2 family has been extensively studied 
for their robust response to CAR ligands in both mouse and humans, notably Cyp2b10 in 
mice and its human orthologue CYP2B6 (Kawamoto et al. 1999, Sueyoshi et al. 1999, 
Kawamoto et al. 2000, Blizard et al. 2001, Ueda et al. 2002, Chen et al. 2003, Kobayashi 
et al. 2003, Tian et al. 2011, Kobayashi et al. 2015). Additionally, there has been increasing 
evidence that CAR regulates Cyp2 genes by directly binding to response elements upstream 
of mouse Cyp2b10 or human CYP2B6 (Park et al. 1996, Sueyoshi et al. 1999, Tian et al. 
2011). In earlier experiments, it was shown that a 5’ flanking region 2kb upstream (-2318 
to -2155) of the human CYP2B1 promotor was required for transactivation of the gene by 
phenobarbital in transfected rat primary hepatocytes and was therefore termed the 
phenobarbital responsive element (PBRE) (Park et al. 1996). That specific region was 
found to be conserved in mouse, rat and human and the core 51 bp sequence containing 
two nuclear receptor binding sites was all that was required for recruitment of CAR and 
activation of Cyp2b10 gene expression in mice (Honkakoski et al. 1998). The 51 bp core 
sequence was named the phenobarbital responsive enhancer module (PBREM) and 
contains two DR4 motifs. Other Cyp2 family members that have been identified as CAR-
inducible include Cyp2c39 and Cyp2c55 (Jackson et al. 2006). In addition to Cyp210, other 
known CAR-inducible genes have PBREM in close proximity to their proximal promotors 
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including the UDP-glucuronyltransferase Ugt1a1 (Kuno et al. 2008). To date, however, 
genome wide mapping of CAR binding to determine how many gene targets CAR 
potentially regulates directly has not been performed due to the lack of a commercially 
available ChIP-Seq quality antibody. 
 
1.3.3.2 Transcriptomic data currently available  
To date, a number of groups have attempted to understand genome wide transcriptional 
regulation in liver by activated CAR. In 2002, Ueda et al. published a microarray analysis 
of the mouse liver transcriptome following phenobarbital injection in wild type and CAR-
null mice (Ueda et al. 2002). In their experiment, the 10 out of 22 genes upregulated in a 
CAR dependent manner were enzymes known to be involved in drug metabolism, 
including Cyp2b10. However, a major limitation of their study was it was done on a 
relatively narrow microarray platform that contained 8,736 cDNA probes and used 
phenobarbital as the CAR agonist, which is now known to activate other NRs including 
PXR. Also, despite probes against seven other cyptochrome P450 genes, surprisingly, no 
other cyp genes were found to be regulated by CAR. In 2012, Aleksunes and Klaassen used 
a panel of arrays to determine the transcriptome profile of wild type and CAR-null mice 
exposed to TCPOBOP and focused on the regulation of drug metabolizing enzymes. In 
addition to Cyp2b10, genes encoding many other drug metabolizing were induced 
following CAR activation. These genes included cytochrome P450 families 1 (Cyp1a2) 
and 3 (Cyp3a11), Aldh family 1 enzymes (Aldh1a1, Aldh1a7), Ugt1 family enzymes 
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(Ugt1a1, Ugt1a9), Ugt2 (Ugt2b35), sulfotransferases (Sult1e1, Sult2a2, Sult3a1 and 
Sult5a1), glutathione transferases (Gsta1, Gsta4, Gstt1, Gstm1, Gstm2, Gstm3, Gstm4) and 
the multidrug resistant-associated transporters (Mrp2, Mrp3, Mrp4) (Aleksunes and 
Klaassen 2012). More recently, Li et al. published an RNA-Seq based study characterizing 
the changes in gene expression in the human hepatocellular carcinoma derived HepRG 
following exposure to the human CAR specific ligand CITCO or phenobarbital (Li et al. 
2015). In addition to the classic responding genes such as CYP2B6 and CYP3A4 (the human 
orthologue to mouse Cyp3a11), they found a number of metabolism related KEGG 
pathways enriched for induced genes in their data set. Such pathways included 1) 
metabolism of xenobiotics by cytochrome P450 2) two separate drug metabolism pathways 
and 3) amino acid metabolic pathways such as valine, leucine and isoleucine degradation 
and clycine, serine and threonine metabolism. KEGG pathways down regulated include 
several related to cancer including 1) p53 signaling 2) cell cycle and 3) pathways in cancer.  
 
1.3.3.3 Sex dependent sensitivity to CAR ligands 
Our laboratory has published several studies on sex differences in the basal expression of 
drug metabolizing enzymes (Waxman et al. 1991, Wauthier and Waxman 2008, Waxman 
and Holloway 2009, Conforto and Waxman 2012). Members of the Cyp2b family (Cyp2b9, 
Cyp2b10, Cyp2b13) and Cyp3a family (Cyp3a1, Cyp3a44), among other DME genes, have 
been shown to be highly female specific (Waxman and Holloway 2009). Many of these 
genes are known CAR targets leading to the hypotheses that basal CAR activity is higher 
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in female liver and that responsiveness to CAR agonist ligands could show sex biasness. 
One gene that appears to be differentially regulated basally is the gene for CAR itself, 
Nr1i3. On the gene expression level, CAR is more highly expressed in untreated female 
mouse liver than in untreated males (Petrick and Klaassen 2007, Lu et al. 2013), which 
may account for some sex differences in target gene expression in the absence of ligands. 
However a confounding factor is the role endogenous steroid hormones play in modulating 
CAR activity in liver. As discussed above, the androgens androstenol and androstanol are 
known inverse agonists of CAR and can lower the efficacy of agonists simultaneously 
present, including the very potent agonist TCPOBOP (Ledda-Columbano et al. 2003). 
Additionally, several steroid hormones that are highly abundant in females including 17β-
estradiol and estrone can activate CAR while progesterone can inhibit CAR activity 
(Kawamoto et al. 2000). Sex differences in responsiveness to activated CAR at select loci 
in mouse liver have been studied, however analysis of genome wide transcription 
regulation via RNA-Seq in male and female mice has not been performed, thus limiting 
our understanding to a narrow field. In the 2012 study by Aleksunes and Klaassen 
discussed above, they found the sulfotransferase Sult3a1 to be induced by TCPOBOP in 
female liver but not male liver and while Sult2a2 was induced in both males and females, 
it was more highly induced in females (Aleksunes and Klaassen 2012). The multidrug 
resistance-associated gene Mrp4 was also induced in both sexes but to a much higher extent 
in females, despite being equally expressed in both sexes basally. Interestingly, several 
genes in their study showed a male bias in responsiveness. The UDP-
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glucuronyltranserfaces Ugt2b34 and Ugt2b35 and the aldehyde dehydrogenase Aldh1a7 
were all more highly induced in males (Aleksunes and Klaassen 2012). There also appears 
to be some physiological outcomes from prolonged CAR activation that are sex dependent. 
In 2013, Saito et al measured higher cell proliferation in female mouse livers exposed to 
TCPOBOP than their male counterparts and differences were partially ablated when 
females were treated with TCPOBOP and androstanol simultaneously (Saito et al. 2013). 
Given the apparent sex biasness measured at select loci, an in depth, RNA-Seq based 
analysis is needed to fully understand global biasness in response to activated CAR in 
mouse liver. 
 
1.3.4 Role of CAR in hepatocellular carcinoma (HCC) 
Men are more susceptible than women to hepatocellular carcinoma (HCC), the fifth most 
common form of cancer world-wide (El-Serag and Kanwal 2014). This sex bias cannot be 
explained by life style differences between the sexes, such as alcohol consumption and 
obesity (El-Serag and Kanwal 2014). Sex bias in HCC incidence is also seen in mice where 
females are more resistant to chemically induced HCC than males (Kalra et al. 2008), a 
trait that may be partially explained by sex hormones and Foxa1/a2 (Li et al. 2012). Typical 
regimens for chemical induction of HCC in mice include long term treatment with a DNA-
damaging carcinogen or tumor initiator, such as DEN (diethylnitrosomine), plus a non-
genotoxic tumor promotor, such as phenobarbital or TCPOBOP to activate CAR 
(Yamamoto et al. 2004, Heindryckx et al. 2009, Li et al. 2012). HCC is not induced when 
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the same treatments are given to CAR-deficient mice (Yamamoto et al. 2004). In female 
mice, high levels of estrogens activate the estrogen receptor (ER). Foxa1-ER complexes 
directly regulate genes associated with tumor formation through binding in upstream 
enhancer regions, including the suppression of the oncogene Myc (Li et al. 2012). In male 
liver, high levels of androgen activate the androgen receptor (AR), which like ER, can also 
directly interact with Foxa1 (Li et al. 2012). However, unlike Foxa1-ER complexes, Foxa1-
AR directly bind to DNA-replication and cell cycle related genes and elicit a pro-tumor 
response (Li et al. 2012). In this way, Foxa1 has both tumor protective and tumor promotion 
properties, depending on which steroid hormones are present. When TCPOBOP+DEN was 
administered to Foxa1-KO mice, female-KO mice showed a dramatic increase in tumor 
formation while male-KO mice showed a dramatic decrease in tumors (Li et al. 2012). 
 
1.3.5 Long non-coding RNA (lncRNA) 
Long non-coding RNAs (lncRNAs) are a class of transcribed genes that are not translated 
into functional protein in the cell. These transcripts are retained in the nucleus to carry out 
various functions as RNAs. The most well-known and characterized lncRNA, Xist, for 
example, is involved in establishing and spreading chromatin marks during X-inactivation. 
These transcripts, however, perform many functions in the cell and as many as 15,000 
lncRNAs have been discovered in the human genome. Recently, our lab has published a 
comprehensive list of ~5,000 liver expressed lncRNAs in mice (Melia et al. 2016). 
However a detailed analysis of which liver expressed lncRNAs are CAR targets has been 
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not performed. Given many of these lncRNAs act in cis to influence the expression of genes 
in close proximity, it is important to understand where the CAR-responsive lncRNA 
transcripts are in the genome in relation to CAR-responsive protein coding transcripts. To 
that end, CAR-responsive lncRNAs will be assessed in both male and female mice for not 
only their responsiveness but also their location in the genome relative to protein coding 
genes.  
 
1.3.6 Regulation of gene expression 
In addition to knowing what genes are regulated by CAR in mouse liver, I am also 
interested in understanding how these genes are regulated. To this end, while the 
epigenome has been well established as playing a critical role in regulating gene expression 
in the cell, lncRNAs are emerging as potential candidates that help establish the epigenome. 
To study the dynamic changes to the epigenome, I am interested in how DNase-I 
hypersensitive sites (DHS) and covalent modifications to the tail region of histone H3 
change in response to CAR activation in mouse liver. 
 
DNase-I hypersensitivity sites are one of the fundamental epigenomic marks used by the 
cell. These areas of open chromatin are defined by their increased sensitive to endonuclease 
activity due to the lack of protective histone proteins. Being devoid of histone proteins 
allows for the binding of transcription factors directly to specific DNA sequences which 
then influence expression of nearby genes, either by increasing or decreasing the 
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expression, or overall chromatin structure. In this way, the DHS itself can be thought of as 
a blank canvas for the cell to dot with transcription factors or to decorate flanking histone 
tails with covalent modifications to drive or halt transcription of a target gene. In this 
section, I will review how the cells modulate the accessibility of DHS to open a site, how 
we can measure their accessibility in mouse liver and the role they play in epigenetic 
regulation of gene expression. 
 
1.3.6.1 Opening the genome 
Chromatin is organized into tightly compacted, nearly inaccessible and transcriptionally 
silent heterochromatin and relatively open, accessible and transcriptionally active 
euchromatin. However, chromatin structure is dynamic and specific regions of the genome 
may rapidly switch from dense heterochromatin to open euchromatin, or vice-versa, during 
development or in response to stimuli if genes in those regions are needed by the cell. How 
the cell rapidly alters chromatin structure will be the focus of this subsection. 
 
1.3.6.1.1 Pioneer factors 
A model for opening closed chromatin is through the action of a pioneer transcription factor. 
Even though heterochromatin is dense and inaccessible to most DNA binding proteins like 
transcription factors, a sub-set of TFs can in fact bind to these regions. These factors are 
known collectively as pioneer factors for their ability to bind dense heterochromatin and 
facilitate chromatin opening to allow for other TFs to subsequently bind in neighboring 
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regions. Some pioneer factors, when expressed ectopically, can trigger massive 
rearrangement of chromatin structure which leads to a change in the cell lineage identity. 
In 2006, Takahashi and Yamanaka famously identified four such pioneer factors, Oct3/4, 
Sox2, c-Myc and Klf4 which, when overexpressed in adult fibroblast cells, can induce 
reprogramming of the fibroblasts into an embryonic stem cell-like state (Takahashi and 
Yamanaka 2006). It was later determined that this reprogramming is driven by changes in 
chromatin structure and in particular the rearrangement of chromatin from heterochromatin 
to euchromatin near genes required for maintenance of a pluripotent state and thus allowing 
them to be expressed (Meshorer and Misteli 2006, Gaspar-Maia et al. 2011, Iwafuchi-Doi 
and Zaret 2014, Soufi et al. 2015).  
 
Several transcription factors expressed in mouse liver are known pioneer factors. Such 
factors include CCAAT/enhancer binding protein α (CEBPα) and β (CEBPβ) (Grontved et 
al. 2013, Madsen et al. 2014), forkhead box A, also known as hepatocyte nuclear factor 3, 
(FoxA/HNF3) and GATA-4 (Cirillo et al. 2002). HNF3 and GATA-4 are factors critical in 
the development of fetal mouse liver as they bind to closed upstream regions of the albumin 
gene (Alb) and drive the opening of chromatin to facilitate expression of Alb (Cirillo et al. 
2002). In adult livers, HNF3 is highly expressed and is involved in maintaining an open 




CEBPα and CEBPβ are also highly expressed in adult mouse liver. These receptors share 
a common DNA binding motif and can be found at an overlapping set of binding sites in 
the mouse genome. Functionally, CEBPα has been show to act as a pioneer factor in mouse 
adipocytes (Madsen et al. 2014) while CEBPβ is required to maintain open chromatin in 
mouse liver (Grontved et al. 2013). CEBPα and CEBPβ have been reported to interact with 
the nuclear receptors peroxisome proliferator-activated receptor γ (PPARγ) and 
glucocorticoid receptor (GR), respectively, to facilitate NR binding to adjacent and newly 
accessible DHS (Grontved et al. 2013, Madsen et al. 2014). Interestingly, some ligand 
activated nuclear receptors themselves also show some abilities to act as pioneer factors. 
Activation of GR, for example, has been shown to synergistically increase the binding of 
ER to a nearby site by utilizing a proposed “assisted loading” mechanism, whereby rapid 
GR binding, recruitment of remodeling complexes and dissociation allows for subsequent 
binding of ER (Voss et al. 2011). However, despite the high overlap of DNA binding motifs 
among nuclear receptors, not all nuclear receptors appear to share pioneer factor properties. 
In the same study that identified GR as a pioneer factor, ER was unable to bind to closed 
DHS without GR first remodeling the target site and was only able to bind opened DHS 
(Voss et al. 2011). In this example, and in the CEBPα/PPARγ example discussed above, 





Mechanistically, pioneer factors appear to begin to facilitate the opening of closed DHS by 
their unique ability to bind motif half-sites found on DNA at the surface of histones (Soufi 
et al. 2015). In contrast, most transcription factors do not have this ability and motifs found 
at the surface of a histone are functionally inaccessible. Once bound, nearby chromatin is 
opened by the recruitment of chromatin remodeling complexes. To that end, CEBPα and 
GR have been shown to directly interact with the well characterized histone remodeling 
complex SWI/SNF, and recruit it to specific sites in the genome (Nagaich et al. 2004, 
Madsen et al. 2014). 
 
1.3.6.2 Measuring DNase I hypersensitivity 
One way to assess the DHS map genome wide is through a technique called DNase-Seq 
(Song and Crawford 2010). DNase-Seq involved digesting intact nuclei with the 
endonuclease DNase-I under tightly controlled conditions such that cutting by the enzyme 
only occurs in sites that are hypersensitive. If two such cuts are made in a region of 
hypersensitivity, a short DNA fragment is released and can be used to assemble a library 
for sequencing. Mapping sequenced reads back to the genome will then result in read 
pileups that correspond to the regions of hypersensitivity. However this technique does 
have limitations as precise digestion conditions are needed to map true DHS. If the nuclei 
are over digested, long DNA fragments resulting from cutting outside of a DHS will be 
released. Subsequent mapping of these long fragments leads to a lawn of reads that may 
dampen the signal coming from true DHS. Under digestion, however, can be equally 
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problematic as the chances of having two cut sites in a single DHS is reduced and thus long 
fragments spanning at least one nucleosome are also produced. 
 
1.3.6.3 DHS mark DNA regulatory elements 
In 2012, the human ENCODE consortium published a study that attempted to map all DHS 
in the human genome by performing DNase-Seq across 125 human derived cell lines 
(Thurman et al. 2012). They reported close to 3 million DHS were found in at least one 
cell line and close to 2 million of those were found in at least two lines while only ~3,000 
were ubiquitously found in all cell lines. The authors determined that while promotors for 
a given gene were highly accessible across many cell types, accessibility at distant 
enhancers were cell line specific (Thurman et al. 2012). This suggests that many genes are 
primed for transcription with open TSS regions and are waiting for the correct cues from 
distal enhancers to be transcribed. The authors of the human ENCODE study also mapped 
DHS to their target genes by  chromosome conformation capture carbon copy (5C) and 
chromatin interaction analysis with paired-end tag sequencing (ChIA-PET). They found 
regulation of target genes by DHS is incredibly complex; 37% of promoters interacted with 
20 or more distal DHS and 52% of DHS interact with 2 or more distal promoters (Thurman 




1.3.6.4 Chromatin marks 
Promotors, enhancers and other distinct DNA regulator elements can be identified by the 
combination of histone marks and DHS present at a given loci and the given loci’s 
proximity to the nearest gene. For example, promotors are located directly upstream of a 
genes TSS and are marked by H3K4me3 (Sugathan and Waxman 2013, Shlyueva et al. 
2014). An active promotor, or a gene that is actively being transcribed, is associated with 
the acquisition of H3K27ac and is marked by the combination of H3K4me3, H3K27ac and 
DHS. Similarly, the acquisition of H3K27me3 at the promotor and the combination of 
H3K4me3 and H3K27me3 without a DHS or with a DHS mark inactive or poised 
promotors, respectively (Sugathan and Waxman 2013, Shlyueva et al. 2014). Distal 
regulatory elements such as enhancers can also be characterized by the histone 
modifications present at H3K4 and H3K27. Inactive enhancers are generally marked with 
H3K4me1 and do not contain a DHS. Activation of such enhancers is associated with 
acquisition of H3K27ac and subsequent opening of a DHS to facilitate transcription factor 
binding (Shlyueva et al. 2014). Poised and latent enhancers are two additional classes of 
enhancers that have been recently characterized. Poised enhancers tend to have both 
activating (H3K4me1) and repressive (H3K27me3) marks and acquire DHS and H3K27ac 
and lose H3K27me3 when activated (Creyghton et al. 2010, Sugathan and Waxman 2013, 
Shlyueva et al. 2014). Latent enhancers lack any histone mark at H3K4 or H3K27 (Ostuni 
et al. 2013). When activated by a stimulus, these loci slowly acquire H3K4me1, H3K27ac 
and a DHS. Interesting, when the stimuli is removed, the H3K4me1 mark is retained while 
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H3K27ac is lost and the DHS is closed, marking the site as an inactive enhancer. When re-
challenged with the same stimulus, the acquisition of H3K27ac and activation of the 
enhancer is more rapid, indicating a short-term memory is established by the persistent 
presence of H3K4me1 (Ostuni et al. 2013). By assaying for the global changes to H3K4me, 
H3K27ac, H3K27me3 and DHS following CAR activation, we can characterize the 
dynamics of many of these types of DNA regulatory elements in mouse liver. By then 
mapping these regulatory elements to their presumed gene targets (protein coding or none 
coding) we can get a better understanding of how these target genes are regulated. 
 
1.4 Thesis goals and hypotheses 
This thesis contains three major goals and hypotheses that are novel and will advance the 
fields of endocrine disruption by xenoestrogens and epigenetic regulation of coding and 
non-coding RNAs by nuclear receptors. In Chapter 2, I characterize the impact of BPA on 
the developing male mouse reproductive system. To achieve this, male mice have been 
exposed to BPA during embryonic development and markers of male reproductive health 
were assayed for during their postnatal lives. In Chapter 3, I determine the sex dependent 
regulation of coding and non-coding genes in mouse liver by CAR. To achieve this, male 
and female mice were exposed to TCPOBOP for 3 or 27h and liver RNA was collected 
and sequenced. Expression of coding and non-coding RNAs in the presence or absence of 
TCPOBOP in these mice was then measured. In Chapter 4, I determine the regulation of 
mouse liver chromatin accessibility, histone modifications and associated early gene 
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responses by CAR. To achieve this, male mice were exposed to TCPOBOP for 3h and 
livers were collected. Chromatin accessibility in these livers was measured by DNase-Seq 
and global maps of histone modifications and transcription factor binding was determined 
by ChIP-Seq. These changes to the mouse liver epigenome were then associated with gene 
expression changes measured in Chapter 3.  
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Fig. 1.1 Non-monotonic dose-response. A non-monotonic dose-response is seen in 
GH3/B6/F10 pituitary tumor cells exposed to a wide range of BPA. Strong ERK 
phosphorylation (activation) peaks at two different dose ranges separated by a period of no 







Fig. 1.2 Chemical structures. Chemical structures of estradiol (E2), 








Fig. 1.3 Testis development. Development of a testis in male mice is driven by SF1, 
SRY and SOX9 during a critical window around embryonic days 10-12. Adapted from 








Fig.  1.4 Male germ cell development.  Primordial Germ Cells (PGC) are first 
specified (GC spec) by embryonic day 7.5 (E7.5) in the mouse and they migrate (GC MI) 
to the genital ridge (GR) soon after.  PGCs mature into gonocytes (GCY) and enter mitotic 
arrest (MA) during the last stages of development before birth.  During embryonic 
development, a massive reprogramming of their epigenome occurs.  In the adult, 
spermatogenesis begins with spermatogonia type A (SGA) cells, which themselves have 
many subtypes.   Spermatogonia stem cells (SSCs; As) self-renew (SR), and through 
mitosis produce Apaired cells(Apr), Aaligned (Aal4 and Aal8), A1-A4, Intermediate (Int) 
and type B (SGB).  Meiosis I yields spermatocytes, which going through multiple cell 
stages, including: Preleptotene cells (Pl), leptotene (L), zygotene (Z), pachytene (P), and 
diplotene (D).  Meiosis II yields haploid round spermatids (RS) and development from this 
point forward is exclusively called spermiogenesis.  During spermiogenesis, nucleosomes 
are replaced by transition proteins (TP) and protamines resulting in an ultra-compact 











Fig. 1.5 Chemical structures of CAR agonists. Chemical structures of CAR 










Fig 1.6 Overview of CAR binding via dimeration with RXR. CAR recognizes a direct 
repeat of the half-site AGGTCA with 4 (DR4) or 5 (DR5) nucleotide spacers in between 
the repeats or an everted repeat with 5 nucleotide spacers (ER5). Adapted from Waxman 












Fig. 1.7 Indirection activation of CAR. Indirect activation of CAR by 
phenobarbital vs direct activation of CAR by TCPOBOP. Figure adapted from Yang et al 










Fig. 1.8 Agonists, antagonists and inverse agonist. Schematic view of how agonist, 
antagonists or inverse agonist can modulate the activity of a receptor that is constitutive 








CHAPTER 2- Impact of Prenatal Bisphenol A Exposure on the Young Adult Male 




During male mouse embryogenesis, critical events occur which convert the bipotential 
gonads into testes.   The gonads are particularly vulnerable to environmental chemical 
exposure during this developmental period, which could lead to long-term, deleterious 
effects on the reproductive system.  In this chapter, we investigated whether changes to the 
anatomy, testis histology, or gene expression occur in young adult male CD-1 mice 
following in utero exposure to BPA.  Mice were exposed from day E9-E18, inclusive, at 
doses of 5, 50 and 500 µg BPA (dissolved in corn oil)/kg dam body weight/day via oral 
bolus.  Other groups of mice were exposed to 5 µg diethylstilbestrol (DES)/kg dam body 
weight/day as a positive control or to corn oil only, as a vehicle control.  Mice were 
euthanized on PND28 or PND49 for gene expression analysis and anatomical 
measurements and on PND49 or between PND63 and PND80 for sperm counts.  Modest 
anatomical changes were seen in the xenoestrogen-exposed offspring.  Anogenital distance 
decreased in PND49 mice exposed to BPA (500 µg/kg dose) compared to unexposed 
controls.  No decrease in sperm count or change in testis histology was seen in any of the 
exposed groups at any age tested.  Microarray analysis performed on pooled whole testis 
tissue RNA identified candidate genes that respond to xenoestrogen exposure, however, 
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none of the genes tested were validated by qPCR due to high individual variation within 
control and xenoestrogen-exposed pools.  In conclusion we found little to no long-term 
effect of a short, in utero BPA exposure to the male mouse reproductive system during 
gonadogenesis at the doses of BPA tested.   
 
2.1 Introduction 
Endocrine disrupting compounds (EDCs) are broadly defined as compounds that have the 
ability to interfere with endogenous hormone signaling. Determining the long-term effects 
of an exposure to low doses of an EDC is vital to human risk assessment as EDCs often do 
not show immediate adverse effects and exhibit nonmonotonic dose response (NMDR) 
pharmacokinetics, particularly if the compound sufficiently mimics a natural hormone in 
its structure and activity (Vandenberg et al. 2009). Therefore, studying EDCs by classical 
methods which include exposing adult animals to high doses and measuring immediate 
effects such as cytotoxicity and carcinogenicity may mask activities of EDCs manifested 
at much lower doses. A specific class of EDCs, known as xenoestrogens (XEs), are 
synthetic chemicals that mimic endogenous estrogens and as such have the capacity to bind 
to and activate estrogen receptor (ER) α or ERβ, or estrogen-related receptor (ERR) γ 
(Montes-Grajales and Olivero-Verbel 2013, La Rosa et al. 2014, Yiu et al. 2014). 
 
Bisphenol A (BPA) is a synthetic chemical that has been used in the production of strong, 
clear polycarbonate plastics and epoxy polymers since the 1950’s. Polycarbonate plastics 
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synthesized from BPA are ubiquitous and found in a wide range of products including 
CD/DVDs, eyeglasses, plastic water coolers and baby bottles while BPA epoxy resins are 
used as dental sealants and also coat the interiors of canned food (source: CDC.gov; 
NIH.gov). Due its durability and broad applications, BPA plastics are in very high demand 
and thus 6+ billion pounds of bisphenol A (BPA) is produced globally each year (Kang et 
al. 2011, Manfo et al. 2014). BPA is currently thought of as a potential XE and EDC and 
is an active area of research.  The current human reference does of BPA (i.e. the dose that 
is considered safe for human exposure) was established using traditional linear 
pharmacokinetics without considering possible endocrine disrupting and natural hormone 
mimic behaviors (vom Saal and Welshons 2006). Studies conducted by the National 
Toxicology Program (NTP) in 1982 indicated that BPA was not carcinogenic at 50 mg/kg 
bw/day in a rat chronic oral exposure via food bioassay (Vogel 2009), and the US 
Environmental Protection Agency subsequently applied an uncertainty factor of 1000 to 
the lowest observed effect level of 50 mg/kg bw/day and established the human reference 
dose as 50 µg/kg bw/day (vom Saal and Welshons 2006). 
 
The effects of exposure to BPA in rodent models are controversial. BPA was originally 
identified as an EDC in male and female mouse reproduction (vom Saal et al. 1998) but 
other reports conflict with that finding (Myers et al. 2009, Gray et al. 2010, vom Saal et al. 
2010). Gray (Gray et al. 2010), Ryan (Ryan et al. 2010) and Tyl (Tyl et al. 2002, Tyl et al. 
2008, Tyl 2009) report no significant effects of BPA in rodents using both in utero and 
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adult exposure models. However, these results may be due to the use of the estrogen-
insensitive Long-Evans rat which then lead them to use inappropriately low doses of both 
BPA and their positive control ethinylestradoil (vom Saal et al. 2010). Additionally, 
polycarbonate cages, which are made from BPA plastics, were used to house the rats used 
in the experiment and thus are a source of uncontrolled contamination (vom Saal et al. 
2010). LaRocca (LaRocca et al. 2011) exposed C57/Bl6 mice, an estrogen sensitive mouse 
strain (Wadia et al. 2007), to 50 µg BPA/kg body weight/day and 1000 µg BPA/kg body 
weight/day and found little effects on the male reproductive tract. However, other animal 
models and exposure windows have found an impact of BPA on the male reproductive 
tract. Several recent studies found BPA exposure altered testicular histology (Fisher et al. 
1999, Atanassova 2000, Chitra et al. 2003, Takahashi and Oishi 2003, Naciff et al. 2005), 
sperm physiology (vom Saal et al. 1998, Sakaue et al. 2001, Al-Hiyasat et al. 2002, Chitra 
et al. 2003, Takahashi and Oishi 2003, Toyama and Yuasa 2004) highlighting a need for 
further research in this field. 
 
Diethylstilbestrol (DES) is a potent XE and was commonly prescribed to pregnant women 
in the United States and Europe from the 1941 to the 1970 to prevent miscarriages and 
premature births (Rubin 2007). However, after DES exposure was found to be associated 
with cervical and vaginal cancers in women prescribed the drug, the FDA banned the use 
of DES in 1971 (Rubin 2007). Male and female children exposed in utero to DES showed 
high incidences of infertility as adults as well as reproductive tract cancers (Newbold et al. 
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1985, Palmlund 1996, Nikaido et al. 2004, Newbold et al. 2007, Vandenberg et al. 2009). 
Studies using rodent models have linked these deleterious effects to a critical window of 
gonadal development in which exposure to DES can permanently disrupt tissue 
development and overall reproductive success of the organism (Colborn et al. 1993, Gupta 
2000, Nikaido et al. 2004, Rubin 2007, Soto et al. 2013). 
 
Embryonic day 9 (E9) through E18 is a critical window of gonadal development as the 
bipotential gonads develop into either the testes in male mice or ovaries in female mice. 
Exposure to EDCs during this window can lead to reduced reproductive success due to 
subfertility (Salian et al. 2009), altered steroid hormone biosynthesis capacity (Naciff et al. 
2005, Ikeda et al. 2008), and external genitalia malformation (Gupta 2000, Honma et al. 
2002, Golub et al. 2010).  
 
First, we aimed to determine the long term, persistent changes to the anatomy and 
physiology of young adult mice following in utero exposure to BPA during a critical period 
of embryogenesis. Second, we aimed to measure changes in testis gene expression in young 
adult male mice following XE exposure using the same model. The window of exposure 
chosen for these experiments, E9 through E18, inclusively, fully encompasses the period 
of sex determination and embryonic gonadogenesis. We found minimal changes in whole 
mouse body weight (BW), abundance of epididymal white adipose tissue (WA), anogenital 
distance (AGD), and sperm count following BPA or DES exposure while no changes in 
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gene expression were consistently measured using global microarray analysis or targeted 




CD-1 mice were purchased from Charles River and housed in polysulfone cages with 
polysulfone water bottles and metal food containers. Mice were subject to a 12 hour light: 
12 hour dark cycle and fed a controlled phytoestrogen diet. Harlan Teklan (Madison, WI) 
2920x low phytoestrogen feed (<20 ppb and < 20 mg total phytoestrogen per kg feed) and 
drinking water prepared using an APEC Water (Industry, CA) RO-90 Ultra Reverse 
Osmosis system were provided ad libitum. Prior to breeding, body weight measurements 
were recorded for seven days to establish a baseline and used as a secondary indicator of 
pregnancy following copulation. Pairings were set up in the evening and the presence of a 
vaginal plug was checked early the next morning. Presence of a plug denoted embryonic 
day 1 (E1). Body weight was monitored daily throughout pregnancy and weight data from 
E1 though E9 was used as a secondary indicator of pregnancy. BPA obtained from the 
NIEHS and DES obtained from Sigma-Aldrich were dissolved in tocopherol stripped corn 
oil at concentrations of 5 µg, 50 µg, or 500 µg BPA/mL and 5 µg DES/mL. BPA or DES 
solutions, or corn oil alone (vehicle control), were administered via oral bolus at a volume 
of 1 μl/gram body weight, from E9 though E18 daily, for a final dose of 5 µg, 50 µg, or 
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500 µg BPA/kg dam body weight/day and 5 µg DES/kg dam body weight /day.  Day of 
delivery was denoted PND1 and pups were weaned and separated by sex at PND21. 
 
2.3.2 Anatomical measurements and organ weights 
Male pups were sacrificed by cervical dislocation at PND28 and PND49. Body weight 
(BW) was measured at time of sacrifice and anogenital distance (ADG) was measured with 
a digital caliper (Fisher Scientific). Epididymal white adipose (WA) tissue was removed 
and weighed. Paired testes were removed, weighed and placed in RNAlater before flash 
frozen in liquid nitrogen and stored at -80°C prior to RNA isolation.   
 
2.3.3 Mature spermatozoa counts 
Paired caudal epididymes were removed, placed in DMEM media pre-heated to 37°C, and 
weighed. The tissue was scored several times with a razor blade before being placed in a 
15 mL conical tube with media and incubated in a 37°C water bath for 10 minutes. The 
tube was inverted three times and the media containing sperm was removed. Media 
containing live spermatozoa was diluted 1:5 in sperm fixation solution (5% Sodium 
bicarbonate, 0.3% paraformaldehyde) and counted on a hemocytometer.   
 
2.3.4 Histology 
In select litters, the left testis was removed and placed in modified Davidsons Fixation 
solution (Latendresse et al. 2002) at 4°C overnight. The tissue was rinsed with PBS and 
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placed in 70% ethanol at 4°C prior to paraffin wax embedding. 5 μM longitudinal sections 
were made on a Leica (model) microtome and stained with hematoxylin and eosin Y using 
a BioGenex i6000 Autostainer (Fremont, CA) for histological analysis. 
 
2.3.5 qPCR and Microarray 
Whole right testes were homogenized in TRIzol reagent (Life Technologies) and RNA was 
extracted according to the manufacturer’s protocol. RNA was quantified using a NanoDrop 
(ND-1000) instrument. Approximately 500 ng of total RNA were loaded on to an Agilent 
RNA 6000 Nano chip and run on a Bioanalyzer 2600 (Agilent Technologies) to measure 
the RNA Integrity Number (RIN). Samples with a RIN >8.0 were considered good quality 
with minimal degradation and used in microarray analysis. Samples were pooled into two 
biological replicate pools per age group per exposure. Pools contained between 5 and 14 
individuals representing between 2 and 4 litters. Dye labeling (Alexa 55 and Alexa 647), 
microarray hybridization (Agilent Whole Mouse Microarray, 44k v1 platform), chip 
scanning, and data extraction were performed at Wayne State University. A dye swap 
strategy was implemented to eliminate dye bias.  Rosetta resolver was used to generate fold 
change and p-values. A threshold of absolute fold change > 2 and p>0.005 was used to 
identify regulated genes. 
 
Quantitative real time PCR (qPCR) was used to validate the results of the microarrays. 
Primer Express v2.0 (Applied Biosystems) was used to design primers against target genes. 
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cDNA was synthesized from an aliquot of RNA pools submitted for microarray analysis.  
Power SYBR Green PCR Master Mix reagent (Applied Biosystems) and an Applied 
Biosystems 7900 Real Time, 384 well format PCR instrument was used for qPCR analysis. 
Ct values were determined using SDS software v3.0 (Applied Biosystems). Primers 
designed against the 18S RNA were used for normalization and the ΔΔCT method was 
used for relative quantification between samples. A t-test was used to determine 
significance between pairs of exposures. Primer sequences used are listed in Table 2. 
 
2.3.6 Statistical Analysis 
All statistical analyses were performed in IBM SPSS Statistics 20. In most experiments, an 
ANOVA with a Bonferoni post hoc test to correct for multiple comparisons was first 
performed to determine if there was a significant change between the vehicle control group 
and any exposure, as well as changes between any two given exposures. An ANCOVA 
was performed to determine if there was a change in body weight between exposure groups. 
Litter size was factored into the analysis as a covariate, given the inverse relationship 
between litter size and body weight. A Bonferoni post hoc test was used to correct for 





2.4.1 Litter size is not impacted by BPA or DES 
We first evaluated the effects of in utero BPA or DES exposure on overall litter size. Dams 
were exposed to BPA (5, 50, or 500 μg BPA/kg dam body weight) or DES (5 μg DES/kg 
dam body weight) daily via oral bolas from E9 through E18, inclusively. A schematic 
overview of the experimental design is outlined in Fig. 2.1. Male pups per litter, as well as 
total litter size, were counted at time of weaning to insure accuracy in sex determination. 
Results are presented in Fig. 2.2. No significant difference was measured in either total 
litter size or number of male pups per litter, as determined by ANOVA. Vehicle control 
treated litters had 12.2 pups on average with 5.8 males per litter while BPA treated litters 
ranged between 11.5-12.2 pups per litter with 6.2-7.3 males per litter for the three 
exposures. Litter sizes from the DES treated dams averaged 11.8 pups with 6.2 males per 
litter.   
 
2.4.2 Anatomical markers show minimal impact following BPA of DES exposure 
To assess changes to the general anatomy of male pups exposed to XEs, we examined 
several endpoints known to be affected by endocrine disruption, including total body 
weight, anogenital distance (AGD), which is controlled by androgen signaling during 
embryonic development and puberty and is a commonly used as a marker of reproductive 
health in males (Thankamony et al. 2016), and abundance of epididymal white adipose 
tissue, which is controlled by estrogen signaling (Cooke et al. 2001, Cooke and Naaz 2004, 
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Pallottini et al. 2008). Anatomical measurements were taken at PND28 to represent 
adolescent stage while PND49 to represent sexually mature, young adult mice. At PND28, 
mice exposed in utero to 50 μg BPA were on average 2.4 grams heavier than unexposed 
controls of the same age. The mean body weight of control mice at PND28 was 22.6 grams 
(+ 2.67 grams; n=30) and the average body weight of exposed mice was 25.0 grams (+ 
2.00; n=18). Significance was determined by an ANCOVA, which considered litter size as 
a co-variant, followed by a Bonferoni post hoc test, as body weight and litter size are 
inversely proportional in young mice. A statistically significant change was only seen in 
mice exposed to 50 μg BPA but not at a lower dose of 5 μg BPA or a higher dose of 500 
μg BPA, indicating a non-monotonic dose response to BPA (Fig. 2.3). At PDN28, there 
was no change to AGD or white adipose tissue accumulation, thus no evidence of endocrine 
disruption of the estrogen or androgen signaling pathways was observed at this time point. 
 
By PND49, the significant differences in BW between 50 μg BPA and vehicle controls 
seen at PND28 was abolished. However, there was a significant decrease in the AGD of 
PND49 mice exposed to the 500 µg dose, although no change was seen at any other dose. 
Mice exposed to 5 µg DES had on average a shorter AGD at PND49 but the results were 
not significant. Given these changes were not seen at PND28 and were only manifested in 
the older animals, this suggests a delay brought on by puberty and potential blockage in 
the androgen biosynthesis pathway. A significant change in abundance of white adipose 




2.4.3 Testis histology is unchanged by BPA or DES  
Next, we analyzed the testis morphology and cellular organization of the seminiferous 
tubules in adolescent and adult male mice to determine if BPA or DES impacted 
spermatogenesis on the cellular level. Testes from mice exposed in utero to BPA or DES 
at PND28 or PND49 were fixed in modified Davidson’s fixative overnight and stored in 
70% ethanol. Tissues were embedded in paraffin and 5 μm sections were stained with 
Harris hematoxylin and eosin Y (Figure 3.4).  Tissues were examined visually for changes 
in gross morphology, including Sertoli cell only (SCO) tubules, empty tubules, sloughing 
off of germ cell layers, or disruption of Leydig cell. Representative images of the vehicle 
control group and the BPA treated groups are shown in Fig. 2.4. No changes in morphology 
or testis histology were evident in any group examined. 
 
2.4.4 Assessing sperm production in male mice exposed to BPA or DES in utero 
To assay the impact of an in utero BPA or DES exposure on male fertility, mature 
spermatozoa were counted in vehicle control, 500 μg BPA, or 5 μg DES exposed mice at 
PND49 or at PND63-80. Mice at PND28 are not sexually mature and produce enough 
mature spermatozoa to count. Mature spermatozoa are stored in the caudal epididymes of 
male mice, thus the epididymes were excised, scored with a blade, and placed in pre-heated 
DMEM media. Following a 10 minute incubation, the supernatant was collected, diluted 
with a fixing solution containing 5% sodium bicarbonate and 0.3% paraformaldehyde, and 
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fixed spermatozoa counted on a hemocytometer. No changes to spermatozoa count were 
observed when the data were when normalized to either the paired epididymal weight or 
to the paired testes weight as a quantification of production efficiency (Fig. 2.5). 
 
2.4.5 Global transcriptional responses to in utero BPA or DES exposure- 
Microarray analysis was performed to assess the global gene expression changes in the 
juvenile and young adult mouse testis following in utero 50 or 500 μg BPA or 5 μg DES 
exposure. Genes with |fold change| > 2 with a pvalue < 0.005 were considered significant. 
At both PND 28 and PND49, more genes were dysregulated in the 500 μg BPA group (114 
and 121 genes, respectively) compared to the 50 μg BPA group (74 and 68 genes, 
respectively), reflecting the higher dose of drug exposure (Fig. 2.6). However, there is 
minimal overlap between the two doses of BPA and the two time points (Fig. 2.6A). At 
PND28, 16 genes are in common between the 74 genes regulated by the 50 μg BPA dose 
and the 114 genes regulated by the 500 μg BPA dose. Similarly, at PND49, 5 genes are 
common between the 68 genes regulated by the 50 μg BPA dose and the 121 genes 
regulated by the 500 μg BPA dose. Additionally, there is little overlap between the two 
times points of a given dose with only 19 genes in common at the 50 μg BPA dose and 16 
genes in common at the 500 μg BPA dose (Fig. 2.6B). Thus, unique sets of genes are 
regulated in the four BPA treated groups with little overlap between them. As a comparison, 
gene expression changes were measured following a DES exposure at PND28. A total of 
330 genes were regulated by DES, which represents the largest set of genes out of the five 
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EDC exposure groups. Of these 330 genes, 38 overlap with either dose of BPA at PND28 
and 292 are unique to DES (Fig. 2.6A). 
 
2.4.6 KEGG pathway analysis of regulated genes 
KEGG pathway analysis was performed using DAVID (david.ncifcrf.gov; version 6.8). 
Pathways enriched for genes regaled by BPA or DES with a minimum pvalue of 0.05 are 
presented in Table 2.1. At the 50 μg BPA dose, the cAMP pathway is the only KEGG 
pathway enriched at PND28 while Insulin secretion and ErbB signaling pathways were 
enriched at PND49. At the 500 μg BPA dose, Steroid hormone biosynthesis and related 
pathways involving drug and retinal metabolism were enriched at PND49 while no 
pathways were identified at PND28. Despite many more genes dysregulated by DES, the 
pyrimidine metabolism pathway was the only enriched pathway in the DES dysregulated 
genes. 
 
2.4.7 qPCR validation of gene responses measured by microarray 
To validate the results from the microarray experiments, a total of 21 genes were selected 
from the gene lists for validation by qPCR. Results from Hdac9 and Apoliprotein C-III 
(Apoc3) are shown and represent the group of genes tested (Table 2.2; Fig. 2.8). Additional 
genes of interest were selected based on their importance in steroid hormone biosysthesis 
(Inhibin beta B; Inhbb) or testis organogenesis (GATA Binding Protein 4, Inhibitor of 
DNA Binding 2; Gata4, Id2). Representative data are presented in Fig. 2.7. None of the 
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genes tested by qPCR showed any significant dysregulation by either BPA or DES, as 
determined by ANOVA followed by a Bonferoni Multiple Comparison post-hoc test.   
Finally, the expression of steroidogenic acute regulatory protein (Star) mRNA was 
measured in the testes of individual mice at PND28 (Figure 2.8). The individuals used were 
the same individuals used to construct the pools used in the microarray experiments as well 




The development of plastic is one of the most significant advances of the 21st century and 
has undoubtedly has had a positive impact on many in the developed world.  However, the 
ever expanding use of plastics today comes with increasing exposure to chemicals used in 
their manufacturing, including BPA.  Human exposure to BPA is ubiquitous, with at least 
90% of all urine samples and 75% of all nursing mothers breast milk contained detectable 
amounts of both free and conjugated BPA (Calafat et al. 2005, Meeker et al. 2010, Nahar 
et al. 2012, Mendonca et al. 2014). 
 
Perhaps related to the ubiquitous present of plastics, obesity in the United States, 
particularly in children, is on the rise. According to the CDC, as of 2010 upwards of 37% 
of adults and 17% of children are classified as obese, which puts them at risk of several life 
threating diseases (www.cdc.gov).  One possible explanation for the rise in obesity is the 
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increased exposure of the human population to EDCs and XEs.  Estrogen and EDCs have 
a well-established role in regulating body weight and adipose tissue in humans (Cooke and 
Naaz 2004, Newbold et al. 2007). BPA specifically been shown to lead to obesity in mice 
(Rubin 2011).  We measured total body weight and abundance of white adipose tissue from 
the epididymal fat pad.  At PND28, pup body weight significantly increased after in utero 
exposure to 50 μg BPA/kg from 22.6 grams in controls to 25.0 grams.  However, by PND49, 
although mice from this exposure group are slightly heavier, the increase is not statistically 
significant.  To calculate significance, an ANCOVA followed by a Bonferroni poc hoc test 
was performed.  The ANCOVA was chosen to factor in litter size as a covariant, because 
pup body weight, particularly in young mice, is inversely proportional to the size of the 
litter.  On a molecular level, the abundance of Apolipoprotein C3 (Apoc3) mRNA was 
measured in our samples at PND28 and PND49.  Deletion of Apoc3 in mice has been shown 
to induce obesity via an increase in adipose tissue and fatty acid uptake from plasma 
triglycerides (Duivenvoorden et al. 2005). In this study, we measured no significant change 
in Apoc3 mRNA between controls and any exposure group.  
 
The most critical endpoint of the male reproductive system is production of healthy, mature 
spermatozoa. In 2012 human sperm production worldwide was found to be decreased 
(Rolland et al. 2013) and could be due to the increasing EDC and XE exposure. The role 
of BPA in inhibiting spermatogenesis remains controversial. In an early study identifying 
BPA as an endocrine disruptor, vom Saal established BPA’s potential for lowering sperm 
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count and sperm production in rodents (vom Saal et al. 1998).  However in a subsequent 
study, no change in germ cell apoptosis or testis pathophysiology were measured (Larocca 
et al. 2011). We examined several male reproductive health endpoints following in utero 
exposure to BPA.  Mature spermatozoa from adult mice in this experiment were collected 
from the caudal epididymis. Mice were grouped into two separate age cohorts. Postnatal 
day 49 mice represented a cohort that was at the beginnings stages of fertility and PND63-
80 represent an age group of mice that are fully mature and fertile. We normalized the 
sperm counts per gram epididymis as a measure of storage capacity and also per gram 
paired testes as a measure of production. No change in sperm counts were measured at any 
age and in any exposure group compared to controls. In addition, seminiferous tubules 
were examined by cross sectioning mouse testis and staining with hematoxylin and eosin. 
No gross changes in tubule structure were seen.   
 
In males, anogenital distance is established during embryogenesis and elongation is driven 
by androgens, particularly 5α-dihydrotestosterone, during puberty and is a marker for male 
reproductive health (Welsh et al. 2010). Recent studies have linked decreased AGD with 
decreased circulating serum testosterone levels and testicular dysfunction in humans 
(Eisenberg et al. 2012). In the male mice, the onset of puberty occurs between PND27 and 
PND34 (Varney et al. 1991) and in our experiments PND28 mice represent a prepubescent 
mouse while PND49 mice have already undergone puberty. AGD was measured at the time 
of euthanasia in all mice included in our experiments. At PND28, no significant change in 
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AGD was measured in any treatment group relative to controls.  However, at PND49 the 
mice exposed in utero to 500 μg BPA/kg body weight had significantly shorter anogenital 
distances than controls. Additionally, the AGD from these mice was unchanged from their 
PND28 counterparts indicating a stunting of elongation during puberty which may be due 
to a disruption of testosterone production. To examine this at a molecular level, we 
measured testis mRNA levels of several members of the steroid hormone biosynthesis 
pathway in the testis of exposed mice. The conversion of plasma cholesterol to androgens 
is achieved by the protein products of three genes, Star, Cyp11a1 and Cyp17a1 (Hanukoglu 
1992). Star is responsible for the cellular uptake of cholesterol and is the rate limiting step 
in the conversion of cholesterol to steroid hormones. The protein product of the Cyp11a1 
gene, cholesterol side-chain cleavage enzyme, converts cholesterol into pregnenolone. 
17α-hydroxylase, the protein product of the Cyp17a1 gene, then converts the pregnenolone 
or progesterone into their 17α-hydroxy derivatives. 17α-hydroxypregnenolone or 17α-
hydroprogesterone can then be further modified by 17α-hydroxylase to the two androgens 
dehydroepiandrosterone and androstenedione respectively. Steroidogenesis is under the 
control of a negative feedback loop initiated by inhibin B secretion, coded by the Inhbb 
gene, from steroidogenic Leydig cells. Expression of Star and Cyp11a1 has been shown to 
be down regaled by BPA in cultured mouse antral follicles cells, resulting in reduced 
steroid hormone production (Peretz and Flaws 2013), while CYP17A1 activity in human 
and rat testis microsomes is decreased following BPA exposure (Ye et al. 2011). Inhibin B 
levels have been shown to be decreased in men associated with urinary BPA concentration 
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(Meeker et al. 2010). In this chapter, we measured the mRNA expression of Star, Cyp11a1, 
Cyp17a1 and Inhbb genes by qPCR at PND28 and PND49. The expression of Star was 
variable among individuals and no clear regulation was seen between the control group and 
mice exposed to 500 μg BPA/kg body weight. The results are similar for Cyp11a1, 
Cyp17a1 and Inhbb.  No change was seen in the expression in Star, Cyp11a1, Cyp17a1 or 
Inhbb indicating a functional steroid hormone biosynthesis pathway in male mice exposed 
in utero to BPA at the doses tested. 
 
Two transcription factors important for testis development and reported to be responsive 
to in utero exposure to XEs, Gata4 and Id2 (Larocca et al. 2011), were assayed by qPCR 
for their mRNA expression levels. Gata4 is critical for steriodogenic Leydig cell formation 
in the developing mouse testis (Bielinska et al. 2007) and is important for Sertoli cell 
function in adult mice (Kyronlahti et al. 2011). Conditional knock-out mouse models show 
the loss of Gata4 expression in adult Sertoli cells leads to infertility (Kyronlahti et al. 2011). 
In our experiment, Gata4 and Id2 expression were unchanged in prepubescent and adult 
mice following in utero exposure to XEs. 
 
In conclusion, we observed no long-term changes in male mouse reproductive health 
following in utero exposure BPA. The goal of the experiments outlined above was to 
determine if exposure to doses related to the human reference dose of BPA exclusively 
during a critical 10 day window of gonadal development was sufficient to permanently 
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alter testis gene expression, morphology, or function. Exposure to DES during the same 
period was used for comparison. The experiments were not designed to test the risk of BPA 
or DES exposure during any period of testis development. We measured no changes in 
mouse body weight or in sperm production in adult animals but did observe a stunting of 
AGD after puberty. Using a global gene expression analysis via microarray followed by a 
more direct and focused method of qPCR, we did not detect permanent changes in mRNA 




Fig 2.1  Schematic overview of experimental design.  Mice were bred in-house 
and the evidence of copulation via detection of vaginal plug denoted embryonic day 1 (E1).  
BPA or DES were dissolved in tocopherol stripped corn oil.  Pregnant dams were separated 
into dosing groups, weighed each day, and administered 1 µL of XE+corn oil solution per 
gram body weight via oral bolus to achieve exposure doses of 5, 50, or 500 µg BPA per 
kilogram body weight per day or 5 µg DES per kilogram body weight per day.  Control 
dams were administered 1 µL of corn oil only per gram body weight to serve as vehicle 
controls.  The exposure window was from E9 though E18, inclusively.  After exposure, 
dams were housed individually and parturition marked postnatal day 1 (PND1).  Mice were 
weaned and separated by sex at PND21.  At PND28 and PND49, mice were euthanized, 
anatomical measurements were taken and testes were either immersed in modified 
Davidson’s fixative for histology or homogenized in TRIzol for RNA extraction.  At 
PND49 or between PND63 and PND80, the caudal epididymes were removed and motile 






Fig 2.2  Litter size following BPA or DES treatment. Pups were counted and 
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Fig 2.3  Adolescent and young adult anatomical measures following BPA or 
DES treatment. Body weight (BW), anogenital distance (ADG) normalized to BW , and 
abundance epididymal white adipose (WA) tissue normalized to BW were quantified at 






























































Fig 2.4  Histology of mature mouse testis following BPA or DES exposure. 
Testes from PND28 and PND49 mice were fixed in modified davidson’s fixative overnight, 
rinsed with PBS and placed in 70% ethanol.  Tissue was embedded in paraffin and 5 µm 
cross sectional slices were stained with Harris hematoxylin and eosin Y.  Representative 
images of control mice and XE treated mice are shown. No obvious pathophysiology (i.e. 
sloughing off of germ cell layers or SCO tubules) was seen at any exposure group and at 












Fig 2.5  Mature spermatozoa counts in the adult male mouse.  Histology of 
mature mouse testis following BPA or DES exposure. Mature spermatozoa counts in the 
adult male mouse.  Cauda epididymes were excised from mice at either PND49 to represent 
a young sexually mature individual or between PND63 and PND80 to represent a fully 
mature individual.  Epididymes were placed in pre-heated DMEM media, scored several 
times with a razorblade, and incubated at 37°C for 10 minutes.  The supernatant was 
removed, diluted 1:5 in a sperm fixation solution, and counted on a hemocytometer.  A. 
Spermatozoa counts normalized per gram of paired cauda epididymis removed.  No change 
in count was seen in any exposure group at both time windows tested.  B.  Spermatozoa 




Fig 2.6  Microarray analysis of testis exposed to BPA or DES. A. The number of 
unique and overlapping genes differentially expressed after in utero exposure to DES or 
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BPA at PND28 or PND49.  Little overlap is seen between the two doses of BPA and DES 
at PND28 as well as the two doses of BPA at PND49.  B.  The number of regulated genes 
at a given exposure that persist from PND28 to PND49. Only 25.5% (19/74) of genes 
dysregulated by 50 ug BPA at PND28 are still dysregulated by PND49. These 19 genes 
only represent 27.9% (19/68) of the total genes dysregulated at PND49. Of the 114 genes 
dysregulated at PND28 in the 500 ug BPA exposure group, only 16 of them (14.0%) are 
still dysregulated at PND49. These 16 genes only represent 12.9% (16/121) of the total 












Fig 2.7  qPCR validation of microarray results. qPCR validation of select genes 
found to be regulated by microarray in the young adult mouse testes following in utero 
xenoestrogen exposure (Hdac9 and Apoc3).  Additional genes shown are markers for 
normal testis development (Gata4 and ID2) and function (Inhbb).  Bars represent pools of 
individuals and are the identical pools to those which were used for microarray.  Variability 
among biological replicates is high in all genes tested and no significant change in the 
expression of any gene was measured.  Statistical significance determined by one way 
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Fig 2.8  Expression of Star measured via qPCR. PCR quantification of the 
expression of Star mRNA at PND28.  Each bar represents data from an individual mouse 
used in the experiment.  Even among control mice, the expression of Star is highly 
inconsistent.  Star gene expression is unchanged following in utero exposure to 500 μg 
BPA/kg.  Statistical significance determined by one way ANOVA followed by Bonferoni 































Table 2.1- KEGG pathway analysis of genes regulated by BPA or DES. KEGG 
functional pathway analysis was performed on sets of genes regulated by 50 μg or 500 μg 
BPA or 5 μg DES compared to vehicle control at PND28 and 50 μg or 500 μg BPA 
compared to vehicle control at PND49. Pathways with a pvalue < 0.05 were considered 










Table 2.2 Regulation of select genes measured by microarray. Summary of 
microarray data for 5 genes tested by qPCR. All probes for each given gene are reported 
with probe sequence. Apoc3 was downregulated in mice treated with 500 ug BPA at 
PND49. Similar fold change and p-values were reported with both probes against this gene. 
One probe for Hdac9 reported significant up regulation in PND28 mice treated with DES 
while no significant change was reported by all other Hdac9 probes at all exposure groups 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2.3 Primer sequences used for qPCR. Sequences used for qPCR validation of 
select genes identified by microarray or in the literature as important markers of testis 









CHAPTER 3- Male-biased response of tumor promotion-associated genes and 
dysregulation of novel long non-coding RNAs in constitutive androstane receptor-




Xenobiotic agonists of constitutive androstane receptor (CAR) induce many hepatic drug 
metabolizing enzymes, but following prolonged exposure, promote hepatocellular 
carcinoma, most notably in male mouse liver. Here, we used nuclear RNA-seq to 
characterize global changes in the mouse liver transcriptome following exposure to the 
CAR-specific agonist ligand 1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP), 
including changes in novel long non-coding RNAs that may contribute to xenobiotic-
induced pathophysiology. Protein-coding genes dysregulated by 3h TCPOBOP exposure 
were strongly enriched in KEGG pathways of xenobiotic and drug metabolism, with 
stronger and more extensive gene responses observed in female than male liver. After 27h 
TCPOBOP exposure, the number of responsive genes increased >8-fold in males, where 
the top enriched pathways and their upstream regulators expanded to include factors 
implicated in cell cycle dysregulation and hepatocellular carcinoma progression (cyclin-
D1, oncogenes E2f, Yap, Rb, Myc, and proto-oncogenes β-catenin, FoxM1, FoxO1, all 
predicted to be activated by TCPOBOP in male but not female liver; and tumor suppressors 
p21 and p53, both predicted to be inhibited). Upstream regulators uniquely associated with 
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3h TCPOBOP-exposed females include TNF/Nf-kB pathway members, which negatively 
regulate CAR-dependent proliferative responses and may contribute to the relative 
resistance of female liver to TCPOBOP-induced tumor promotion. Many novel long non-
coding RNAs were identified in livers of mice exposed to TCPOBOP or to a pregnane-X-
receptor agonist, including lncRNAs proximal to the CAR target genes Cyp2b10, Por and 
Alas1. These data provide a comprehensive view of the CAR-regulated transcriptome and 




Many foreign chemicals, including industrial chemicals, environmental pollutants and 
pharmaceuticals alter gene expression through receptor-based mechanisms involving 
ligand-activated transcription factors, such as the nuclear receptors CAR (constitutive 
androstane receptor; NR1I3) and PXR (pregnane X receptor; NR1I2) (Chang and Waxman 
2006, Cherian et al. 2015). CAR and PXR are expressed at highest levels in mammalian 
liver, where they act as xenobiotic sensors that detect and respond to foreign chemicals. 
Some chemicals bind directly to the large and promiscuous ligand binding pockets of CAR 
and PXR (Cherian et al. 2015), while others activate cell signaling pathways linked to 
nuclear receptor activation, as exemplified by the activation of CAR by phenobarbital (Hori 
et al. 2016). Activated CAR and PXR rapidly translocate to the nucleus, where they form 
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heterodimers with retinoid X receptor (NR2B1), bind DNA, and trans-activate many genes 
(Kobayashi et al. 2015). 
 
CAR and PXR induce overlapping sets of genes in liver, including many drug metabolizing 
enzyme members of the cytochrome P450 (Cyp) gene superfamily, as well as phase II 
conjugation enzymes and drug transporters (Timsit and Negishi 2007, Cui and Klaassen 
2016). Thus, activation of either CAR or PXR may increase the metabolism and clearance 
of xenobiotics sensed by these receptors. CAR also regulates the expression of genes that 
impact diverse physiological pathways, including lipid metabolism, glucose homeostasis, 
inflammation, and hepatogenesis (Moreau et al. 2008, Yan et al. 2015). While some effects 
of CAR activation are beneficial, others are deleterious. TCPOBOP and other foreign 
chemical CAR activators can increase the hepatotoxicity of alcohol and drugs (Chen et al. 
2011, Yamazaki et al. 2011), hepatomegaly, liver tumor promotion and 
hepatocarcinogenesis (Kazantseva et al. 2016). Activators of CAR can also induce non-
alcoholic steatohepatitis (Takizawa et al. 2011) and increase serum triglycerides in diabetes 
and liver disease (Maglich et al. 2009). CAR activators can thus dysregulate a wide range 
of metabolic and other physiological processes in the liver. 
 
CAR regulates several genes that show female-bias in expression in liver, including 
Cyp2b10, suggesting that CAR may impact gene expression in a sex-biased manner. The 
greater abundance of CAR in female compared to male mouse liver (Hernandez et al. 2009, 
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Lu et al. 2013) further suggests female mice may be more sensitive than males to CAR 
activators. While liver sex differences and their impact on expression of drug-metabolizing 
enzymes and many other genes are well-studied (Waxman and Holloway 2009), studies of 
the sex-dependent effects of CAR are limited to CAR-regulated Cyps (Hernandez et al. 
2009) and a few other genes (Ledda-Columbano et al. 2003), or use phenobarbital, which 
activates both CAR and PXR (Geter et al. 2014). Furthermore, many genome-wide studies 
of CAR transcriptional responses are limited by their use of microarray technology (Ross 
et al. 2009, Tojima et al. 2012, Oshida et al. 2015), which cannot reliably distinguish 
closely related genes within a family or superfamily. RNA-seq technology does address 
this concern, however, to date, RNA-seq analysis of CAR transcriptional responses has 
been limited to male liver (Selwyn et al. 2015, Cui and Klaassen 2016). Further, several 
studies employ exposures lasting days or even weeks (Ross et al. 2009, Luisier et al. 2014, 
Cui and Klaassen 2016), which do not elucidate early, and potentially transient, effects 
CAR on the transcriptome, and stimulate a complex array of responses, including both 
primary and secondary consequences of CAR activation. A further limitation is that current 
studies of CAR activation only investigate protein-coding genes; however, it is becoming 
increasingly clear that non-coding RNAs, in particular long non-coding RNAs (lncRNAs), 
play vital roles in regulating protein-coding genes both in cis and trans (Goff and Rinn 
2015, Sun and Kraus 2015). Based on our recent work, at least 5,000 lncRNAs are 
expressed in mouse liver, many of which of which show strong tissue-specific expression, 
and a subset of which have  homologs in other species, including humans (Melia et al. 
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2016). The responsiveness of such liver-expressed lncRNAs to activators of CAR and other 
nuclear receptors is unknown. 
 
Here, we use RNA-seq to characterize in a comprehensive manner early responses of the 
mouse liver transcriptome to a short, 3 h exposure of male and female mice to the CAR 
agonist ligand TCPOBOP (Tzameli et al. 2000), including changes in expression of 
protein-coding and non-coding genes. Results are compared to the short-term effects of 
PXR activation in male liver. We also assess transcriptional responses 27 h after initiation 
of TCPOBOP exposure, to identify persistent changes in gene expression, and to capture 
delayed primary gene responses as well as secondary responses. We report striking sex 
differences in gene responses to CAR activation, including stronger initial responses in 
female liver, as well as important qualitative differences after 27 h TCPOBOP exposure, 
including more extensive dysregulation of many key cell cycle control genes linked to liver 
tumor promotion in male compared to female mouse liver. We also identify 530 liver-
expressed lncRNAs that show strong (>4-fold) changes in expression induced by activators 
of CAR or PXR, in some cases in association with activation of nearby, co-regulated 




3.3 Materials and Methods 
3.3.1 Animals 
All mouse work was carried out in compliance with procedures approved by the Boston 
University Institutional Animal Care and Use Committee. Male and female CD-1 mice, 7 
wk old, were purchased from Charles River Laboratories (Wilmington, MA) and kept on a 
12-hour light cycle (7:30 AM – 7:30 PM). 1,4-Bis-[2-(3,5-dichloropyridyloxy)]benzene 
(TCPOBOP) and pregnenolone 16α-carbonitrile (PCN), purchased from Sigma-Aldrich (St. 
Louis, MO), were dissolved in a 1% DMSO solution in corn oil (vehicle) to give 0.15 
mg/mL TCPOBOP or 2.5 mg/mL PCN. Mice were administered each chemical, or vehicle 
control, by i.p. injection of 20 μL/g body weight, resulting in a final dose of 3 mg/kg 
TCPOBOP or 50 mg/kg PCN. Injections were given at a fixed time of day (between 8:00 
AM and 8:45 AM of treatment day 1) to control for circadian effects on liver gene 
expression (Kettner et al. 2016). Mice were euthanized between 11:00 AM and 11:45 AM 
on day 1 (3 h treatment and control groups) or between 11:00 AM and 11:45 AM on day 2 
(27 h treatment and control groups) to give either a 3 h or 27 h exposure (+/- 5 min) for 
each individual mouse. A small piece of each liver was snap frozen in liquid nitrogen for 
whole tissue RNA extraction (total RNA). The remainder of the liver was fixed for 




3.3.2 Tissue fixation, cyrosectioning and CAR immunostaining 
Fresh mouse livers were each placed in ~20 mL isopentane in a stainless-steel beaker on 
dry ice until frozen. Livers were then removed and stored at -80°C. Each liver was later 
mounted on metal chucks in a Leica Cyrostat (CM1950) and embedded in OCT compound 
at -
stored at -80°C. Sections were fixed in 100% methanol at -20°C for 15 min. Following 
fixation, tissue was rinsed with cold PBS three times. Hydrogen peroxide (0.3%) was added 
to the slides for 30 min at room temperature followed by a PBS rinse. Slides were blocked 
for 30 min with avidin solution (30 uL goat serum + 4 drops avidin block (Vector 
Avidin/Biotin Blocking Kit, Vector Laboratories, cat. #SP-2001) in 1 mL of PBS) at room 
temperature, then rinsed with PBS. Slides were then blocked for 30 min with biotin solution 
(30 uL goat serum + 4 drops biotin block (Vector Avidin/Biotin Blocking Kit) in 1 mL of 
PBS) at room temperature, then rinsed with PBS. Slides were stained overnight at 4°C with 
antibodies against mouse CAR (30 uL goat serum in 1 mL PBS + 1:150 dilution of antibody 
sc-50462) (Santa-Cruz Biotechnology) or with IgG as a negative control. Slides were 
rinsed with PBS and incubated for 1 h at 4°C with secondary antibody (30 uL goat serum 
in 1 mL PBS + 1:200 dilution of goat-anti-rabbit secondary antibody). Slides were 
developed with Vectastain ABC Elite reagent (5 mL PBS + 2 drops of reagent A + 2 drops 
of reagent B) for 30 min at room temperature and rinsed with PBS. DAB color reagent was 
prepared by adding 2 drops of buffer stock to 15 mL of distilled water, followed by 4 drops 
of Vector Peroxidase Substrate Kit DAB (Vector Laboratories, cat. #SK-4100) and 2 drops 
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of hydrogen peroxide solution, with thorough mixing. DAB solution was added to each 
slide and color allowed to develop for 2 to 10 min at room temperature. Slides were flushed 
with distilled water to stop the reaction and photographed.  
 
3.3.3 Nuclear extraction and RNA purification 
Livers were homogenized on ice in a Potter-Elvehjem homogenizer in 8 mL of 
homogenization buffer (10 mM HEPES buffer (pH 7.9) containing 10% (v/v) glycerol, 2 
M sucrose, 25 mM KCl, 0.15 mM spermine, 0.5 mM spermidine trihydrochloride and 1 
mM EDTA). The homogenate was layered onto 3 mL of fresh homogenization buffer and 
spun in a Thermo Fisher TH-641 ultracentrifuge rotor at 25,000 rpm for 35 min. The pellet 
(intact nuclei) was resuspended in 20 mM Tris HCl buffer (pH 8.0) containing 75 mM 
NaCl, 0.5 mM EDTA, 50% (v/v) glycerol, 0.85 mM DTT and 0.125 mM PMSF, then 
aliquoted and stored at -80°C. TRIzol LS reagent was used according to the manufacturer’s 
protocol (Life Technologies) to purify liver nuclear RNA from ~25% of the nuclei in a 
mouse liver. 
 
3.3.4 qPCR analysis 
cDNA synthesis reactions were performed using either liver total RNA or liver nuclear 
RNA (1 μg) after digestion with DNase I to eliminate genomic DNA contaminants. Reverse 
transcription and cDNA synthesis were performed using the Applied Biosystems High 
Fidelity RT kit (ThermoFisher). Primers specific for Cyp2b10, Cyp2c55 and other genes 
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of interest were designed using Primer Express software. Primer pairs were placed in 
adjacent exons of target genes with amplicons spanning long introns to decrease the 
possibility of having genomic DNA contamination contribute to the qPCR signal, and are 
detailed in Table 3.1. Quantitative real time PCR (qPCR) was performed using Power 
SYBR Green PCR Master Mix (ThermoFisher) in 384 well plates and read on an ABI 7900 
Real Time PCR system. Fold change values were calculated using the ∆∆Ct method, using 
the expression of 18S ribosomal RNA as the background Ct value for normalization 
between samples. 
 
3.3.5 High throughput RNA sequencing (RNA-seq) and differential expression 
analysis 
Nuclear RNA-seq was performed using two or three biological replicate pools for each 
treatment group, with each pool representing liver nuclear RNA from n=3-4 individual 
mouse livers. Sequencing libraries were prepared from 1 μg of pooled liver nuclear RNA 
by poly(A) selection using the NEBNext Poly(A) mRNA Magnetic Isolation Module, 
followed by processing with the NEBNext Ultra Directional RNA Sequencing for Illumina 
kit (New England Biolabs). Sequencing was performed at the New York Genome Center 
(New York, New York) on an Illumina HiSeq2500 instrument and 50 bp paired-end 
sequence reads were obtained. Data were analyzed using a custom RNA-seq analysis 
pipeline described elsewhere (Connerney et al. 2017). Briefly, sequence reads were 
mapped to the mouse genome (release mm9) using TopHat (v2.0.13). Genomic regions 
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that contain exonic sequence in at least one isoform of a gene (exon collapsed regions; 
(Connerney et al. 2017)) were defined for each RefSeq gene and for each lncRNA gene. 
HTSeq (0.6.1p1) was then used to obtain read counts for exon collapsed regions of RefSeq 
genes, and featureCounts (1.4.6-p5) was used to obtain read counts for exon collapsed 
regions of lncRNAs. A set of 15,558 liver-expressed lncRNA transcripts was considered 
for differential expression analysis. These lncRNAs are based on the set of intergenic liver 
lncRNAs that we defined earlier (Melia et al. 2016), 2016) which we  updated by including 
lncRNAs that are anti-sense or intragenic with respect to RefSeq genes, and by increasing 
the number of mouse liver RNA-seq datasets used for lncRNA discovery from 45 to 186. 
RefSeq and lncRNA genes that showed significant differential expression following 
exposure to TCPOBOP or PCN were identified by EdgeR as outlined elsewhere (Melia et 
al. 2016). RefSeq genes dysregulated with an expression fold-change (i.e., either up 
regulation or down regulation) > 1.5 and a false discovery rate (FDR), i.e., an adjusted p-
value < 0.001 were considered significant and are shown in Table S3.2. 530 liver-expressed 
lncRNAs responded to either TCPOBOP or PCN exposure with an expression fold-change 
> 4 at FDR < 0.05 and were considered significant. 252 of the 530 lncRNAs (48%) are 
multi-exonic-exonic and 278 are mono-exonic. A fold-change > 2 at FDR < 0.05 was then 
applied to the 530 lncRNAs to determine significant regulation in each of the five data sets 
for downstream analysis, as shown in Table S3.3. Of the 530 lncRNAs, 22 have RefSeq 
NR designations; 18 of these (17 multi-exonic and 1 mono-exonic) are also included in the 
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listings of responsive RefSeq genes in Table S3.2. Raw and processed RNA-seq data are 
available at GEO (https://www.ncbi.nlm.nih.gov/gds) accession number GSE95685.  
 
3.3.6 Pathway and upstream regulator analysis 
RefSeq genes showing differential expression following exposure to TCPOBOP or PCN 
were submitted to DAVID Bioinformatics Resources (https://david.ncifcrf.gov/) for 
KEGG pathway analysis. Separate gene lists were submitted for each of the 5 mouse liver 
RNA-seq data sets (TCPOBOP exposure of males and females, for both 3 h and at 27 h, 
and PCN exposure of males for 3 h). 26 unique KEGG pathways were considered 
significant at FDR <0.05 (as controlled by the Benjamini-Hochberg method) in at least one 
of the 5 data sets (Table S3.4). Pathways were categorized as broadly related to either 
drug/xenobiotic metabolism or cell cycle/DNA replication/cancer by inspection of the lists 
of differentially regulated genes associated with each pathway. In separate analyses, data 
for the full set of 24,197 RefSeq genes for each of the 5 data sets was uploaded to Ingenuity 
Pathway Analysis (IPA; https://www.qiagenbioinformatics.com/products/ingenuity-
pathway-analysis/) and Upstream Regulator analysis was performed on genes showing 
significant differential expression, as defined above. Upstream regulators with p-value of 
overlap < 0.001 and |activation z-score| > 2 and a minimum of 5 target genes were 
considered significant and are listed in Table S3.5, ranked based on p-value of overlap. 
Upstream regulators identified by IPA as molecular type ‘chemical’ or ‘biologic drug’ were 
excluded, as were redundant terms. Upstream regulators were categorized as follows: 
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Nuclear receptor-related, factors broadly related to either drug/xenobiotic or lipid 
metabolism; factors that are key regulators of CAR-mediated hepatocarcinogenesis 
(Kazantseva et al. 2016); factors related to TNF and Nf-κB signaling; and factors related 
to non-liver cancers. Cancer-related regulators were further categorized as pro-tumor or 
anti-tumor, based on their activation state, as predicted by IPA Upstream Regulator 
analysis, and their known function (e.g. activation of a tumor promotor is pro-tumor and 
activation of a tumor suppressor is anti-tumor, etc.). 
 
3.3.7 Statistics 
Student t-test implemented using Prism 6 (Graphpad) was used to assess statistical 
significance for all qPCR analysis and for comparing RNA-Seq induction values between 
male and female livers. An exact binomial test implemented in the statistical analysis 
package R was used to determine statistical significance of liver cancer pathway 
enrichments in male and female liver, and to evaluate the enrichment of multi-exonic 
lncRNAs in the induced gene sets. 
 
3.4 Results 
3.4.1 Nuclear RNA analysis to assess short-term responses to CAR and PXR 
agonists 
We first verified by immunohistochemistry that CAR protein was present in a large fraction 
of the hepatocytes in mouse liver and translocated to the nucleus within 3 h of i.p. injection 
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of the CAR-specific agonist ligand TCPOBOP (Fig. 3.1). Next, we evaluated the effects of 
3 h TCPOBOP exposure on gene expression by qPCR analysis of liver nuclear RNA to 
capture early transcriptional changes. Results were compared to analysis of total 
(unfractionated) liver RNA. Much stronger induction (stronger up regulation) of the CAR 
target genes Cyp2b10 and Cyp2c55 was observed in the nuclear RNA fraction (65-fold and 
70-fold, increases, respectively; Fig. 3.2A) as compared to total liver RNA (15-fold and 6-
fold increases, respectively). Similarly, the PXR activator PCN, after a 3 h exposure, 
repressed the expression of Hsd5b and Apol7a to a greater extent in the liver nuclear RNA 
fraction than in total liver RNA: 2.4-fold and 4.8-fold repression, respectively, in nuclear 
RNA vs. only 1.4-fold and 1.5-fold repression, respectively, in total RNA (Fig. 3.2A). All 
four genes showed lower basal expression in the nuclear than in the total RNA fraction 
(Fig. 3.2B), which contributes to the greater sensitivity of the nuclear RNA fraction to a 
change in transcription rate induced by activators of CAR and PXR. 
 
Next, we examined the effect of TCPOBOP exposure for either 3 h or 27 h on liver nuclear 
levels of CAR target genes Cyp2b10, Cyp2c55 and Akr1b7 in both male and female mice. 
These time points were set 24 h apart to fix the time of day for all treatment groups and 
thereby control for circadian effects on CAR-dependent gene expression (Lu et al. 2013). 
TCPOBOP induction of all three genes was not detectable at 30 min and 1 h (data not 
shown) but was readily apparent after 3 h (Fig. 3.3). Cyp2b10 induction was near maximal 
at 3 h in both males and females, whereas Cyp2c55 was sub-maximally induced at 3 h (50-
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70-fold increases) compared to 27 h (375-400-fold increases) in both sexes. Akr1b7 also 
showed a delayed response to TCPOBOP. This delay was more pronounced in male liver, 
resulting in a sex difference in induction at 3 h: 3-fold increase in Akr1b7 in male liver vs. 
14-fold increase in female liver.  
 
3.4.2 Global transcriptomic responses to CAR and PXR activation 
Nuclear RNA-seq analysis was carried out to identify on a global scale TCPOBOP-
stimulated RNA responses in both male and female mouse liver. Responses of male liver 
to 3 h PCN exposure were also examined. In 3 h TCPOBOP-exposed mice, many more 
RefSeq genes showed significant changes in expression in female liver (206 genes) than in 
male liver (105 genes) (Table 3.2), as detailed in Table S3.2. This result is consistent with 
the higher levels of CAR expression reported in female liver (Lu et al. 2013). 968 genes 
responded to PCN exposure in male liver, of which 121 genes responded in the same 
manner (i.e. induction or repression) following TCPOBOP exposure in either male or 
female liver (Fig. 3.4A). In all five exposure groups, more genes were up regulated than 
down regulated (Table 3.2). While 63 genes showed a common response to 3 h TCPOBOP 
exposure in males and in females, many other genes were responsive in only one sex: 41 
genes were uniquely responsive to 3 h TCPOBOP in male liver and 142 genes were 
uniquely responsive in female liver (Fig. 3.5A). These sex differences are not an artifact of 
the threshold values (fold-change and FDR) used to identify significant response genes, as 
many of the genes showed strong responses to TCPOBOP in the responsive sex but were 
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marginally, if at all, responsive in the opposite sex. Examples include Slc15a2 and Prss22 
in male liver and Akr1b7 in female liver (Fig. 3.5A).  
 
Many more genes were responsive to TCPOBOP exposure after 27 h as compared to 3 h 
(Fig. 3.4B), with more genes responding in male liver (871 genes) than in female liver (558 
genes), in contrast to the 3 h results (Table 3.2). 344 of the genes that responded at 27 h 
were regulated in common in both sexes (Fig. 3.5B), with 119 genes down regulated and 
225 genes up regulated. Although fewer genes responded to TCPOBOP in females than in 
males at 27 h, the magnitude of the response for the up regulated male-female common 
genes was significantly greater in females at both time points (Fig. 3.6A). Similar results 
were apparent when all of the common response genes were examined individually (Fig. 
3.6B). Furthermore, a majority of all genes that showed a common response to TCPOBOP 
in both sexes were more strongly induced, or were more strongly repressed, in female 
compared to male liver (Fig. 3.6C). Individual examples are highlighted in Fig. 3.5A and 
Fig. 3.5B (center panels). 
 
3.4.3 KEGG pathway analysis 
KEGG pathway analysis of the gene sets responsive to 3 h TCPOBOP identified 12 
significant pathways in male liver and 11 in female liver (Fig. 3.7 Nine of these pathways 
were common between the two 3 h data sets. These pathways all relate to xenobiotic and 
lipid metabolism and related metabolic processes, consistent with the known role of CAR 
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as a xenobiotic sensor. The KEGG pathway cell cycle showed significant, albeit weak 
enrichment in the male but not the female gene set at 3 h. Many more KEGG pathways 
were identified at 27 h than at 3 h, in both males and females (Fig. 3.7), consistent with the 
expanded list of responsive genes at 27 h (Table 3.2). Whereas xenobiotic and lipid 
metabolism and related terms were prominent on the list of enriched KEGG pathways at 
27 h in both males and females, cell cycle and DNA replication showed significant 
enrichment in male liver only. Further, many more cell cycle pathway genes were 
dysregulated in male liver at 27 h (30 genes; FDR <E-10) than at 3 h (5 genes, FDR = 0.04). 
PCN dysregulated close to 1,000 genes at 3 h (Table 3.2), but only 10 enriched KEGG 
pathways were identified, with biosynthesis of antibiotics being the only pathway not 
related to drug and lipid metabolism (Fig. 3.7). 
 
3.4.4 Identification of upstream regulators of CAR gene responses 
IPA Upstream Regulator analysis identified CAR and PXR as top upstream regulators of 
the genes that respond to TCPOBOP or PCN in all five data sets (Fig. 3.8). This finding 
reflects the commonality of the gene responses to TCPOBOP and PCN, described here, 
with those reported previously for various activators of CAR and PXR, which populate the 
gene-gene regulator association database queried by IPA. Many unique upstream 
regulators apparently unrelated to the primary CAR-induced xenobiotic and lipid 
metabolism responses were identified in male but not female liver after 27 h TCPOBOP 
exposure. Included are 10 key regulatory factors linked to cell cycle dysregulation and 
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hepatocellular carcinoma progression (Ledda-Columbano et al. 2000, Zhang et al. 2009) 
that are specifically associated with CAR activation (Kazantseva et al. 2016), namely, the 
cyclin-dependent kinase inhibitor CCND1/cyclin D1, the oncogenes E2f, Yap and Rb, and 
proto oncogenes CTNNB1/β-catenin, Myc, FoxM1 and FoxO1, all of which were predicted 
to be activated by TCPOBOP, and the tumor suppressors p21 and p53, which both were 
predicted to be inhibited (Fig. 3.8). Mechanistic networks involving these factors, and their 
prevalence in TCPOBOP-exposed male but not female liver are shown in Fig. 3.9. Overall, 
the predicted activation states of these regulatory factors of CAR-induced 
hepatocarcinogenesis indicate that TCPOBOP stimulates a prominent pro-tumor response 
in male liver, insofar as oncogenic factors are predicted to be activated and tumor 
suppressors are predicted to be inhibited by TCPOBOP exposure. Other pro-tumor factors 
identified as activated upstream regulators for the male 27 h TCPOBOP dataset included 
TBX2, a cell cycle regulator and direct repressor of p21, RABL6 (RBEL1A), a negative 
regulator of p53, and growth factors CSF2, VEGF, and HGF (Fig. 3.8). Of note, for each 
of the 10 hepatocarcinogenesis-associated upstream regulators, the number of target genes 
that responded to 3 h TCPOBOP exposure was greater in female than in male liver, 
consistent with the greater hepatoproliferative responses reported for short-term 
TCPOBOP-treated female mouse liver (Ledda-Columbano et al. 2003); however, by the 
27 h time point, many more target genes of these regulators responded to TCPOBOP in 
male than in female liver (Fig. 3.10). Indeed, the number of up regulated liver cancer 
pathway-associated genes (i.e., genes downstream of these 10 upstream regulators) unique 
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to 27 h-TCPOBOP male liver (153 genes) as compared to 27 h-TCPOBOP female liver 
(26 genes) was significantly greater (p=0.002 by exact binomial test) than the 
corresponding numbers of total genes up regulated in each sex (349 in males vs. 93 in 
females; Fig. 3.11). Thus, there is a significantly stronger enrichment in male compared to 
female liver for TCPOBOP-responsive liver cancer pathway genes as compared to 
TCPOBOP-responsive genes in other pathways. Consistent with these findings, while 3 of 
the 10 factors linked to CAR-dependent hepatocarcinogenesis were identified as upstream 
regulators of female liver responses to TCPOBOP at the 3 h time point (FoxM1, E2F1 and 
CTNNB1/β-catenin), the p-values of overlap for their target genes were much weaker in 
female than in male liver (Table 3.3). FGF19, which was specifically associated with 
female liver responses to TCPOBOP at 27 h (Fig. 3.8) induces hepatocellular carcinoma in 
human liver but not mouse liver (Zhou et al. 2017).  
 
Next, we considered whether any of the upstream regulators activated in female liver might 
lessen the heptocarcinogenic potential of TCPOBOP in females. We identified 13 upstream 
regulators that were specific to 3 h TCPOBOP-exposed female liver, and were also 
common to 3 h PCN-exposed male liver, neither of which show the strong 
hepatocarcinogenic responses to TCPOBOP exposure seen in male liver (Shizu et al. 2013) 
(Fig. 3.8). Strikingly, five of the 13 upstream regulators found only in these two exposure 
models (TNF, Nf-kB, RELA, IKBKB, CHUK (IKBKA) are linked to TNF/NFκB signaling, 
indicating that this pathway is preferentially activated by both exposures (Fig. 3.12). The 
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TNF/NFκB pathway exerts negative cross-talk to CAR gene responses (Van Ess et al. 2002) 
and to the hepatoproliferative response to TCPOBOP (Columbano et al. 2005), suggesting 
that these five upstream regulators contribute to the relative resistance of female liver to 
TCPOBOP hepatocarcinogenesis. Consistent with this, the Nf-kB inhibitor NFKBIA was 
identified as a much stronger activated upstream regulator in 27 h-TCPOBOP male liver 
than in 3 h-TCPOBOP-female liver (Table 3.3).  
 
3.4.5 Impact of TCPOBOP and PCN on non-coding transcriptome 
Given the increasing recognition that many non-coding RNAs regulate gene expression via 
epigenetic and other mechanisms, we used the five RNA-seq datasets described above to 
investigate the impact of TCPOBOP and PCN exposure on 15,558 non-coding RNA 
transcripts identified in mouse liver (see Methods). These transcripts include long non-
coding RNAs (lncRNAs) that are intergenic, intragenic, or antisense with respect to protein 
coding genes. A total of 530 liver-expressed lncRNAs showed significant responses to 
either TCPOBOP or PCN, with at least a 4-fold change in expression in one of the 5 
datasets at FDR <0.05 (Table 3.4). 80 of 402 TCPOBOP-responsive lncRNAs also 
responded to PCN treatment, while an additional 118 lncRNAs were uniquely responsive 
to PCN, a majority of which were down regulated (73 of 118 lncRNAs; Table 3.5). The 
overall set of 530 responsive lncRNAs was significantly enriched for multi-exonic lncRNA 
genes, which are more likely to be functional than mono-exonic lncRNAs (Liu et al. 2017). 
Thus, 252 of the 530 responsive lncRNAs (47.5%) are multi-exonic as compared to only 
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20.2% of the overall set of 15,558 liver-expressed lncRNAs (2.35-fold enrichment; p<E-
15, exact binomial test). 30 lncRNAs were induced by TCPOBOP early (3 h) and persisted 
at 27 h in both sexes (Table 3.5), with inductions as high as ~400-fold seen for 
lncRNA_5998, which is which is upstream of Cyp2b10 (see below). 15 of these 30 
lncRNAs were also induced by PCN. Early gene responses – both induction and repression 
– characterized many other lncRNAs, a subset of which showed sex-specificity in their 
response to TCPOBOP (Table 3.5). Some of these early lncRNAs could contribute to the 
late (secondary) changes in expression of TCPOBOP-responsive protein coding genes. 
Other lncRNAs showed a delayed response to TCPOBOP (i.e., lncRNA induction not seen 
until 27 h): 67 such late lncRNAs responded to TCPOBOP in both male and female liver, 
94 responded in male liver only, and 117 responded in female liver only (Table 3.5, Fig. 
3.13). The sex-specificity of the late lncRNA responses is intriguing, given the striking sex 
differences in late protein coding gene responses in male liver associated with liver tumor 
promotion, described above. Considering only multi-exonic lncRNAs, 3 h TCPOBOP 
exposure altered the expression of 52 and 62 lncRNAs in male and female liver, 
respectively, a majority of which were up regulated (Table 3.6). After 27 h TCPOBOP 
exposure, 112 multi-exonic lncRNAs were dysregulated in male liver and 131 multi-exonic 
lncRNAs were dysregulated in female liver; again, a majority (72-76%) were up regulated 
(Table 3.6). Examples of multi-exonic lncRNAs responsive to TCPOBOP are shown in 
Fig. 3.14, Fig. 3.15, Fig. 3.16, and Fig. 3.17. 126 multi-exonic lncRNAs were responsive 
to PCN, 57% of which were down regulated (Table 3.6). This is consistent with the greater 
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proportion of protein coding genes down regulated by PCN as compared to TCPOBOP 
(Fig. 3.4).  
 
3.4.6 LncRNAs proximal to regulated RefSeq genes are responsive to TCPOBOP 
LncRNAs are frequently co-expressed with nearby protein-coding genes, and often 
regulate expression of protein-coding genes in cis (Engreitz et al. 2016). Accordingly, we 
examined the proximity of the lncRNAs responsive to TCPOBOP or PCN to the nearest 
regulated protein-coding gene. Across the five RNA-seq data sets, a total of 129 responsive 
multi-exonic lncRNAs overlapped or were within the same genomic topologically 
associating domain (TAD) (Vietri Rudan et al. 2015) as a co-responsive RefSeq gene (cis 
co-expression, 45-58% of the responsive multi-exonic lncRNAs; Table 3.6). 21 other 
multi-exonic lncRNAs (2-8%) were cis to RefSeq genes showing the opposite response to 
TCPOBOP or PCN in one or more datasets (Table 3.6). Since gene regulatory elements are 
largely contained within TADs, whose boundaries form looped, insulated domains (Hnisz 
et al. 2016), these lncRNAs have the potential to regulate their nearest responsive RefSeq 
gene through a cis mechanism, involving either positive regulation (129 cis co-expressed 
gene pairs) or negative regulation (21 cis opposite gene pairs). 
 
The cis co-expressed lncRNAs comprise four classes of orientation relative to their nearest 
co-regulated RefSeq genes: 1) lncRNAs upstream of and transcribed from the opposite 
strand as the RefSeq gene. Two examples are lncRNA_5998, which is 5.2 kb upstream of 
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Cyp2b10 (Fig. 3.14A), and lncRNA_8301, which is 15.6 kb upstream of Alas1 (Fig. 3.14A). 
Cyp2b10 and Alas1 are well known CAR and PXR targets and are highly induced in all 
five data sets, as are their adjacent co-regulated lncRNAs (Fig. 3.14D, Fig. 3.14E). 2) 
lncRNAs characterized by anti-sense transcription starting within the first intron of the co-
regulated RefSeq gene. Examples include lncRNA_8460, which is anti-sense to Ginm1 
(Fig. 3.14C) and lncRNA_4655, which is anti-sense to Por (Fig. 3.15A). lncRNA_4655 is 
expressed at a low level, but is induced in all five data sets (Table S3.3), as is Por (Fig. 
3.15B). Conversely, lncRNA_8460 is highly expressed and rapidly induced in all five data 
sets, while the overlapping RefSeq gene, Ginm1, is expressed at a low level and not induced 
by TCPOBOP until 27 h in both males and females (Fig. 3.15C, Fig. 3.15F). 3) lncRNAs 
found within an intron of a highly expressed RefSeq gene and often spanning multiple 
genes. Examples include two lncRNAs in the Cyp2c locus that span the genomic region 
from Cyp2c37 through Cyp2c50. lncRNA_15011 originates in intron 5 of Cyp2c37 and 
ends in intron 4 of Cyp2c50 (isoform 2), while lncRNA_15014 originates in intron 7 
of Cyp2c37 and ends in intron 6 of Cyp2c50 (isoform 2) (Fig. 3.16A). Both lncRNAs are 
highly expressed and are induced in all five datasets (Fig. 3.16B), as are Cyp2c37 and 
Cyp2c50 (Fig. 3.16C). 4) lncRNAs that are within the same TAD as a regulated RefSeq 
gene, but are distant in terms of linear chromosome distance. The DNA loop that anchors 
the TAD structure has been shown to bring these linearly distant sequences into close 3-
dimensional proximity and allow for cis regulation (Hnisz et al. 2016). An example is 
lncRNA_3779, which is highly induced in TCPOBOP-exposed male and female liver at 
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27 h (Fig. 3.17A, Fig. 3.17C). In male liver, the TCPOBOP-responsive RefSeq protein 
coding gene closest to lncRNA_3779 is Klhdc7a, which is ~455 kb away, while in female 
liver the nearest responsive RefSeq gene is Padi4, which is ~313 kb away. LncRNA_3779, 
Klhdc7a and Padi4 are all located within the same TAD. Interestingly, lncRNA_3779 is 
upregulated in both data sets while Klhdc7a is down regulated in both and Padi4 is 
upregulated in TCPOBOP-treated females at 27 h but not males (Fig. 3.17C).  
 
3.4.7 LncRNAs distal to regulated RefSeq genes also respond to TCPOBOP 
In addition to the above lncRNAs, which are cis to TCPOBOP or PCN responsive protein 
coding genes, we identified ~100 other lncRNAs – some highly expressed – whose nearest 
regulated RefSeq gene is not in the same TAD. These distal lncRNAs comprise 35-51% of 
the responsive multi-exonic lncRNAs in each data set (Table 3.6). One example is 
lncRNA_8767 (Fig. 3.17B. Fig. 3.17D). The distant location of this TCPOBOP-induced 
lncRNA relative to the nearest responsive protein coding gene, and its complex gene 
structure (4 multi-exonic isoforms; Fig. 3.17B) indicates this lncRNA – and many others 
in this class – is specifically targeted for transcription and is not a spurious by-product of 
the very active transcription of a highly expressed nearby protein coding gene. Since cis 
gene–gene regulatory element interactions are largely contained within TADs (Hnisz et al. 
2016), these lncRNAs are unlikely to regulate TCPOBOP or responsive protein coding 
genes by a cis mechanism, but rather, may utilize one of the trans regulatory mechanisms 





The impact of the CAR-specific agonist ligand TCPOBOP on the mouse transcriptome has 
been investigated after exposures lasting several days or weeks (Ross et al. 2009, Luisier 
et al. 2014, Cui and Klaassen 2016), which gives insights into the long-term effects of CAR 
activation, but does not inform about early transcriptional responses, including early events 
associated with hepatocyte proliferation linked to tumor promotion. Here we identify genes 
induced or repressed after exposure to TCPOBOP for either 3 h (presumed primary 
response genes) or 27 h (primary + secondary response genes). The set of genes 
dysregulated in 3 h TCPOBOP-treated mouse liver is enriched for xenobiotic and lipid 
metabolism, and includes Cyp2b10 and other established primary targets of CAR. Many 
more genes were dysregulated by TCPOBOP at 27 h, likely reflecting secondary 
transcriptional responses. Moreover, at 27 h, CAR responses in male but not female liver 
showed strong enrichment for genes functionally linked to CAR-dependent hepatocyte 
proliferation and hepatic tumor promotion (Kazantseva et al. 2016) and for their upstream 
regulators. These regulators include cyclin D1, which was predicted to be activated, and 
p53 and p21, which were predicted to be inhibited (Kazantseva et al. 2014). These findings 
are consistent with the greater susceptibility of male mice to CAR-dependent tumor 
promotion (Li et al. 2012) and suggest that the molecular events that lead to hepatic tumor 




It is unclear what triggers the broadening of TCPOBOP gene responses in male liver from 
the narrow focus on genes of xenobiotic and lipid metabolism seen at 3 h, to genes linked 
to cell cycle dysregulation and liver hepatocellular carcinoma promotion seen at 27 h. This 
striking change in gene responses at 27 h to encompass genes active in liver tumor 
promotion was not seen in female liver, which may in part be due to the robust early 
activation of TNF and Nf-κB signaling pathways that we observed in TCPOBOP-treated 
female but not male liver. Importantly, TNF/NFκB signaling exerts negative cross-talk on 
CAR-dependent gene responses (Van Ess et al. 2002) and suppresses the 
hepatoproliferative effects of TCPOBOP exposure (Columbano et al. 2005), suggesting 
that TNF-activated Nf-κB contributes to the partial resistance of female liver to the hepato-
proliferative response to TCPOBOP. TNF/NFκB signaling was also predicted to be 
activated in 3 h PCN-exposed male liver, which also does not exhibit the strong 
hepatocarcinogenic responses associated with male liver TCPOBOP exposure (Shizu et al. 
2013). Additional mechanisms for male-biased liver tumor promotion may involve the pro-
tumor actions of androgen receptor-FoxA1 complexes and the anti-tumor effects of 
estrogen receptor-FoxA1 complexes, via the inhibition of Myc (Li et al. 2012). Of note, 
Foxa1 was induced 2-fold in our 27 h TCPOBOP data sets, in both male and female liver. 
 
We detected TCPOBOP-induced changes in gene expression with increased sensitivity by 
RNA-seq analysis of liver nuclear RNA, rather than by analysis of total (unfractionated) 
liver RNA. The increased sensitivity provided by the nuclear fraction likely reflects a 
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buffering of the induction response by the comparatively stable pool of transcripts found 
in the cytoplasm. Nuclear RNA was also more sensitive for detection of gene down 
regulation, where the buffering effect of preexisting mature cytoplasmic mRNA can mask 
a decrease in gene transcription, especially for mature mRNAs that are relatively stable 
and when the analysis is carried out at an early time point, i.e., before a new steady state 
level of cytoplasmic mRNA is established. The use of nuclear RNA-seq also increased the 
sensitivity for detecting changes in expression of lncRNAs, a large majority of which show 
strong nuclear localization (Melia et al. 2016). 
 
Female mice were more responsive than males to TCPOBOP-induced changes in gene 
expression, as indicated by the ~2-fold greater number of responsive genes at 3 h in females 
than in males, and by the greater magnitude of gene responses in females both 3 h and 27 
h after initiating TCPOBOP exposure. This is consistent with earlier reports that CAR is 
more highly expressed and more active in female than male mouse liver (Hernandez et al. 
2009, Lu et al. 2013), and with the finding that the androgens androstanol and 
androstenedione are inverse agonists of CAR activity (Kawamoto et al. 2000, Kohalmy et 
al. 2007) that can compete with exogenous CAR agonists for CAR binding in male liver. 
In addition, estradiol and estrone act as agonists of CAR (Kawamoto et al. 2000) that 
stimulate basal CAR activation in female liver (Koh et al. 2012). Despite this intrinsic 
female bias in CAR responsiveness, a male-biased gene response pattern emerged 27 h 
after TCPOBOP exposure, when many genes involved in cell cycle control and 
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hepatocellular carcinoma progression were preferentially dysregulated in male liver, as 
discussed above.  
 
Female mice are more resistant to hepatocellular carcinoma induced by the tumor initiator 
diethylnitrosamine when combined with a non-genotoxic tumor promotor, such TCPOBOP 
or phenobarbital (Kalra et al. 2008). However, exposure to TCPOBOP alone induces 
hepatocyte proliferation more frequently in female than in male liver (Ledda-Columbano 
et al. 2003). There are several possible explanations for the apparent disparity between 
those findings and our findings here. First, the reported female bias in hepatocyte 
proliferation is limited to TCPOBOP exposures up to 36 h, as there is no apparent sex bias 
after 48 h (Ledda-Columbano et al. 2003). This is consistent with our finding of an early 
female bias in cell proliferation gene expression (Fig. 3.10). Conceivably, the reversal of 
the sex bias in expression of cell cycle control genes by 27 h in our dataset may account 
for the loss of sex bias in hepatic proliferation at 48 h (Ledda-Columbano et al. 2003). 
Second, given our finding of a strong enrichment for key mediators of CAR-dependent 
liver tumor promotion in 27 h-TCPOBOP-treated male but not female liver, as well as the 
early activation in female liver of TNF/NFκB signaling, which is associated with inhibition 
of hepatoproliferative response to TCPOBOP (Columbano et al. 2005), the transcriptional 
environment in male liver may be poised for stronger and more rapid liver tumor 
progression than female liver, despite lower overall cell proliferation rates. Indeed, acute 
activation of CAR can lead to increased cell proliferation but not liver tumor formation 
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(Dong et al. 2015). Thus, early measurements of cell proliferation alone may not be 
sufficient to predict the hepatocellular promotion effects of TCPOBOP and perhaps other 
CAR agonists. 
 
Cyclin D1 regulates cell cycle progression from G1 to S phase, as well double-strand break 
repair by homozygous recombination (Bartek and Lukas 2011, Jirawatnotai et al. 2011). 
Overexpression or dysregulation of cyclin D1 drives tumor formation in many tissues, 
including liver (Deane et al. 2001, Bartek and Lukas 2011, Jirawatnotai et al. 2011, 
Kazantseva et al. 2014). Cyclin D1 (Ccnd1 gene) is induced in TCPOBOP-exposed mouse 
liver and is a key mediator of CAR-dependent increases in hepatocyte proliferation (Ledda-
Columbano et al. 2003, Kazantseva et al. 2014). We observed early induction of cyclin D1 
in female but not male liver, consistent with prior reports (Ledda-Columbano et al. 2003), 
followed by strong up regulation of cyclin D1 in both sexes at 27 h. However, we also 
found that cyclin D1 is a highly significant upstream regulator of downstream TCPOBOP 
responses in male but not in female liver, with 52 cyclin D1 target genes being responsive 
to TCPOBOP in males compared to only 11 target genes in females at 27 h. The increase 
in hepatocyte proliferation within 24 h of TCPOBOP treatment (Ledda-Columbano et al. 
2000, Li et al. 2012) is reduced in cyclin D1-deficient mice (Ledda-Columbano et al. 2000, 
Ledda-Columbano et al. 2002), consistent with our finding that liver cyclin D1 induction 
is an early response to TCPOBOP exposure. However, longer exposures to TCPOBOP 
(>36 h) in the same cyclin D1-deficient mice showed no difference in hepatocyte 
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proliferation, apparently due to compensatory effects of cyclin E (Ledda-Columbano et al. 
2002). Thus, while cyclin D1 is not strictly necessary for long-term TCPOBOP mediated 
hepatocyte proliferation, it is required for the initial response.  
 
Other key factors in cell cycle control that are disrupted by TCPOBOP in a CAR-dependent 
manner include the tumor suppressor p53 and its target gene p21 (Ledda-Columbano et al. 
2002, Kazantseva et al. 2014). In healthy cells, p53 induces p21, and p21, in turn, inhibits 
cyclin D1 signaling to trigger cell cycle arrest (Xiong et al. 1993). Disruption of either p53 
or p21 signaling is linked to liver cancer progression (Deane et al. 2001, Zhang et al. 2009). 
Here, we show that p21 and p53 are upstream regulators of TCPOBOP gene responses 
whose activity is inhibited by TCPOBOP in male but not female liver. Interestingly, 151 
of the 217 male liver TCPOBOP-responsive genes that are downstream of either p53, p21 
or cyclin D1 are unique to only one of these three regulators, suggesting these regulators 
may in part act independently of the canonical p53  p21  cyclin D1 pathway that 
connects them. 
 
Our comprehensive characterization of the non-coding liver transcriptome led to the 
discovery of 530 lncRNAs, including 252 multi-exonic lncRNAs, whose expression is 
either induced or repressed following exposure to TCPOBOP or PCN. LncRNAs have 
diverse actions, which include tethering to their site of transcription (Werner and 
Ruthenburg 2015), which enables them to recruit activating or repressive histone mark 
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writers to nearby target genes in cis, as well as distal actions by epigenetic and other 
mechanisms that operate in trans (Goff and Rinn 2015, Sun and Kraus 2015). 150 of the 
252 multi-exonic lncRNAs are encoded by genes that are either proximal to, or are found 
within the same genomic TAD (Hnisz et al. 2016) as a TCPOBOP or PCN responsive 
protein coding gene, with 129 of these lncRNAs showing co-expression and 21 showing 
the opposite response to TCPOBOP or PCN as the associated protein coding gene. 
Examples include lncRNA_5998, which is upstream and antisense to Cyp2b10, is proximal 
to an enhancer that binds CAR and contributes to Cyp2b10 induction (Honkakoski and 
Negishi 1997), and is induced to similar levels as Cyp2b10 (Fig. 6). Other examples include 
lncRNAs transcribed anti-sense to an overlapping, responsive protein coding gene that they 
may regulate. This regulation may involve anti-sense mechanisms (Pelechano and 
Steinmetz 2013) that lead to decreased sense transcription by RNA polymerase II (Hobson 
et al. 2012), recruitment of histone modifiers to silence the genomic region (Rinn et al. 
2007), or other mechanisms. Examples include lncRNA_8450, which is induced by 
TCPOBOP to very high levels (~100 FPKM) and is transcribed anti-sense to the weakly 
induced overlapping protein-coding gene Ginm1 (Fig. 3.14 C), suggesting lncRNA_8450 
may actively interfere with Ginm1 expression. Many other TCPOBOP or PCN responsive 
lncRNAs are distant from other TCPOBOP or PCN responsive genes and some of these 
may operate through trans regulatory mechanisms. Further study is required to elucidate 
the functions of the CAR and PXR-responsive lncRNAs described here and their impact 
on CAR and PXR dependent physiological and pathophysiological processes. 
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Fig. 3.1 I.P injection of TCPOBOP stimulates CAR nuclear localization in 
mouse liver within 3 h. Immunohistochemical analysis of male mouse liver showing CAR 
localized to the cytoplasm in the absence of TCPOBOP (vehicle control) but translocated 
to the nucleus after 3 h TCPOBOP exposure. Male mice were injected with TCPOBOP (3 
mg/kg body weight) at 8 am. Liver was collected and fixed in ~20 mL isopentane in a 
stainless-steel beaker on dry ice until frozen. Tissue was sectioned at 5 μM, adhered to 








Fig. 3.2 TCPOBOP induces the expression of Cyp2b10 and Cyp2c55 while PCN 
represses the expression of Hsd3b and Apol7a. A. Induction of Cyp2b10 and Cyp2c55 
by TCPOBOP (3 h) and suppression of Hsd3b5 and Apol7a expression by PCN (3 h) in 
male mouse liver, as measured by qPCR. RNA isolated from whole liver tissue (‘Total’) 
shows modest induction of Cyp2b10 and Cyp2c55 by TCPOBOP (t-test: *, P<0.05; **, 
P<0.01; ***, P<0.001 vs. vehicle controls), while RNA purified from liver nuclei 
(‘Nuclear’) shows much strong induction (higher fold change) for both genes (t-test: +, 
P<0.05; ++, P<0.01; +++, P<0.001 for difference in induction between Total and Nuclear). 
Down regulation of Hsd3b5 and Apol7a is also significantly stronger in nuclear RNA 
compared to total RNA. B. Expression levels measured by qPCR analysis of total liver 
RNA is higher than for the corresponding nuclear liver RNA samples, all from vehicle 









Fig. 3.3 TCPOBOP induces Cyp2b10, Cyp2c55, and Akr1b7 in male and female 
mice. Induction of Cyp2b10, Cyp2c55 and Akr1b7 in livers of mice treated with 
TCPOBOP or PCN in males (M) or females (F) for 3 h (3) or for 27 h (27), as indicated at 
the bottom. Expression level for the male 3 h vehicle control samples was set to 1. Strong 
and statistically significant (ANOVA; t-test, P<0.05, not marked) induction of all 3 genes 
was seen in both male and female livers after 3 h. A significantly greater increase in 
expression at 27 h compared to 3 h is seen in males for all three genes, and in females for 
Cyp2c55 and Ark1b7 (ANOVA; t-test; ‡, P<0.05; ‡‡‡, P<0.001). A significant sex bias 
was found for the induction of all three genes, with females showing a stronger induction 
of Cyp2b10 and Akr1b7 than males at 3 h, and stronger induction of Cyp2c55 at 3 h and 27 
h than males (ANOVA; t-test; ^, P<0.05; ^^, P<0.01). For panels B, C and D, n=5-12 









Fig. 3.4 Nuclear RNA-Seq identifies RefSeq genes responsive to activators of 
CAR or PXR. Overlap between sets of genes responsive at 3 h in males and females treated 
with TCPOBOP (TCPO) and in males treated with PCN. C. Overlap of genes responsive 
to TCPOBOP in males (top) and in females (bottom) at 3 h vs. 27 h. Genes that were 
responsive in multiple data sets, but in opposite directions, were omitted from these 










Fig. 3.5 Sex differences in TCPOBOP gene responses identified by nuclear 
RNA-seq. A and B. Top – Overlap of genes responsive to TCPOBOP (TCPO) exposure in 
male vs female liver after 3 h (A) or after 27 h (B) at |fold change| > 1.5 and FDR < 0.001. 
Omitted are 3 genes that responded in the opposite direction in males vs females at 27 h. 
Bottom – Plot of FC (fold-change) values for genes responsive to TCPOBOP in male liver 
only, female liver only or in both sexes, which each individual gene shown as a separate 
data point. Genes that did not meet the fold change and FDR cutoff values are in the two 
outmost groups (gray dots). Dashed horizontal lines indicate a fold-change of 1.5. 
Examples of genes showing a strong sex bias in their response include Slc15a1 and Prss22 
(3 h male only), Akr1b7 (3 h female only), Gjb4 and Sult3a1 (27 h male only) and Gm16432 
(27 h female only), as marked. Many genes that respond to TCPOBOP in common in both 
sexes are more strongly induced in females, as highlighted by Ces2a (3 h) Cyp2c55 and 









Fig. 3.6 Genes that respond to TCPOBOP in males and females are more highly 
induced in females. A. Box plot of log2 fold-change values showing that genes up 
regulated by TCPOBOP in both sexes, after either 3 h (top) or 27 h (bottom), are 
significantly more strongly induced in female liver (t-test; **, P< 0.01). B. Fold change 
values of individual TCPOBOP common response genes in male (blue) and female liver 
(red), as marked, ranked by decreasing fold change in female mice. C. Numbers of 
TCPOBOP common response genes whose |fold change| is larger in male liver or in female 








Fig. 3.7 KEGG pathways enriched in sets of RefSeq genes responding to 
TCPOBOP or PCN. Shown are gene numbers and Benjamini p-values for KEGG 
pathways enriched in responsive genes (|FC|>1.5 and FDR<0.001) in each of the indicated 
five RNA-seq data sets, based on DAVID analysis. Pathways not directly related to 
metabolism are shown in lighter color (red). Pathways related to drug metabolism or other 
liver metabolic processes are found in all data sets, while pathways related to cell cycle 
and DNA replication are found exclusively in TCPOBOP exposed males at 27 h. 










Fig. 3.8 Upstream regulator analysis of TCPOBOP and PCN responsive genes. 
Shown are up to the top 10 upstream regulators identified in each RNA-seq data set by IPA. 
Green bars identify upstream regulators related to activation CAR or other nuclear 
receptors (NR). Orange bars identify upstream regulators associated with a pro-tumor 
response, and purple bars identify upstream regulators associated with an anti-tumor 
response based on their known biological functions and direction of the activated z-score 
calculated by IPA. Blue arrow heads mark upstream regulators known to be involved in 

































Fig. 3.9 Mechanistic networks related to CAR-mediated HCC are found in 
TCPOBOP treated males but not females. IPA upstream regulator mechanistic networks 
relating to CAR-dependent liver tumor promotion. Orange color indicates activation of the 
upstream regulator while blue color indicates inhibition. The intensity of color indicates 
strength of activation or inhibition. Strong activation of pathways related to TP53 and 
CDKN1A (p21) are seen in TCPOBOP-treated males at 27 h, while minimal activation of 
TP53 is seen in TCPOBOP-treated females at 27 h. 16 out of the 17 upstream regulators 
identified in the TP53 mechanistic network in male liver show strong activation/strong 
inhibition, while 12 out of 14 upstream regulators in the p21 network also showed strong 
activation/strong inhibition. In contrast, although IPA identified a mechanistic network for 
TP53 in females, 0 out of the 20 upstream regulators showed either strong activation or 
strong inhibition. A mechanistic network related to CDKN1A (p21) in 27 h TCPOBOP-










Fig. 3.10 Gene targets of 10 factors involved in CAR-mediated HCC. Gene targets 
were identified by IPA for each of the 10 indicated pro-tumor upstream regulators 
identified in male liver at 27 h (see Table S3.5). Shown is the number of gene targets for 












Fig. 3.11 Genes regulated by TCPOBOP in males only are enriched for the CAR-
mediated HCC pathway. A single gene list was obtained from the union of all 27 h 
TCPOBOP-responsive gene targets of the 10 pro-tumor upstream regulators (HCC 
pathway gene targets) in male and female liver (Table S3.4). Shown is the overlap of the 
HCC gene pathway gene targets that are up regulated by TCPOBOP at 27 h in male vs. 
female liver (top), and the overlap of all genes up regulated by TCPOBOP at 27 hr in male 
vs. female liver (bottom). These patterns of overlap differ at p=0.002 (exact binomial test) 










Fig. 3.12 The Nf-kB pathway is active in PCN treated males and TCPOBOP 
treated females but not TCPOBOP treated males. IPA upstream regulator mechanistic 
network related to Nf-κB. Results are shown for 3h TCPOBOP exposed male and female 
liver, and for 3 h PCN exposed male liver. It is apparent that activation of Nf-κB along 
with its downstream gene targets occurs in TCPOBOP exposed females and PCN exposed 










Fig. 3.13 TCPOBOP responsive mouse liver lncRNAs. Venn diagram showing 
overlap within the set of 402 TCPOBOP responsive mouse liver lncRNAs across 4 RNA-
seq data sets (251 up regulated, 151 down regulated; Table 1). lncRNAs that were 
responsive to TCPOBOP in multiple datasets but in opposite directions were excluded from 
this analysis. For example, 3 lncRNAs that were down regulated in female liver at 3 h but 
were up regulated in female liver at 27 h were not included in the list of 5 lncRNAs shown 











Fig. 3.14 Liver-expressed lncRNAs responsive to TCPOBOP or PCN that are 
proximal to regulated RefSeq genes. A-C, Structure and relative position of select 
regulated multi-exonic lncRNAs that are in close proximity to, or overlapping, a responsive 
RefSeq gene. Shown are RNA-seq read densities for male liver after 3 h and 27 h 
TCPOBOP treatment, as well as vehicle control tracks. D-F, Relative expression (FPKM, 
fragments per kilobase per million sequence reads) for each lncRNA and its nearby 
responsive RefSeq gene, as measured by RNA-Seq. The mean expression level (FPKM) of 
each transcript in the vehicle control samples was as follows: Cyp2b10, 1.2; lncRNA_5998, 
0.1; Ginm1, 6.3; lncRNA_8460, 1.4; Alas1, 32.1; and lncRNA_8301, 0.3, and is marked 












Fig. 3.15 lncRNA_4655 may negatively related Por. A. Structure and orientation 
of lncRNA_4655 and its overlapping RefSeq gene Por. B. Relative expression of 
lncRNA_4655 and Por. The mean expression level (FPKM) of each transcript in the 










Fig. 3.16 Two regulated lncRNAs are anti-sense to Cyp2c37 and Cyp2c50. A. 
Structure and relative orientation of two lncRNAs (lncRNA_15011 and lncRNA_15014) 
and two highly expressed RefSeq genes (Cyp2c37 and Cyp2c50). B. Relative expression 
of lncRNA_15011 and lncRNA_15014. C. Relative expression of Cyp2c37 and Cyp2c50. 
The mean expression level (FPKM) of each transcript in the vehicle control samples was 










Fig. 3.17 LncRNAs responsive to TCPOBOP or PCN that are not proximal to 
the nearest regulated RefSeq gene. A, Structure of lncRNA_3779 and a subset of its 
isoforms (also see Fig. S4G), which is in the same TAD but > 300 kb away from the closest 
TCPOBOP responsive transcript (Table S3.6). B, Structure of lncRNA_8767, whose 
nearest TCPOBOP responsive RefSeq gene is in a different TAD (i.e., is distal). Also 
shown are RNA-seq read densities for male liver after 3 h and 27 h TCPOBOP treatment, 
as well as vehicle control tracks. C-D, Expression levels (FPKM values) of lncRNA_3779 
and lncRNA_8767 across the five data sets, as measured by RNA-Seq. The mean 
expression level (FPKM) of each transcript in the vehicle control samples was as follows: 




















Table 3.2 Regulation of RefSeq genes by TCPOBOP or PCN in mouse liver. 
Differentially expressed genes were identified using edgeR. Numbers of genes that respond 













Table 3.3 Output from IPA upstream regulator analysis. Shown are select 
predicted upstream regulators in TCPOBOP treated female mice (3h) and TCPOBOP 















































































































































































































































































































Table 3.5 Mono-exonic and multi-exonic lncRNAs that respond to TCPOBOP or 
PCN at |fold-change|>2 and FDR<0.05. Shown are: lncRNAs that respond to TCPOBOP 
in at least one of the four TCPOBOP treatment groups (All TCPOBOP-responsive); 
lncRNAs that respond in all 4 TCPOBOP datasets and in the same direction (i.e. up in all 
4, or down in all 4) (Common responses in all 4); lncRNAs that respond to TCPOBOP at 
3 h in males and/or females, as indicated, irrespective of their response to TCPOBOP at 27 
h (Early responding); lncRNAs that respond to TCPOBOP at 27 h but not at 3 h (Late 
responding); and lncRNAs responsive to PCN in male liver at 3 h but that did not respond 
in any of the four TCPOBOP datasets (Responsive to PCN only). For both early responding 
and late responding lncRNAs, 'both Male and Female' indicates the lncRNA is either up 
regulated or down regulated in both sexes. The last column indicates the number of 
TCPOBOP-responsive lncRNAs in each category that responded in the same direction to 
3 h PCN treatment in male liver. Ten lncRNAs whose response to TCPOBOP was 









TCPOBOP response profile Up Down
Also PCN responsive 
(same direction)
All TCPOBOP-responsive lncRNAs 251 151 80
Common responses in all 4 TCPOBOP datasets 30 0 15
Early responding, both Male and Female 34 3 20
Early responding, Male only 7 10 7
Early responding, Female only 19 20 15
Late responding, both Male and Female 50 17 7
Late responding, Male only 50 44 10
Late responding, Female only 68 49 9




Table 3.6 TCPOBOP and PCN responsive multi-exonic lncRNAs and their 
relationship to co-regulated RefSeq genes. Shown are responsive multi-exonic lncRNAs 
(|FC|>2, FDR<0.05) in each data set and their genomic location relative to the nearest 
responsive RefSeq gene (|FC|>1.5, FDR<0.001). Cis co-expression and cis opposite 
expression refer to lncRNA-RefSeq gene pairs where both genes respond to TCPOBOP or 
PCN and either overlap in their genomic coordinates by at least 1 base pair, or are within 
the same topologically associating domain (TAD), as indicated under Proximity to RefSeq. 
The lncRNA and RefSeq genes in each pair can either be co-expressed or show opposite 
expression, as indicated. Distal lncRNAs are those whose nearest regulated RefSeq gene is 























































































































































































































































































































































The impact of activated nuclear receptors on the epigenome has been studied for several 
nuclear hormone receptors but the genome-wide chromatin remodeling induced by CAR 
activation has not been investigated. Here, we provide a detailed analysis of the rapid 
changes to the mouse liver epigenome following short-term exposure to the mouse CAR-
specific agonist ligand TCPOBOP for 3 h or 27 h. By using previously characterized mouse 
liver topologically associating domain (TAD) boundaries, we show that ~50% of 
TCPOBOP-responsive genes cluster in TAD regions. Next, DNase-seq analysis revealed 
several thousand genomic regions in mouse liver that respond to TCPOBOP-exposure, 
which also cluster into highly responsive TADs and map to highly responsive protein 
coding and non-coding genes. ChIP-seq analysis of three activating histone modifications 
(K4me1, K4me3, and K27ac) identified enhancer regions that become activated in mouse 
liver upon TCPOBOP-exposure. Finally, we observed a temporal relationship between 
gene induction and epigenomic modifications; some ∆DHS that open or close at 3 h map 
to genes that respond to TCPOBOP only after 27 h while some genes that are induced 
respond before new enhancers are activated. These studies provide a comprehensive view 
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of rapidly changing epigenomic medications in mouse liver following in vivo exposure to 
the mouse CAR agonist ligand, TCPOBOP. 
 
4.2 Introduction 
The nuclear receptor (NR) superfamily includes the steroid hormone receptors, such as 
androgen receptor (AR; Nr3c4), glucocorticoid receptor (GR; Nr3c1), and estrogen 
receptor α and β (ERα, ERβ; Nr3a1, Nr3a2), as well as the xenobiotic sensing receptors 
constitutive androgen receptor (CAR; Nr1i3) and pregnane X receptor (PXR; Nr1i2). 
Following activation of these receptors by steroid hormones, in the case of AR, ER, and 
GR, or xenobiotic chemicals, in the case of CAR and PXR, NRs translocate to the nucleus 
where they act as transcription factors that induce or repress target gene expression.  
 
Epigenetic modifications of the genome mark genes that can be rapidly targeted for 
induction or repression by activated NRs. The genome-wide effects of ERα (Mann et al. 
2011, Abdel-Hafiz and Horwitz 2015), AR (Cucchiara et al. 2017), and GR (Nagaich et al. 
2004, Burd et al. 2012, Grontved et al. 2013) on epigenomic remodeling of chromatin 
following activation has been widely studied, but comparatively little is known about the 
xenobiotic sensing receptors, particularly TCPOBOP-activated CAR. For example, GR 
induces chromatin opening and closing through direct DNA binding events (Nagaich et al. 
2004, Burd et al. 2012), while activation of AR and ER in prostate and breast cancers, 
respectively, have been associated with widespread changes in histone modifications 
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(Mann et al. 2011, Abdel-Hafiz and Horwitz 2015, Cucchiara et al. 2017). Previous 
methods used to characterize epigenetic modifications that influence the induction of CAR 
target genes, such as Cyp2b10 (Honkakoski and Negishi 1997, Chen et al. 2012), its human 
ortholog CYP2B6 (Inoue and Negishi 2009), and other DME gene targets (Sugatani et al. 
2001, Chen et al. 2003, Kuno et al. 2008), have been limited to low throughput techniques 
focused on a few select genomic regions. However, to date, a genome wide analysis of 
potential DNA regulatory elements and epigenomic changes that occur following CAR 
activation in liver has not been performed. 
 
Transcriptional regulatory elements can be identified by analysis of chromatin accessibility, 
which reflects the presence or absence of nucleosomes at specific loci, and can be 
determined genome wide by limited DNase-I digestion of isolated nuclei followed by 
massively parallel sequencing (DNase-Seq) to identify DNase-I hypersensitivity sites 
(DHS) (Thurman et al. 2012, Ling and Waxman 2013, Ling and Waxman 2013). DNase-
seq, in combination with chromatin immunoprecipitation with sequencing (ChIP-seq) for 
various histone modifications, has been used to identify functional cis-regulatory elements 
in mammalian cells (Shlyueva et al. 2014), including mouse liver (Sugathan and Waxman 
2013, Yue et al. 2014). Recent advances led by the Mouse ENCODE Consortium have 
identified several hundred thousand putative regulatory elements across many mouse cell 
lines and tissues, including liver, through a combination of DNase-seq and ChIP-seq for 
histone proteins and transcription factors (TFs) (Yue et al. 2014). However, by design, 
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tissue samples analyzed by the ENCODE consortium were derived from mice that were 
not subjected to any experimental treatments and thus do not identify regulatory elements 
that may be dynamically activated or repressed following exposures to chemicals that 
activate TFs such as CAR. Chromatin sites that are DHS and contain the histone 
modifications H3 lysine 4 monomethylation (K4me1) and H3 lysine 27 acetylation 
(K27ac), mark active enhancer regions (Creyghton et al. 2010, Shlyueva et al. 2014), while 
DHS in combination with  H3 lysine 4 trimethylation (K4me3) and K27ac is a mark of 
active promoters (Shlyueva et al. 2014). Thus, using these three chromatin marks in 
conjunction with DHS data can be effective at identifying major cis-regulatory elements 
that control gene expression.  
 
Historically, our understanding of how genomes are organized was based on a few select 
locus control regions (LCRs) that were known to influence the expression of genes within 
a localized cluster (Fraser and Grosveld 1998), however, recent studies show the 
mammalian genome is organized into mega-base scale structures by a series of chromatin 
loops known as topologically associating domains (TADs) (Rao et al. 2014, Bonev and 
Cavalli 2016). TAD regions are delineated by chromatin boundaries that functionally 
separate large genomic regions from each other. Thus a refined approach to identifying 
DNA regulatory elements that influence target gene expression is to limit the interactions 
to within inter-TAD connections. Additionally, TAD regions provide a series of insulated 
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regions that may allow for rapid, coordinated gene regulation of gene families within a 
localized genomic cluster (Le Dily and Beato 2015). 
 
Here, we use DNase-seq to identify DHS in male and female mouse liver that open or close 
following TCPOBOP treatment. These ∆DHS regions are identified both early (3 h) and 
late (27 h) after TCPOBOP treatment, and are shown to be enriched proximal to CAR 
responsive coding and non-coding genes within the same TAD. ChIP-seq experiments 
targeting the activating histone modifications K4me1, K4me3 and K27ac were performed 
in male mice to characterize the TCPOBOP-induced changes in local chromatin 
environment around DHS and responsive genes. ChIP-seq data were used in conjunction 
with male liver DNase-seq data described above to identify DNA regulatory elements that 
respond to CAR activation in male mouse liver, including active enhancers and active 
promoters and their putative gene targets. Through global analysis of DHS and histone 
marks we present a comprehensive overview of changes to the epigenome that may 
influence mouse liver gene expression following TCPOBOP exposure. 
 
4.3 Materials and Methods 
4.3.1 Animal procedures and tissue extraction 
All mouse work was carried out in compliance with procedures approved by the Boston 
University Institutional Animal Care and Use Committee. Animal handling and treatments 
were performed as described in Chapter 3. Briefly, male and female mice, 7-weeks old, 
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were purchased from Charles River Laboratories (Wilmington, MA) and kept on a 12-hour 
light cycle (7:30 AM – 7:30 PM). Mice were treated with TCPOBOP (Sigma Cat. # T1443) 
at a dose of 3 mg/kg body weight or with vehicle alone (corn oil with 1% DMSO) by i.p. 
injection between 8:00 AM and 8:45 AM on day 1. Livers were collected after 3 h, or after 
27 h (3 h + 24 h), between 11:00 AM and 11:45 AM on day 1 or day 2, respectively, to 
control for the strong circadian rhythm effects on gene expression seen in mouse liver 
(Kettner et al. 2016).  
 
Nuclei were isolated from individual vehicle-treated (control) and TCPOBOP-treated 
mouse livers as described in Chapter 3. Briefly, fresh liver tissue was homogenized in 
buffer on ice in a Potter-Elvehjem homogenizer. The homogenate was layered on fresh 
homogenization buffer and spun at 4°C in an ultracentrifuge for 35 min at 25,000 RPM. 
For DNase-I hypersensitivity assays (see below), nuclear pellets containing approximately 
150 million nuclei were resuspended in 400 μL of nuclei storage buffer and either 
crosslinked immediately with formaldehyde, as described below, or stored at -80°C for 
DNase digestion and DNase hypersensitivity analysis.  
 
4.3.2 Sonication of liver chromatin and ChIP analysis 
Chromatin immunoprecipitation (ChIP) analysis of histone marks was carried out using 
sonicated liver chromatin, either prepared by sonication of cross-linked liver nuclei, or by 
sonication of whole liver tissue that was initially snap-frozen in liquid nitrogen and then 
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crosslinked with formaldehyde and then sonicated, in experiments carried out by Aram 
Shin of our laboratory. 
 
To crosslink nuclei, ~100 milion nuclei freshly isolated from male mouse livers were 
resuspended in 1 mL of crosslinking buffer (10 mM HEPES pH 7.6, 25 mM KCl, 0.34 M 
sucrose, 2 mM MgCl2, 0.15 mM 2-mercaptoethanol) preheated to 30°C. Formaldehyde 
(37% stock solution) was added to give a final concentration of 0.8% (v/v), followed by 
incubation at 30°C for precisely 9 min with periodic mixing to crosslink the nuclei. Glycine 
was then added to a final concentration of 0.1 M to quench the crosslinking reaction at 
room temperature. Crosslinked nuclei were layered on 3 mL of fresh homogenization 
buffer and centrifuged at 4°C for 30 min at 25,000 RPM. Crosslinked nuclear pellets were 
resuspended in RIPA buffer (50 mM Tris-HCl pH 8.1, 150 mM NaCl, 1% (v/v) NP-40, 
0.5% (v/v) deoxycholic acid, Na salt; 0.1% (v/v) sodium dodecyl sulfate, and 1 tablet 
Roche cOmplete Protease Inhibitor Cocktail™ per 50 mL (Sigma, catalog number 
11697498001)). Nuclei were then sonicated in a Bioruptor Twin sonicater on high until 
chromatin was ~100-300 bp in length (80-100 cycles; 1 cycle = 30 sec on and 30 sec off). 
Sonicated material from vehicle and 3 h TCPOBOP-treated livers was then used for ChIP 
for histone marks (see below).  
 
To crosslink whole liver tissue, a third of each liver (previously snap-frozen in liquid 
nitrogen and stored at -80˚C) was retrieved and placed on ice for 5 min, followed by tissue 
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disruption in a glass Dounce homogenizer with 4 mL of cross-linking buffer (50 mM 
HEPES [pH 7.5], 100 mM NaCl, 1 mM EDTA, and 0.5 mM EGTA) containing protease 
inhibitors (Thermo Scientific Pierce Protease Inhibitor Tablets, EDTA-free). The tissue 
homogenate was passed through a 70-micron cell strainer in a petri dish. Additional cross-
linking buffer was added to the homogenizer to rinse out the remaining tissue and passed 
through the cell strainer. Formaldehyde was added to the homogenate to a final 
concentration of 1% and mixed rapidly in a conical tube. The mixture was rocked for 10 
min at 22˚C, followed by the addition of glycine to a final concentration of 0.125 M. The 
sample was rocked for 2 min at 22˚C and then centrifuged at 4˚C for 5 min at 2,500g. The 
pellet was washed twice in 10 mL of PBS, resuspended in 10 mL of lysis buffer 1 (50 mM 
HEPES [pH 7.5], 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% IGEPAL CA-630, 
0.25% Triton X-100, and protease inhibitors) and rocked for 10 min at 4˚C. The sample 
was then centrifuged at 4˚C for 5 min at 2,000g, and the resultant pellet was resuspended 
in 10 mL of lysis buffer 2 (200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 10 mM Tris-HCl 
[pH 8.0], and protease inhibitors) and rocked for 5 min at 4˚C. After another centrifugation, 
the pellet was resuspended in RIPA buffer to a final volume of 2 mL. The sample was 
transferred to a 15-mL TPX tube (Diagenode) containing 0.3 mL polypropylene beads 
(Diagenode), and sonicated for 35 cycles (30s on, 30s off) at 4˚C using a Bioruptor Pico 
sonicator (Diagenode). Sonicated material from vehicle-treated and 27 h TCPOBOP-




4.3.3 Chromatin Immunoprecipitation (ChIP) assay 
Protein A Dynabeads (Invitrogen #1002D) were used for all ChIP reactions in the 3 h 
exposure group and Protein A/G Magnetic Beads (Bimake #B23030) were used for in the 
27 h exposure group. For K4me1, K4me3, and K27ac, 15 μL of Dynabeads or 10 μL of 
Bimake beads were used. For K27me3, 10 μL of Dynabeads or 5 μL of Bimake beads were 
used. Beads were washed three times with 1 mL of blocking solution (0.5% (w/v) BSA in 
PBS). 300 uL of fresh blocking solution was then added to each tube containing beads, 
followed by antibody specific for histone H3 K4me1 (1.2 μg, Abcam ab8895), K4me3 (3 
μg, Abcam ab8580), K27ac (1.2 μg, Abcam ab4729), or K27me3 (2 μg, Abcam ab6002). 
Beads and antibody in blocking solution were incubated for 3 h at 4°C with rocking. Beads 
with bound antibody were washed three times with blocking solution and the following 
amounts of sonicated chromatin were then added: 10 μg for K27me3; 15 μg for K4me1, 
K4me3, and K27ac. ChIP reactions were incubated overnight at 4°C with rocking. The 
next day, ChIP samples were centrifuged at 2,000 RPM for 2 min at 4°C and washed with 
RIPA buffer three times. Next, ChIP samples were washed three times with RIPA 
containing 0.5 M NaCl, followed by a single wash with TE buffer. After the final wash, 50 
μL elution buffer (50 mM Tris-HCl, pH 8.1, 10 mM EDTA, 1% (v/v) SDS) was added and 
samples were incubated in a 65°C water bath for 35 min with periodic mixing. The 
supernatant containing eluted chromatin was adjusted to an NaCl concentration to 0.2 M 
and then incubated at 65°C to reverse crosslinks. RNase A (ThermoFisher E0531, 10 
mg/mL) was then added to a final concentration of 0.12 mg/mL and the samples were 
150 
 
incubated at 37°C for 30 min. Proteinase K (Bioline BIO-37084, 20 mg/mL) was added to 
a final concentration of 0.39 mg/mL and samples were incubated at 37°C for 2 h. Finally, 
DNA was purified using QIAprep 2.0 spin columns (Qiagen) according to the 
manufacturer’s manual and eluted in a final volume of 50 μL TE buffer. 
 
4.3.4 DNase-I hypersensitivity assay 
Frozen liver nuclei in nuclei storage buffer, corresponding to ~30 million nuclei, were 
rinsed in ice-cold Buffer A (15 mM Tris-Cl pH 8.0, 15 mM NaCl, 60 mM KCl, 1 mM 
EDTA pH 8.0, 0.5 mM EGTA pH 8.0, 0.5 mM spermidine, 0.3 mM spermine 
tetrahydrochloride) three times by adding 500 μL Buffer A and centrifuging at 1,500 RPM 
at 4°C for 10 min. Following the final rinse, nuclear pellets were resuspended in Buffer D 
(Buffer A + 6 mM CaCl2, 75 mM NaCl) pre-warmed to 37°C, to give a final concentration 
of 5.88 x 106 nuclei per mL. 32 units of DNase-I enzyme (RQ1 RNase-Free DNase, 1 U/μL 
(Promega, catalog number M610A) was added to 68 μL of pre-warmed Buffer D in a 2-
mL tube and incubated for 30 sec at 37°C. 850 μL of resuspended nuclei (5 x 106 nuclei) 
were added to the 2-mL tube and digested with DNase I for precisely 2 min. After 2 min, 
950 μL of Stop Buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.1% (v/v) SDS, 100 mM 
EDTA pH 8.0, 1 mM spermidine, 0.3 mM spermine tetrahydrochloride, 20 μg/mL RNase 
A) was added and the sample was immediately placed in a 55°C water bath. DNase-I 
digestion was done on 30 x 106 total nuclei per mouse, divided into 6 separate tubes, in 
parallel. Samples were then incubated at 55°C for >15 min. 5 μL proteinase K was then 
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added and samples were further incubated at 55°C overnight. The six parallel DNase 
digestions were pooled and the DNA was isolated by phenol:chloroform extraction. The 
final supernatant was adjusted to 0.8 M NaCl. Digested material was size-selected by 
sucrose gradient centrifugation, as follows. First, phenol:chloroform extracted material 
(11.4 mL) was loaded on a sucrose gradient containing following layers (bottom to top: 12 
mL of 20% sucrose buffer (20 mM Tris-HCl pH 8.0, 5 mM EDTA pH 8.0, 1 M NaCl, 
containing 20% sucrose) and 3 mL each of 17.5%, 15.0%, 12.5%, and 10.0% sucrose buffer, 
for a total volume of 34.5 mL. The sucrose gradient was then spun in an ultracentrifuge at 
25,000 RPM for 24 h at 25°C. Fractions (1.9 mL) were sequentially removed from the top 
of the gradient, and fractions number 7-11, corresponding to digested material ~100 bp to 
~1,000 bp in length, were isolated and pooled. Material from fractions 7-11 was further 
purified on a QIAprep 2.0 spin column (Qiagen) according to the manufacturer’s manual. 
Agencount AMPure XP bead purification was performed using the manufacturer’s 
protocol with ratios of 0.6x and 1.9x for double sized size-selection to obtain 125-400 bp 
DNA fragments. 
 
4.3.5 DNase-seq and ChIP-seq libraries, sequencing and data analysis 
DNase-seq was performed using two biological replicate pools for each of four treatment 
groups (males and females, TCPOBOP treatment for 3 h or 27 h, and time-matched vehicle 
controls). Each replicate pool consisted of DNA fragments released by DNase-I from n=3-
5 individual livers; released fragments from each individual liver in a separate DNase 
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digestion reaction were purified and then pooled and used for library preparation. ChIP-
seq was carried out on three biological replicates (chromatin prepared from individual 
mouse livers) for each ChIP target in male mice (TCPOBOP treatment for 3 h or 27 h and 
time-matched vehicle controls). Sequencing libraries were prepared from 5 ng of ChIP 
DNA or 5 ng DNase-I released DNA material using the NEBNext Ultra DNA Library Prep 
Kit for Illumina (New England Biolabs). Sequencing was performed at the New York 
Genome Center (New York, New York) on an Illumina HiSeq 2500 instrument. Single end 
sequence reads, 50 bp in length, were obtained for the DNase-seq samples, and 50 bp paired 
end reads were obtained for the ChIP-seq samples.  
 
Sequencing data was analyzed using a custom DNase-seq/ChIP-seq pipeline developed by 
Andy Rampersaud of this laboratory. The pipeline processes raw FASTQ files and outputs 
various quality control metrics, including FASTQC reports (FASTX-Toolkit v0.0.13.2), 
confirmation of read length, verification of the absence of read strand bias, quantification 
of contaminating adapter sequence (Trim_galore v0.4.2), and distributions of insert-size 
lengths (for paired-end read sequencing), as calculated and visualized using Picard 
(v1.123). Reads were mapped to the mouse genome (release mm9) using Bowtie2 (v2.2.6) 
(Langmead et al. 2009). All DNase-seq and ChIP-seq peak sets, discovered as described 
below, were filtered to remove ENCODE blacklisted regions (Consortium 2012) as well 





Regions of DNase hypersensitivity (DHS) were discovered as peaks identified by MACS2 
(v2.1.0.20150731) (Zhang et al. 2008) run using the options (--nomodel --shift -100 --
extsize 200), to inhibit read shifting, and (--keep-dup), to retain all reads contributing to a 
peak signal. Peaks were discovered for each of n=4 samples per TCPOBOP treatment 
condition, i.e. n=2 vehicle-treated and n=2 TCPOBOP-treated DNAse-seq samples x 4 
conditions (male and female at 3 h and 27 h). The 16 resultant DHS peak lists were merged 
using mergeBed (BEDtools) to give a single list of 60,739 peaks, based on the union of all 
DHS peak regions. This DHS set was used for all downstream analysis involving DHS. 
Genomic regions that were more open or more closed (|fold-change| > 2 and FDR < 0.05 
(Benjamini-Hochberg adjusted p-value)) following TCPOBOP treatment were discovered 
using diffReps (Shen et al. 2013) using the nucleosome option (200 bp window size) and 
setting (--frag) to zero for all comparisons. MACS2 peaks (DHS) that overlapped with a 
diffReps identified region, as determined by BEDtools (Quinlan and Hall 2010), were 
annotated as ∆DHS, while MACS2 peaks that did not overlap a diffReps region were 
designated static DHS. The full listing of DHS regions is reported in Supplemental Table 
S.4.1. 
 
ChIP-seq peaks were identified for three activating histone H3 marks, K4me1, K4me3, and 
K27ac, using MACS2 (v2.1.0.20150731) using the option (--keep-dup); all other 
parameters were set to the default option. For each chromatin mark, peak unions were 
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generated based on the union of peaks called in the n=12 male mouse liver ChIP-seq 
samples (n=3 vehicle, n=3 TCPOBOP at 3 h, and n=3 vehicle, n=3 TCPOBOP at 27 h). A 
single list of 78,340 K27ac peaks was generated using this method. Genomic regions that 
showed significantly differential ChIP-seq signals between vehicle-treated and 
TCPOBOP-treated samples were discovered separately at 3 h and at 27 h using the 
nucleosome option (200 bp window) in diffReps and |fold-change| > 2 and FDR < 0.05 
(Benjamini-Hochberg adjusted p-value) thresholds. The overlap between K27ac diffReps 
regions at 3 h or at 27 h and the list of 78,340 MACS2 peaks was determined using 
BEDTools, and peaks were annotated as differential K27ac peaks based on overlap results. 
K27ac MACS2 peaks that did not have a corresponding overlapping diffReps region were 
annotated as static K27ac peaks. K4me1 and K4me3 peaks were annotates using the same 
method as K27ac.  139,460 K4me1 peaks and 43,120 K4me3 peaks were identified based 
on the unions of n=12 sequenced samples for each mark. The full listings of all K27ac, 
K4me1, and K4me3 peak regions with annotations is found in Supplemental Table S4.2 
A-C. 
 
4.3.6 Peak normalization  
For DHS and ChIP-seq peak visualization in the UCSC genome browser 
(https://genome.ucsc.edu/), peaks were normalized using reads in peak per million mapped 
sequence reads (RiPPM) as a scaling factor. First, to obtain a comprehensive list of peaks 
for each data set (termed peak union), FASTQ files from individual replicates were 
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concatenated to produce combined replicates. For each data set, a vehicle-treated combined 
sample, TCPOBOP-treated combined sample, and all-replicates (vehicle-treated and 
TCPOBOP-treated) combined sample was generated. Peak calls from individual and 
combined samples were concatenated into a single file. BEDtools merge was then used to 
generate a single peak list. The fraction of reads in peaks for each sample was then 
calculated to obtain a scaling factor. Raw read counts were divided by the per-million 
scaling factor to obtain the RiPPM normalized read counts. 
 
4.3.7 TAD definitions and grouping 
Topologically associated domains (TADs) were those defined for mouse liver (Vietri 
Rudan et al. 2015). TAD regions were identified that contained at least one regulated gene 
whose expression was altered by TCPOBOP in either male or female liver at either time 
point. The number of genes in each TAD that were up regulated or were down regulated 
was counted for each condition of TCPOBOP exposure (male and females at each time 
point), allowing us to separate TADs into three distinct groups for each exposure condition: 
TADs that contain at least one up regulated gene but no down regulated genes (up-only 
TAD), TADs that contain at least one down regulated gene but no up regulated genes 
(down-only TAD), and TADs that contained both up and down regulated genes (mixed 





4.3.8 TCPOBOP-responsive gene sets 
Lists of TCPOBOP-responsive RefSeq and lncRNA genes were generated as described in 
Chapter 3, based on a gene list comprised of 24,197 RefSeq genes and 3,152 multi-exonic 
lncRNA genes. This list of candidate gene targets was used for peak mapping (see below). 
Each gene was mapped to a TAD region based on the location of its transcription start site 
(TSS). TCPOBOP-responsive lncRNA genes were defined by |fold change| >2 and 
adjusted p-value (FDR) <0.05; responsive RefSeq genes were defined by a |fold change| 
>1.5 and adjusted p-value (FDR) <0.001, the same as in Chapter 3. Additionally, genes 
that are downstream targets of 10 known CAR-dependent upstream regulators – cyclin D1, 
p53, p21, FoxO1, FoxM1, Rb, b-catenin, E2f, Yap, Myc – which were previously identified 
by Ingenuity Pathway Analysis in Chapter 3 (Lodato et al. 2017), were flagged and used 
for further downstream analysis. 
 
4.3.9 DHS and K27ac peak mapping 
Genomic regions that show a TCPOBOP-induced change in chromatin accessibility, i.e., 
∆DHS that open or that close following TCPOBOP exposure, as well as static DHS, were 
mapped to mouse liver TAD regions for each given experiment (male and female, 3 h or 
27 h TCPOBOP exposure). For each experiment, we counted the number of up regulated 
and down regulated genes within each TAD that contained a DHS (an opened ∆DHS, a 
closed ∆DHS, or a static DHS). DHS where then classified based on their DHS status 
157 
 
(opened, closed, or static) and if they were found within a TAD that also contained a 
regulated gene, or not. 
 
A single putative gene target was assigned for each DHS, and separately, for each K27ac 
peak, using BEDtools, to map the above lists of 60,739 DHS peaks and 78,340 K27ac 
peaks to the nearest gene TSS within the same TAD. Full listing of mapping results can be 
found in Supplemental Table S4.3.  
 
Regions of interest based on their DHS and K27ac patterns were defined genome wide. 
First, the overlap of the sets of 60,739 DHS and 78,340 K27ac peaks was determined using 
BEDtools. Given DHS, by their definition, lack histone proteins, DHS and K27ac regions 
that were <1000 bp (1 kb) apart were considered overlapping. Overlapping regions that 
contain both a static DHS and a static K27ac peak following TCPOBOP treatment were 
termed ‘stable active regions’, while ∆DHS that also overlapped with a ∆K27ac were 
termed ‘dynamic active enhancers’. Full listing of dynamic active enhancers and stable 
active regions can be found in Supplemental Table S4.3. 
 
4.3.10 DHS and K4me3 clustering 
∆DHS were grouped by k-means clustering based on K4me3 signal in a 2-kb window 
centered at the DHS midpoint using deepTools.  For 3 h ∆DHS, two clusters (k=2) was 
used to differentiate regions with low K4me3 signal (putative enhancer regions) from 
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regions with high K4me3 (putative promoter regions).  For 27 h ∆DHS, three clusters (k=3) 
was used to distinguish low and high K4me3 signal, like 3 h ∆DHS, and an additional 
cluster with intermediate K4me3 signal. Three clusters was not used for analysis of 3 h 
∆DHS due to two subsequent resulting clusters being indistinguishable. Full listing of 
K4me3 clustering results can be found in Supplemental Table S4.4. 
 
4.3.11 Statistics 
Fisher exact test was implemented in the analysis package R to assess the statistical 
significance of enrichment calculations. Where noted, student t-test was implemented 
using Prism 7 (Graphpad) to assess pair-wise relationships.  
 
4.4 Results 
4.4.1 TAD boundaries separate up and down regulated genes 
Mammalian genomes are organized at multiple levels, including functional segmentation 
into large megabase-scale DNA loops, called topologically associating domains (TADs). 
TADs function to insulate genomic regions by allowing intra-TAD, but not inter-TAD, 
interactions (Oti et al. 2016) and provide a context for potential coordinated transcriptional 
responses to stimuli (Le Dily and Beato 2015). To investigate whether TCPOBOP-
responsive genes cluster in TAD regions, we used the ~3,600 sets of TAD boundaries 
established for mouse liver (Vietri Rudan et al. 2015) to identify TADs that contain genes 
that respond to TCPOBOP exposure. ~70-80% of TCPOBOP-responsive TADs contain 
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only a single regulated gene (Fig. 4.1A). The other ~20-30% of responsive TADs contain 
multiple (2 to 12) responsive genes, encompassing 41-52% of TCPOBOP-responsive 
genes (Fig. 4.1B, Table 4.2). The TADs that have multiple TCPOBOP-responsive genes 
were further classified by the concurrence of gene responses within the TAD (Table 4.2). 
~64-81% of TADs with multiple responsive genes show concurrent regulation, with 46-
77% having genes that are up regulated without any down regulated genes, and 4-30% 
having genes that are down regulated without any up regulated genes (Table 4.2, 
Supplemental Table S4.5). 
 
4.4.2 DHS dynamically open and close and cluster in TADs with co-responsive 
genes 
To ascertain whether TCPOBOP treatment alters liver chromatin accessibility, we carried 
out DNase I hypersensitivity analysis (DNase-seq) to identify open chromatin regions as 
DHS in liver nuclei harvested from TCPOBOP-treated mice and vehicle-treated controls. 
Genomic regions that showed statistically significant differences in accessibility to DNase-
I cleavage following TCPOBOP treatment (∆DHS) were identified at two time points (3 h 
and 27 h) in both male and female mouse liver (Fig. 4.2 A-D and Table 4.3). TCPOBOP 
induced DHS opening as well as DHS closing, with some ∆DHS regions responding early 
(3 h) and others responding late (27 h) to TCPOBOP treatment (Table 4.5, Fig. 4.2 A-B) 
were identified. In both sexes, many more ∆DHS were found in the 27 h TCPOBOP-treated 
livers, which is consistent with the larger number of genes and greater magnitude of gene 
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induction responses reported in Chapter 3 for 27 h compared to 3 h TCPOBOP exposure 
(Fig. 4.2 A-B). Further, a majority ∆DHS were unique to one sex (Fig. 4.2 C-D and Table 
4.5), consistent with the sex-differences in gene responses described in Chapter 3.  
 
∆DHS were grouped based on whether they mapped to a TAD that contains only up 
regulated genes, only down regulated genes, a mixture of up and down regulated genes, or 
no regulated gene (Table 4.3, Fig. 4.2 E-F). At both 3 h and 27 h, a majority of ∆DHS are 
not in a TAD with a regulated gene (Fig. 4.2 E-F, grey). Of the ∆DHS that open after 3 h, 
and are within a TAD containing a regulated gene(s), 76-90% are associated with up 
regulated genes (Table 4.3, Group_1A). Many more ∆DHS were identified after 27 h 
TCPOBOP treatment, and a higher fraction of these ∆DHS (40-45%) mapped to TADs 
with TCPOBOP-responsive genes (Fig. 4.2 E-F), primarily TADs with up regulated genes 
in the case of ∆DHS that opened (Table 4.3, Group_1A) , and TADs with down regulated 
genes for ∆DHS that closed (Table 4.3, Group_3B). These findings indicate that 
TCPOBOP-associated ∆DHS regions are generally associated with positive regulation of 
gene expression. 
 
4.4.3 ∆DHS responses precede changes in gene expression 
Unexpectedly, a majority of the ∆DHS that open following TCPOBOP exposure were 
found in TADs that do not contain a TCPOBOP-responsive gene (Fig. 4.2 E-F and Table 
4.3, Group_2 and Group_4). We considered the possibility that the gene targets of these 
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∆DHS (putative enhancers; see below) might respond more slowly to TCPOBOP than their 
associated ∆DHS regions. Indeed, we found that a substantial fraction of the 3 h ∆DHS 
without any 3 h TCPOBOP-responsive genes within the same TAD are in TADs that 
contain one or more TCPOBOP-responsive genes at 27 h (Fig. 4.2 G; 128 out of 366 such 
∆DHS in male liver (37.5%), and 102 out of 358 such ∆DHS in female liver (28.5%)). 
Similarly, a subset of the 3 h-closing ∆DHS within a TAD that do not contain a regulated 
gene at 3 h acquire one or more responsive genes by 27 h (Fig. 4.2 G; 9 of 62 such ∆DHS 
(14.5%) in male liver, and 32 of 87 such ∆DHS (37%) in female liver). Thus, gene 
expression changes lag behind chromatin opening or closing for a subset of 3 h TCPOBOP-
responsive ∆DHS. Furthermore, in male liver, 92 of the 128 ∆DHS that open with a delayed 
gene response were in a TAD that contained an up regulated gene(s), while 3 of the 9 ∆DHS 
that close with a delayed gene response were in a TAD that contained a down regulated 
gene(s) (Fig 4.2 H). Similarly, in female liver, 83 of the 102 ∆DHS that open with a delayed 
gene response were in a TAD that contained an up regulated gene(s), while 22 of the 32 
∆DHS that close with a delayed gene response were in a TAD that contained a down 
regulated gene(s) (Fig. 4.2 H). Several TADs that contain TCPOBOP-induced DME gene 
families also contain many ∆DHS, including TAD3479, which contains 9-12 inducible 
Cyp2c genes and up to 38 ∆DHS (Table 4.4, Supplemental Table S4.5). Other highly active 
TADs that contain DME gene families include TAD110, which contains Ugt1a genes; 
TAD694, which contains Gstm genes; TAD1156, which contains Cyp3a genes; and 




4.4.4 ∆DHS are enriched nearby TCPOBOP-responsive genes 
Putative gene targets for each DHS were assigned by mapping the DHS to the nearest gene 
transcription start site (TSS) within the same TAD, considering both RefSeq genes and 
liver-expressed multi-exonic lncRNA genes (see Methods, Supplemental Table S4.1). Next, 
we examined the relationship between changes in chromatin accessibility and gene 
expression for the set of 121 ∆DHS that open in both sexes at 3 h and remain open at 27 h 
(i.e., ∆DHS common to all 4 TCPOBOP treatments; Table 4.5, Supplemental Table S4.1). 
These ∆DHS, whose induced open chromatin state persists for at least 24 h in both sexes, 
showed an exceptionally strong, 121-fold enrichment (p<E-43; Fisher exact test) for genes 
that showed a common response to TCPOBOP in all four treatments (Table 4.6). 27 of 
these 121 ∆DHS map to 19 TCPOBOP-responsive genes, including 6 lncRNA genes 
(Table 4.7). Protein-coding RefSeq genes in this group include Cyp2b10, Cyp3a11 and Por, 
all known targets of TCPOBOP-activated CAR. 
 
Further, in each of the 4 TCPOBOP experiments, we observed a strong enrichment of 
∆DHS that open for up regulated genes, as compared to a background set comprised of 
static DHS (Table 4.6). Similarly, in both sexes, ∆DHS that close were strongly enriched 
for genes that are down regulated at 27 h. There was also a weak enrichment of ∆DHS that 
close for genes that are down regulated in at 3 h in females, but not in males (Table 4.6). 
These findings support the proposal that these sets of TCPOBOP-responsive ∆DHS 
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encompass regulatory elements (enhancers and promoters) that activate by TCPOBOP 
treatment and regulate TCPOBOP-stimulated gene responses. 
 
4.4.5 ∆DHS Open and Close nearby TCPOBOP-responsive HCC genes 
We previously reported a striking male-bias for TCPOBOP activation of CAR-dependent 
hepatocellular carcinoma promoting pathways, specifically after 27 h TCPOBOP exposure 
(Lodato et al. 2017). One hypothesis is that this sexually dimorphic genic response is driven 
by a corresponding male bias ∆DHS response. To test this hypothesis, we counted the 
number of ∆DHS that map to downstream gene targets of a set of 10 known CAR-
dependent HCC upstream regulators (see Methods and Chapter 3) in both male and female 
mouse liver (Fig. 4.2 I). Surprisingly, we observe no significant sex bias in the number 
∆DHS that map to these genes (enrichment score = 1.0, p = 0.97; Fig. 4.2 I, left), even if 
we restrict the genes to only those HCC downstream targets that are responsive to 
TCPOBOP (enrichment score = 1.07, p=0.58; Fig. 4.2 I, right).  
 
4.4.6 Chromatin marks flanking ∆DHS 
To better understand the dynamic changes in the epigenome after TCPOBOP exposure, we 
performed genome-wide ChIP-seq analysis of TCPOBOP-treated mouse liver chromatin, 
and vehicle-treated controls, to map three histone-H3 chromatin marks commonly seen at 
promoters or enhancers flanking DHS (Shlyueva et al. 2014): K4me3, which is commonly 
found at promoters; K4me1,which marks distal enhancer regions; and K27ac, which marks 
164 
 
active enhancers when found in combination with K4me3, or active promoters when found 
in combination with K4me1 (Mann et al. 2011, Abdel-Hafiz and Horwitz 2015). We used 
the K4me3 mark intensities in a 2-kb window surrounding each TCPOBOP-induced ∆DHS 
region to cluster the sets of ∆DHS found at 3 h and 27 h. Two clusters of ∆DHS were 
obtained from the 3 h TCPOBOP dataset, one with strong K4me3 marks (promoter-like 
∆DHS) and one with weak K4me3 marks (enhancer-like ∆DHS) (Fig. 4.3A). A third 
cluster (intermediate K4me3 marks; weak promoter-like ∆DHS) was obtained at 27 h (Fig. 
4.3B) in addition to strong and weak K4me3 clusters, as was found at 3 h. At 3 h, the 
median distance from the ∆DHS to the nearest TSS was 0 bp and 16 kb for the strong and 
weak K4me3-marked ∆DHS clusters (Fig. 4.4), while at 27 h, the median distance was 0 
bp, 1 kb, and 25 kb for the weak, intermediate, and strong K4me3 clusters, respectively 
(Fig 4.4). These results are consistent with the K4me3-marked ∆DHS being promoter-like 
∆DHS (Shlyueva et al. 2014). The ∆DHS distal to TSS had the highest K4me1 signals at 
both time points, consistent with their designation as enhancer-like ∆DHS (Fig. 4.3 A-B). 
Both ∆DHS classes (i.e. promoter-like and enhancer-like) showed strong K27ac, consistent 
with their being active promoters and active enhancers, respectively.    
 
Significant changes in K27ac mark intensity (∆K27ac) were seen in TCPOBOP-exposed 
liver chromatin, with ~1,200 sites showing an increase and ~500-600 sites showing a 
decrease in this mark after 3 h or 27 h (Table 4.8, Supplemental Table S4.2 A). Many fewer 
K4me1 sites were responsive to TCPOBOP, with only 324 sites showing a significant 
165 
 
change after 3 h, and 366 sites changing at 27 h (Table 4.8, Supplemental Table S4.2 B). 
K4me3 is the most stable, with only 188 sites at 3 h and 87 sites at 27 h showing significant 
changes following TCPOBOP exposure (Table 4.8, Supplemental Table S4.2 C). Only a 
fraction of these ∆K27ac sites were at or nearby (within 1 kb) ∆DHS; many more were at 
or nearby static DHS at both 3 h and 27 h and about ~50% were not found near any DHS 
(Fig. 4.5 A). Likewise, a majority of ∆DHS were associated with static K27ac at 3 h or no 
K27ac at 27 h (Fig. 4.5 B). Since K27ac plus DHS mark active promoters and enhancers, 
this finding suggests that TCPOBOP activation of liver regulatory elements can be 
manifested in several ways: by an increase in K27ac marks at DHS that are constitutively 
open (static DHS), and by chromatin opening (∆DHS) at genomic regions that in many 
cases are already marked by K27ac, but in some cases are associated with a further increase 
in K27ac (∆K27 in combination with ∆DHS) (Fig. 4.5 A-B). 
 
4.4.7 Activated enhancers map to responsive genes 
DHS and K27ac were used in combination with the enhancer DHS definition described 
above (i.e. DHS with nearby K27ac) to define (1) dynamic enhancers, i.e. genomic regions 
whose accessibility and K27ac were both induced (∆DHS and ∆K27ac) following 
TCPOBOP treatment; and (2) static active enhancers (marked by both a static DHS and a 
static K27ac mark; see Methods) (Fig. 4.5 C). All active regions, defined by the presence 
of a DHS and a K27ac peak (i.e. static and ∆DHS in combination with either static or 
∆K27ac), were mapped to the all genes within the same TAD. The number of TCPOBOP-
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responsive genes that had only static active enhancers within the same TAD, and genes 
that had both static active regions and dynamic active enhancers were counted and are 
reported at both 3 h (Fig. 4.5 D) and 27 h (Fig. 4.5 E). There was a strong enrichment, at 
both 3 h (59-fold; p<E-14, Fisher exact test) and 27 h (18-fold; p<E-141), of the responding 
genes for a mapped dynamic enhancer as compared to a static active enhancer when only 
the single nearest gene target within the TAD was considered (Fig. 4.5 F). There was an 
equally strong enrichment of the up regulated genes for a mapped dynamic enhancer as 
compared to inactive regions (i.e. static DHS without a K27ac mark) at 3 h (46-fold; p<E-
27) and also at 27 h (17-fold; p<E-134) (Fig. 4.5 F). 
 
Genes with dynamic enhancer sites within their TADs represent only a small subset of the 
total number of genes up regulated at each time point (Fig. 4.5 D, brown). Thus, 24 out of 
the 67 ∆DHS-∆K27ac dynamic active enhancer sites map to 34 of the 138 genes up 
regulated at 3 h (Fig. 4.5 D, brown), while 199 out of the 480 ∆DHS-∆K27ac dynamic 
active enhancers map to 255 of the 708 genes up regulated at 27 h (Fig. 4.5 E). Genes with 
associated ∆DHS-∆K27ac dynamic active enhancers within their TADs, however, were 
more strongly induced by TCPOBOP than those genes that were targeted by static active 
enhancers alone (Fig. 4.5 G). Examples of dynamic active enhancers and stable active 
regions were visualized near three highly TCPOBOP-inducible genes described in Chapter 
3, Cyp2b10, lnc_5998 and Cyp3a11 (Fig. 4.6 A-B). Cyp2b10 and an induced upstream 
lncRNA, lnc_5998, are found on chromosome 7 within TAD1421, while Cyp3a11 is found 
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on chromosome 5 within TAD1156. Six dynamic active enhancers are found upstream of 
Cyp2b10, three of which are within the gene body of lnc_5998 (Fig. 4.6 A, yellow arrow 
heads). Two dynamic active enhancers are proximal to the Cyp3a11 TSS (Fig. 4.6 B, 
yellow arrow heads) while three static DHS are found upstream (negative strand) of the 
TSS, two of which are flanked by ∆K27ac (Fig. 4.6 B, purple arrow heads) and one of 
which is flanked by static K27ac (Fig. 4.6 B, blue arrow heads, stable active region).  
 
4.4.8 Genes responding to 3 h TCPOBOP exposure prior to enhancer activation 
As shown above, a minority of TCPOBOP-responsive genes have a dynamic active 
enhancer in the same TAD at either 3 h or 27 h (Fig. 4.5 D-E, orange). One hypothesis is 
that the early induction of these genes by TCPOBOP is mediated by static active enhancer 
regions, and that other enhancer regions become active after longer exposure to TCPOBOP. 
To test this hypothesis, the 138 genes induced by TCPOBOP at 3 h were mapped to the 
active regions defined after 27 h of TCPOBOP exposure. Remarkably, 90 out of the 138 
genes acquire a dynamic active enhancer within their TAD boundaries by 27 h, 
representing nearly three times as many genes that had a dynamic active enhancer within 
their TAD at 3 h (Fig. 4.7 A). An example of this can be seen in TAD2089, located on 
chromosome 10, which contains the highly induced protein coding gene Gadd45b (Fig. 4.7 
B). At 3 h, static active enhancer regions, characterized by static DHS and static K27ac, 
are found ~25-50 kb downstream of Gadd45b (Fig 4.7 B, blue arrow heads). ∆DHS regions 
that respond to TCPOBOP at 3 h are flanked by low, static levels of K27ac at 3 h (Fig. 4.7 
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B, green arrow heads). At 27 h, however, several dynamic active enhancers are found 
within this same cluster as the static enhancer regions, and show clear increases in K27ac 
associated with strong ∆DHS (Fig. 4.7 B, green arrow heads). A promoter-associated 
∆DHS (K4me3 cluster 2 at 27 h, see above), was also identified only at 27 h and is flanked 
by a strong ∆K27ac peak (Fig. 4.7 B, black arrow head). The emergence of delayed 
dynamic active enhancers within TADs that contain genes regulated early is associated 
with further induction of the regulated gene at 27 h. 20 out of the 54 genes that respond 
before dynamic active enhancers appear within their TADs show a further increase in the 
fold change of their induction at 27 h (>2-fold increase) , including Gadd45b (Fig. 4.7 C).  
 
4.5 Discussion  
Epigenomic reorganization has been characterized following activation of several nuclear 
receptors, including estrogen receptor and glucocorticoid receptor (Nagaich et al. 2004, 
Siersbaek et al. 2011, Voss et al. 2011, Grontved et al. 2013, Abdel-Hafiz and Horwitz 
2015, Cucchiara et al. 2017), but the genome-wide chromatin remodeling induced by CAR 
activation has not been investigated. Here, we provide a detailed analysis of the rapid 
epigenomic remolding of mouse liver chromatin following exposure to the mouse CAR 
specific agonist ligand TCPOBOP for 3 h or 27 h. We found that ~50% of TCPOBOP-
responsive genes cluster in TADs (Fig. 4.1 B), and TCPOBOP-induced genes and 
TCPOBOP-repressed genes were generally found in separate TADs (Table 4.2). DNase-
seq analysis identified several thousand genomic regions where TCPOBOP exposure 
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induces chromatin opening or chromatin closing (Table 4.3, Supplemental Table S4.1). 
Mapping of these regions to the closest gene within the same TAD revealed a strong 
enrichment for ∆DHS that open mapping to genes that are induced by TCPOBOP, and 
∆DHS that close mapping to genes that are repressed (Table 4.6, Supplemental Table S4.1). 
We also observed a temporal relationship between DHS opening and closing and gene 
regulation; some ∆DHS that open or close at 3 h map to genes that respond to TCPOBOP 
only after 27 h (Fig 4.2 G) while some genes that are induced by TCOPOBOP respond 
before new enhancers are activated (Fig. 4.7). Finally, ChIP-seq analysis of three activating 
histone modifications (K4me1, K4me3, and K27ac), combined with DNase-seq data, was 
used to identify active enhancer and promoter regions that respond to CAR activation in 
association with putative target gene expression (Fig. 4.3, Fig. 4.4). We found that active 
enhancers cluster in active TADs that contain multiple dysregulated Cyp gene family 
members, including TAD1421, which contains Cyp2b10 and lnc_5998, and TAD1156, 
which contains several TCPOBOP-responsive Cyp3a genes (Fig. 4.6, Table 4.4).  
 
4.5.1 Regulated genes cluster in TADs 
We found that ~50% of TCPOBOP-responsive genes cluster with other, similarly 
responsive genes in TAD regions (Fig 4.1, Table 4.2). TADs function to organize mega-
base sized sections of the genome into three-dimensional compartments (Dixon et al. 2016), 
which enable linearly distant chromosomal regions to interact via a series of DNA loops 
that segment each chromosome (Faure et al. 2012, Rao et al. 2014, Nora et al. 2017). TADs 
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insulate regulatory elements within a TAD from neighboring genes in adjacent TADs, 
thereby increasing the specificity of regulatory interactions (Vietri Rudan et al. 2015, Oti 
et al. 2016). TADs that contain the Cyp2b, Cyp2c and Cyp3a gene families were 
particularly responsive to the transcriptional and epigenetic stimulatory actions of 
TCPOBOP, as exemplified by TAD3479, which contains the Cyp2c cluster with its 12 
TCPOBOP-responsive genes and a total of 38 ∆DHS across the four TCPOBOP exposure 
conditions we investigated (Table 4.4, Supplemental Table S4.5). Clustering of Cyps into 
TAD regions that can be rapidly activated following xenobiotic exposure may be 
advantageous from an evolutionary perspective, as it allows for a limited number common 
regulatory elements to induce multiple but distinct genes within a family, and thereby allow 
for induction of a broad range of xenobiotic metabolic activities following xenobiotic 
exposure. 
 
Whereas Cyp2b10 was highly induced by TCPOBOP along with several ∆DHS within 
TAD1421, Cyp2b9 and Cyp2b13, also found in TAD1421, did not respond to TCPOBOP, 
even after 27 h of TCPOBOP exposure (See Chapter 3). Presumably, the latter two Cyp2b 
genes are shielded from the DNA looping that is expected to bring the promoter of Cyp2b10, 
but not promoters of the other, nearby Cyp2b genes, in contact with the ∆DHS/putative 
regulatory elements (see below) that lead to the rapid and robust activation of Cyp2b10. 
Interestingly, others have reported that Cyp2b9 and Cyp2b13 become TCPOBOP-inducible 
after 4 days of exposure (Cui and Klaassen 2016), suggesting a requirement for more 
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complex epigenetic reprogramming than for Cyp2b10, perhaps related to the preferential 
epigenetic suppression of Cyp2b9 and Cyp2b13 (but not Cyp2b10) in male as compared to 
female mouse liver (Sugathan and Waxman 2013). Other DME gene families also show 
clustered induction patterns. Thus, in the cluster of glutathione S-transferase family Gstm 
genes in chromosome 3/TAD694, Gstm3 is strongly induced by TCPOBOP by 3 h in both 
male and female liver, whereas other Gstm genes in the same TAD, including Gstm1, 
Gstm2, and Gstm4, respond at 27 h, while Gstm6 and Gstm7, also found in TAD694, are 
unresponsive (Table 4.4, Supplemental Table S4.5). It is not certain what factors determine 
the specificity of TCPOBOP for particular genes within a responsive TAD or cause the 
delayed induction of a subset of genes within a highly active cluster, but the underlying 
basal chromatin state may contribute to the time differences in responsiveness, as suggested 
by other studies of time-dependent responses to hormonal stimuli in the same mouse liver 
model (Lau-Corona et al. 2017). 
 
4.5.2 ∆DHS as positive regulators of gene expression 
TCPOBOP-responsive ∆DHS, like the TCPOBOP induced and repressed genes discussed 
above, cluster into highly active TAD regions (Supplemental Table S4.5). Mapping of 
these ∆DHS to TCPOBOP-responsive RefSeq and multi-exonic lncRNA genes in the same 
TAD, on a per experiment basis (e.g. mapping ∆DHS in males treated with TCPOBOP for 
3 h to genes regulated in males treated with TCPOBOP for 3 h, etc.) revealed a strong 
enrichment of ∆DHS that open for genes that are induced (Table 4.6, Supplemental Table 
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S4.1). Further, ∆DHS that close were enriched for genes that were repressed by TCPOBOP 
(Table. 4.6, Supplemental Table S4.1). When examining whole TADs, ∆DHS that open 
tend to be in TADs with >1 induced gene but no repressed gene(s), while ∆DHS that close 
tend to be in TADs with >1 repressed gene but no induced gene(s) (Table 4.3, Supplemental 
Table S4.5). Together, these findings suggest these ∆DHS are positive regulators (i.e., 
promoters and enhancers) of gene expression, and that factors bound to these regions, e.g., 
TCPOBOP-activated CAR, stimulate increases in gene transcription. Exactly how these 
chromatin regions open or close chromatin is not yet known, but likely involves the 
SWI/SNF chromatin remodeling complex (Tang et al. 2010). The rapid opening of ∆DHS 
within 3 h of TCPOBOP treatment may, in part, be driven by direct CAR binding. 
Supporting this proposal, TCPOBOP is a highly specific agonist ligand of CAR, and further, 
there is a well characterized CAR binding motif (DR4, PBREM sequence) centered within 
the cluster of ∆DHS that open upstream of Cyp2b10 (Honkakoski and Negishi 1997). 
Moreover, PXR, a NR closely related to CAR, binds to DR4 motifs upstream of several 
DME genes that are induced in common by CAR and PXR, such as Cyp3a11 and Gstm3 
(Cui et al. 2010), where we also found several TCPOBOP-activated ∆DHS. Given the 
specificity of TCPOBOP for CAR and the short time frame (within 3 h) for the early ∆DHS 
responses, it seems unlikely that secondary transcriptional responses (i.e. induction of a 
CAR gene target) contribute to chromatin opening at this time point. Of note, direct binding 
of other NRs to closed chromatin has been associated with chromatin remodeling, 
including GR and PPAR (Nagaich et al. 2004, Siersbaek et al. 2011, Voss et al. 2011). The 
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~1,000 ∆DHS that do not open until after 27 h of TCPOBOP exposure (Table 4.5) may be 
the result of secondary responses, which could include epigenetic actions by one or more 
of the few hundred multi-exonic lncRNA genes that are rapidly induced by TCPOBOP in 
mouse liver (Lodato et al. 2017); these include lnc_5998 (Fig. 4.6 A). 
 
4.5.3 Active enhancers target Cyp2b10 and other induced genes 
Histone H3 K4me3 is a mark associated with promoters in mammalian tissues while 
K4me1 and K27ac mark active enhancers (Barski et al. 2007, Sugathan and Waxman 2013, 
Shlyueva et al. 2014). We used DNase-seq in combination with ChIP-seq targeting K4me3 
to define enhancer and promoter regions that become more active (∆DHS) in mouse liver 
following TCPOBOP exposure.  Static enhancers (static DHS and static K27ac) and 
dynamic enhancers (∆DHS and ∆K27ac) were defined using DNase-seq and ChIP-seq 
targeting K27ac in vehicle and TCPOBOP-treated mouse liver (Fig. 4.5 C, Supplemental 
Table 4.3). Mapping dynamic enhancer regions and static active enhancers to the nearest 
gene TSS within the same TAD, we observed a striking enrichment for dynamic enhancers 
as compared to stable active regions, at both 3 h and 27 h of TCPOBOP exposure (Fig. 4.5 
F). Based on a detailed analysis of specific genomic loci, we report several of these 
dynamic enhancer regions are likely targeting Cyp2b10 (Fig 4.6 A), Cyp3a11 (Fig. 4.6 B), 
and other highly responsive genes. The increased in K27ac at these sites is likely due to 
the histone acetyl transferase p300 (Pradeepa et al. 2016). Histones surrounding upstream 
putative enhancer regions of CYP3A4 were recently shown to be modified following 
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treatment with the human PXR ligand rifampicin for 48 h, in a PXR-dependent manner, in 
human-derived LS174T cells (Yan et al. 2017). It was also shown that PXR recruits the 
histone acetyltransferase p300 and the nuclear receptor co-activator NCOA6 to these sites 
through protein-protein interactions, and both p300 and NCOA6 are necessary for the 
observed rifampicin-mediate histone mark remodeling (Yan et al. 2017).  
 
4.5.4 Conclusions 
We present a genome-wide view of the dynamic epigenomic changes that occur in mouse 
liver following short exposures to the mouse CAR agonist ligand TCPOBOP, and we use 
mouse liver TAD definitions to map changes in epigenetic elements to putative gene targets 
to discovered DNA regulatory elements that respond to drug treatment. We observe a 
coordinated regulation of target gene families grouped by TAD and associated DHS that 
open rapidly. Lastly, we report increases in the activating histone mark K27ac that are 
associated with ∆DHS at putative promoter regions that likely target several highly 




Fig. 4.1  TCPOBOP-responsive genes cluster in TADs. A. Percent of 
topologically associating domains (TADs) that contain either a single TCPOBOP-
responsive gene (black) or multiple TCPOBOP-responsive genes (red) in male or female 
liver treated with TCPOBOP for 3 h or 27h.  B. Percent of TCPOBOP-responsive genes 
found within TADs that contain either a single TCPOBOP-responsive gene (black striped) 
or multiple TCPOBOP-responsive genes (red striped). Approximately 50% of TCPOBOP-
responsive genes cluster in TADs together. See Supplemental Table S4.5 for a full listing 





Fig. 4.2 ∆DHS respond to TCPOBOP in mouse liver. A-D. Overlap analysis of 
∆DHS regions discovered in male and female liver after TCPOBOP treatment for 3 h or 
27 h. ∆DHS were determined for each experiment based on the full list of 60,739 DHS (see 
Methods). Only ∆DHS that responded in the same direction were considered overlapping 
(e.g. ∆DHS that open in males at 3 h and ∆DHS that open in males at 27 h; ∆DHS that 
close  in males at 3 h and ∆DHS that close in males at 27 h, etc.). E-F. ∆DHS were assigned 
to TAD regions based on their location in the genome. The number of TCPOBOP-
responsive genes within the same TAD was then counted for each ∆DHS. A minority of 
∆DHS had a TCPOBOP-responsive gene within the same TAD (black), while the majority 
did not (grey). G. Number of ∆DHS identified in male and female liver at 3 h that did not 
have a 3 h TCPOBOP-responsive gene in the same TAD (grey bars in Fig. 4.2 E-F) but 
that do have one or more responsive genes at 27 h in the same TAD (white). H. Direction 
of regulation for genes that show a delayed responsive relative to ∆DHS within the same 
TAD (white bars in Fig. 4.2 G) was analyzed. Genes that responded in the same direction 
at 27 h as their co-TAD ∆DHS (blue) and genes that responded in the opposite direction 
(yellow) were counted. I. ∆DHS that map to genes targets of 10 CAR-dependent HCC 
upstream regulators, as defined in Chapter 3, were counted. Despite dysregulation of these 
genes showing a strong male-bias, ∆DHS mapped to either all downstream genes (right) or 
dysregulated downstream genes at the same frequency in both male and female mice. E.S. 
= Enrichment Score (ratio of number of female ∆DHS that map to HCC gene to all female 
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Fig. 4.3  Promoter-like and Enhancer-like ∆DHS. Shown is a heatmap of 
normalized sequence reads for 3 h male ∆DHS regions (A) and 27 h ∆DHS regions (B). 
DNase-seq signals (black), and ChIP-seq signal for K4me1 (orange), K4me3 (blue), and 
K27ac (green) at ∆DHS, in vehicle treated (Vh) and TCPOBOP-treated (TC) liver, were 
visualized in a 2 kb window centered on the ∆DHS midpoint (+1 kb downstream and –1 
kb upstream) using deepTools (see Methods). ∆DHS were clustered by the K4me3 ChIP-
seq signal via k-means using deepTools. A. Two clusters were used to separate ∆DHS at 3 
h into one promoter-like cluster (cluster 1, high K4me3) and one enhancer-like cluster 
(cluster 2, low K4me3). B. Three clusters were used to separate ∆DHS at 27 h into two 
promoter-like clusters (cluster 1, high K4me3; cluster 2, intermediate K4me3) and one 
enhancer-like cluster (cluster 3, low K4me3). Scales shown are linear intensity values 






Fig. 4.4 Distance from ∆DHS to the nearest TSS.  ∆DHS were mapped to the 
nearest gene within the same TAD. Shown are box plots of the genomic distance was 
determined for each ∆DHS in each promoter-like and enhancer-like cluster defined in Fig. 
4.3. Values shown above each box are the median distances from the DHS within the 











Fig 4.5  Static active and dynamic active enhancers. A. Shown is the number of 
differential K27ac peaks (∆K27ac) that overlap with ∆DHS, static DHS (sDHS), or no 
DHS, determined using BEDtools. Given DHS, by their definition, lack histone proteins, 
DHS and K27ac peaks were considered overlapping if found within 1 kb of each other. Bar 
graphs show the overlap of ∆K27ac with ∆DHS (grey), sDHS (black), or no DHS (white) 
in male mice after TCPOBOP-treatment for 3 h or 27 h. B. Shown is the number of ∆DHS 
that overlap with ∆K27ac (grey), sK27ac (black), or no K27ac (white) using the same 1 kb 
distance metric as in A. C. Number of static active enhancers and dynamic active regions 
were defined in male liver following 3 h or 27 h TCPOBOP exposure. D-E Number of 
dynamic active enhancers and static active enhancers were counted in TADs that contained 
TCPOBOP-responsive genes at 3 h or 27 h. Genes that were within TADs that only 
contained static active enhancers (orange) or genes that were within TADs with both static 
active enhancers and dynamic active enhancers (brown) were identified. No TCPOBOP-
responsive genes were found within a TAD with only dynamic active enhancers. F. 
Enrichment scores were calculated to compare the mapping of dynamic active enhancers 
(Dyn. act.) to TCPOBOP-responsive genes to the mapping of static active enhancers (static 
act.) or inactive regions (static DHS without a K27ac mark) to TCPOBOP-responsive 
genes. G. Fold inductions of genes found within the same TAD as dynamic active 







Fig. 4.6 Dynamic active enhancers near Cyp2b10 and Cyp3a11. DHS and K27ac 
peaks were visualized around the Cyp2b10 and Cyp3a11 loci. Differential peaks at 27 h, 
as defined by the overlap of a diffReps region and a MACS2 peak (see Methods) are 
denoted by red bars under the K27ac tracks and the DHS tracks. Static K27ac or DHS are 
marked by blue bars. A. Six dynamic active enhancers (∆DHS and ∆K27ac, yellow arrow 
heads) are found upstream of Cyp2b10, three of which are within the gene body of 
lnc_5998. B. Two dynamic active enhancers (∆DHS and ∆K27ac, yellow arrow heads) are 
found near the Cyp3a11 TSS, while one static active enhancers (static DHS and static 
K27ac, blue arrow head) is found ~10 kb upstream. Two static DHS with flanking ∆K27ac 








Fig. 4.7 Gene induction precedes dynamic active enhancer formation. A. Shown 
is the number of genes that respond to TCPOBOP at 3 h that were within TADs that only 
contained static active enhancer (orange striped) at 27 h, and genes that were within TADs 
with both static and dynamic active enhancers (grey striped). B. Example of a gene whose 
induction by TCPOBOP precedes dynamic active enhancer formation (Gadd45b). 
Differential peaks at 3 h or 27 h, as defined by the overlap of a diffReps region and a 
MACS2 peak (see methods) are denoted by red bars under the corresponding K4me1, 
K4me3, K27ac, and DHS tracks. Static K4me1, K4me3, K27ac, and DHS are marked by 
blue bars. K27ac is stable at 3 h and several static K27ac peaks are found downstream of 
Gadd45b and within the gene body of Gng7, which is unresponsive to TCPOBOP (blue 
arrow heads). At 27 h, several dynamic active enhancer regions are seen within the same 
cluster of enhancers (green arrow head). A promoter-like region that contains a ∆DHS and 
∆K27ac is found at the Gadd45b TSS. C. Induction of Gadd45b, as measured by RNA-seq 
reported in Chapter 3. FPKM (fragments per kilobase length per million sequenced reads) 







Table 4.1  Sequencing reads obtained and peaks called. Shown are the number of 
raw sequenced reads (TOTAL_READ_COUNT) obtained for DNase-seq in male and 
female mouse liver and for ChIP-seq in male liver for K27ac, K4me1, and K4me3. 
Number of mapped reads (MAPPED_READ_COUNT), ratio of mapped to unmapped 
reads (MAPPED_READ_RATIO), MACS2 peaks called (MACS2_PEAK_COUNT, see 
Methods), number of reads in the MACS2 peaks called (READ_IN_PEAK_COUNT), 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4.2  Genes cluster in TADs. Analysis of TADs with a cluster of regulated genes 
(>2 genes) in male or female liver following 3 h or 27 h TCPOBOP exposure. Responsive 
TADs (i.e. a TAD with >2 genes) were classified by the response pattern of the 
dysregulated genes within the TAD. Up Only TADs contain at least 2 dysregulated genes 
that are up regulated but do not contain any down regulated genes. Down Only TADs 
contain at least 2 dysregulated genes that are down regulated but do not contain any up 
regulated genes. Mixed TADs contain genes that are up regulated and genes that are down 
regulated. Percentage of TADs and dysregulated genes for the Up Only, Down Only and 
Mixed designation are based on the number of TADs or genes that show a clustered 
response. Total number of TADs that showed a clustered response and the percentage of 
all responsive TADs, is shown as is the total number of genes and percentage of all 
responsive genes. See Supplemental Table S4.5 for a full listing of responsive TADs and 





TAD Group TADS (%) Genes (%) TADS (%) Genes (%) TADS (%) Genes (%) TADS (%) Genes (%)
Total 26 77 206 432 43 127 149 413
Up Only 20 (76.9) 61 (79.2) 94 (45.6) 246 (56.9) 21 (48.8) 64 (50.4) 69 (46.3) 196 (47.5)
Down Only 1 (3.8) 2 (2.6) 38 (18.4) 38 (8.8) 11 (25.6) 28 (22.0) 45 (30.2) 108 (26.2)
Mixed 5 (19.2) 14 (18.2) 74 (35.9) 148 (34.3) 11 (25.6) 35 (27.6) 35 (23.5) 109 (26.4)
Male 3 h Male 27 h Female 3 h Female 27 h
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Table 4.3 ∆DHS map to responsive genes. ∆DHS that open (Group_1 and Group_2), 
∆DHS that close (Group_3 and Group_4), and static DHS (sDHS; Group_5) found in male 
or female mouse liver following TCPOBOP exposure for 3 h or 27 h were discovered using 
a combination of MACS2 and diffReps (See Methods). ∆DHS were mapped to specific 
TADs within the mouse genome. Number of dysregulated genes and the direction of their 
regulation were examined at each TAD that contained a ∆DHS. ∆DHS that are in a TAD 
with >1 upregulated gene but no down regulated gene (Group_1A, Group_3A), ∆DHS that 
are in a TAD with >1 down regulated gene but no upregulated gene (Group_1B, 
Group_3B), and ∆DHS that were in a TAD with both up and down regulated genes 
(Group_1C, Group_3C) were counted. ∆DHS that are in a TAD with no regulated gene(s) 








Table 4.4 Highly active TADS. Five examples of highly active TADs after 






Male 3 h Male 27 h Female 3 h Female 27 h Male 3 h Male 27 h Female 3 h Female 27 h
TAD3479_chr19 7 35 14 38 11 12 9 9 Cyp2c locus
TAD1421_chr7 6 16 8 15 3 3 3 4 Cyp2b10 and 2 lncRNAs locus
TAD1156_chr5 1 9 4 10 4 4 3 9 Cyp3a locus
TAD110_chr1 1 2 3 1 1 2 1 2 Ugt1a1 locus





Table 4.5 ∆DHS that respond in multiple data sets. All TCPOBOP-responsive DHS 
is the union of all ∆DHS regions discovered in all 4 groups. Common responses in all 4 
TCPOBOP datasets are those ∆DHS that respond in all 4 groups. Responds in male only 
(or female only) are ∆DHS that respond in males (or females) at 3 h or 27 h and do not 
respond in female (or males) at any time point. Early responding, both male and female are 
∆DHS that respond at 3 h in either sex, independent of their responsiveness at 27 h. Late 





Table 4.6  Enrichment scores. All 60,739 DHS (∆DHS and static DHS) were 
mapped to a single putative gene target (closest TSS within the same TAD) and 
enrichment scores were calculated based on the number of a given set of ∆DHS (e.g. 
∆DHS that open) to a given set of regulated genes (e.g. genes up regulated) in a given 
treatment group (males at 3h) compared to the ratio of static DHS mapping to the same 
given set of regulated genes. For example, in males treated with TCPOBOP for 3 h, 70 
∆DHS that open map to TCPOBOP-induced genes and 402 ∆DHS that open map to 
uninduced genes (70/402 = 0.174) , while 393 static DHS map to TCPOBOP-induced 
genes and 55,473 static DHS map to uninduced genes (393/55,474 = 0.007) for an 
enrichment score of 24.6 (0.174/0.007 = 24.6). Enrichment of common peaks to common 
genes was calculated based on the mapping of ∆DHS that are open in all four 
experimental conditions (males and females, 3 h and 27 h) and the mapping of static DHS 
in all four experimental conditions to genes that respond in common in all four 
experimental conditions.  
 
    
Enrichment 
Score pval 
Common Peaks to Common Genes 121.3 <E-43 
Male 3 h Open Peaks to Up genes 24.6 <E-64 
Close Peaks to Down Genes 1.0 - 
Male 27 h Open Peaks to Up genes 8.3 <E-199 
Close Peaks to Down Genes 36.5 <E-27 
Female 3 h Open Peaks to Up genes 24.3 <E-92 
Close Peaks to Down Genes 5.2 <E-2 
Female 27 h Open Peaks to Up genes 10.6 <E-277 




Table 4.7  Common gene targets. 19 genes that are regulated by TCPOBOP in all 4 







Table 4.8 Results from ChIP-Seq. Total number of peaks discovered by MACS2 
and number of overlapping diffReps regions (see Methods). See Supplemental Table S4.2 






Increase in mark Decrease in mark Increase in mark Decrease in mark
K27ac 78,340 1,222 606 1,219 470
K4me1 139,460 214 110 174 192
K4me3 43,120 143 45 46 41








5.1  Chapter 2: In utero exposure to BPA does not permanently impact mouse 
testis function 
5.1.1 Chapter 2 summary 
In Chapter 2, we provide evidence of minimal long term endocrine disruption in male mice 
following an in utero exposure to BPA during a critical window of testis gonadogenesis. 
Mice were exposed to human-relevant doses of BPA during embryonic days 9 through 18 
and several measurements of markers of endocrine disruption were taken during postnatal 
development (Fig. 2.1). BPA had no impact on overall litter size or survivability of male 
mice exposure to BPA (Fig. 2.2), indicating there was no toxicological effects of the 
exposure. BPA also had minimal impact on several markers of endocrine disruption 
including body weight, anogenital distances, white adipose accumulation, testis 
histopathology, and sperm production (Fig. 2.3 – Fig. 2.5). Microarray analysis was 
performed on testis from young adult (postnatal day 28; PND29) and sexually mature adult 
mice (PND49) following in utero exposure to BPA. Few genes were identified as 
dysregulated (Fig. 2.6) and none of the genes tested were able to be confirmed by qPCR, 
driven by high variance among biological replicates (Fig. 2.8). Together, these results 
suggest effects of BPA on male mouse development are minimal, are limited to short-term 
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effects that are corrected or repaired after the exposure has ceased, or the window chosen 
does not represent the true critical window in testis development. 
 
5.1.2 Chapter 2 discussion and future directions 
5.1.2.1 Other exposure routes or chronic exposures may result in changes to testis 
function 
In my experiments, I was interested in the effects of oral exposure to endocrine disruption 
chemicals during a specific window of supposed gonadal susceptibility. This window 
corresponded to the time in which the developing bipotential gonads develops into 
embryonic testis in males or ovaries in females, and thus has been shown to be vulnerable 
to endocrine disruption (Ikeda et al. 2008, Golub et al. 2010). However, given the 
ubiquitous presence of BPA-derived plastics in the environment, human exposures to BPA 
are often chronic. Indeed, several studies of humans subjected to chronic BPA contact have 
shown exposed individuals had lower semen quality and higher instance of infertility 
(Meeker et al. 2010, Meeker et al. 2010). 
 
A further complication in studying effects of BPA using rodent models and using the 
results to hypothesize human outcomes is the exposure is often limited to a single route of 
exposure in a laboratory setting while humans are exposed to environmental chemicals 
through multiple routes, and sometimes concurrently. For example, BPA is used in thermal 
paper used for printing receipts (Bernier and Vandenberg 2017), was once used to coat the 
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interiors of cans used for food (Lorber et al. 2015), and can be found at high levels in the 
air around contaminated water ways (Kassotis et al. 2015), thus, one may be exposed to 
BPA through dermal contact, ingestion, and inhalation simultaneously or within a short 
period. While studying the impact of each of these individual exposures is critical for 
human health and safety, multifaceted combinatorial approaches may be needed to fully 
understand human risks.  
 
5.1.2.2  Limitations of microarray analysis 
While microarray technology is useful for assessing genome wide changes to gene 
expression in some cases, there are limitations to the technology. For example, one major 
limitation is the inability to differentiate between individual genes within a highly 
homologous gene family, such as the cytochrome P450 family enzymes. Cyp enzymes, 
particularly those in the Cyp11, Cyp17 and Cyp19 families, are responsible for several key 
steps in steroid hormone biosynthesis and can be targets of endocrine disruption 
(Sanderson 2006). Due to the high sequence similarity in Cyp family genes, probes 
designed for a specific member can detect the presence of many closely related transcripts. 
Therefore, if one or a select few Cyp genes are highly dysregulated while others are not, 
the microarray signal from probes designed against these genes may not detect changes in 
gene expression. Conversely, if microarray analysis identifies a dysregulated gene that is a 
part of a large gene family, the wrong gene may be identified due to poor probe annotations, 
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and thus would lead to false-positive identifications and difficulty in confirming the 
regulation by other methods, such as qPCR. 
 
We used microarray analysis to measure global gene expression changes in mouse testis 
following in utero BPA exposures and found (1) relatively few genes were regulated by in 
utero BPA exposure and (2) genes identified were unable to be confirmed by qPCR. 
Limitations discussed above may be the cause of these two issues and thus future 
experimentation using RNA-seq may be needed to better understand gene expression 
changes in this system. 
 
5.2 Chapter 3: Male-based response of tumor promotion-associated genes and 
dysregulation of novel long non-coding RNAs in constitutive androstane receptor-
activated mice 
5.2.1 Chapter 3 summary 
In Chapter 3, I presented a detailed analysis of mouse liver nuclear RNA-seq following 
short-term exposures (3 h and 27 h) to the mouse CAR direct agonist, TCPOBOP. First, 
we show a clear advantage of nuclear RNA-seq over traditional whole tissue RNA-seq as 
nuclear RNA is better able to detect gene induction and repression following a short 
activation of CAR (Fig. 3.1). This is likely due to the relatively large pool of fully mature 
and stable mRNA in the cytoplasm could dampen any emerging changes in gene expression. 
This is particularly problematic when attempting to measure repressed gene expression as 
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stable mRNA may persist in the cytoplasm even after extended periods of transcriptional 
silencing. Using nuclear RNA-seq, I discovered a strong male-bias in the activation of 
CAR-dependent hepatocellular carcinoma pathways after TCPOBOP exposure in mouse 
liver (Fig. 3.7 – Fig. 3.10). Additionally, there was a female-bias activation of the Nf-κB 
pathway, which exerts a negative cross-talk with CAR gene responses, suggesting a 
protective role of Nf-κB in HCC progression. CAR-induction and repression of novel long 
non-coding RNAs was also explored in Chapter 3. We identified as many as 530 CAR-
responsive lncRNAs in mouse liver, many of which are directly adjacent or near a regulated 
protein-coding gene. While the exact functions of these non-coding transcripts are 
unknown, given the number regulated lncRNAs and the magnitude of their regulation, it is 
reasonable to assume a subset of them may be functioning to mediate CAR-dependent gene 
expression. 
 
5.2.2  Chapter 3 discussion and future directions 
5.2.2.1 NFκB may protect females from HCC 
Female mice have been shown to be more resilient to TCPOBOP-dependent HCC tumor 
promotion despite having higher basal levels of CAR protein (Kalra et al. 2008, Hernandez 
et al. 2009, Lu et al. 2013). We present evidence in Chapter 3 that the Nf-κB/TNF pathway 
is more active in female liver than male mouse liver following TCPOBOP exposure. One 
possible hypothesis is Nf-κB activity is necessary in female, but not male, liver due to the 
higher basal level of CAR as a mechanism to prevent low-to-moderate xenobiotic 
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exposures to leading to over activation of the CAR-dependent HCC tumor promotion 
pathway in females. A potential future experiment would be to knock down key 
components in the Nf-κB pathway to see (1) if basal expression of HCC pathway genes are 
dysregulated in the absence of xenobiotic exposures or (2) if the male-bias activation of 
the CAR-dependent HCC pathway is ablated.  
 
5.2.2.2 Role of sex hormones in CAR activation 
CAR was first identified as an orphan nuclear receptor with unknown endogenous ligands 
and it was later discovered that several steroid hormones such as testosterone, androstanol, 
androstenol, progesterone, estradiol, and estrone (Forman et al. 1998, Kawamoto et al. 
2000, Handschin and Meyer 2003, Maglich et al. 2003) act as ligands. Interestingly, while 
estradiol and estrone are agonist, testosterone, androstanol, androstenol, and progesterone 
are antagonist or inverse agonists. In male mice, this results in the near continuous 
suppression of CAR through the presences of high levels of testosterone, androstanol, and 
androstenol. In females, however, this results in cyclic basal activity of CAR, due to the 
spiking of estrone, estradiol, and progesterone during different stages of the estrus cycle. 
Given these differences, it would be interesting to see if performing RNA-seq on 
gonadectomized mice also ablates the sex differences associated with CAR activation 




5.2.2.3 LncRNA function 
LncRNA biology is an emerging field that can lead to many exciting and novel discoveries 
of mechanism for gene regulation in the cell. To date, several mechanisms for how a non-
coding transcript can play a function role in regulating protein-coding genes have been 
identified and were discussed in Chapter 3. Briefly, these mechanisms include tethering of 
chromatin modifying enzymes to the site of lncRNA transcription, acting as molecular 
scaffolds to keep large protein complexes intact and guiding them to specific sequences 
through RNA-DNA interactions, and physical disruption of RNAPII via head-to-head 
collisions (Pelechano and Steinmetz 2013, Goff and Rinn 2015, Werner and Ruthenburg 
2015). Given the sheer number of regulated lncRNAs we discovered in Chapter 3, it is 
likely some of them are functioning to mediate TCPOBOP-induced DME gene expression 
or CAR-dependent HCC tumor promotion.  
 
A drawback of discovering several hundred candidates with potential function is it is 
difficult to perform in-depth experimentation on each individual candidate to test for 
functionality. However, in Chapter 3, I detailed several filters that can be applied which 
greatly reduce the number of candidate lncRNAs. One such filter is the identification of 
lncRNAs that are regulated in common across multiple data sets. By applying this filter, 
the list of regulated lncRNAs is reduced to 30 transcripts that are in common between the 
four TCPOBOP exposure conditions and only 15 of those transcripts are also found 
regulated in the PCN treated group. Given pathways and genes that were in common 
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between these groups include many DME and related genes, an initial screen perturbing 
the expression of these 15 or 30 lncRNAs and testing for the expression of the common 
DME gene targets is a reasonable approach. Other approaches to filter our lncRNAs 
include (1) proximity and orientation to the nearest regulated protein-coding genes, with a 
priority given to those lncRNAs close to inducible protein coding genes or (2) lncRNAs 
that show a strong sex-bias in activation and/or are in close proximity to protein-coding 
genes that show a strong sex-bias in activation.   
 
Knockdowns can be achieved using the anti-sense oligonucleotides and RNAi techniques. 
However, a disadvantage of these techniques is RNAi is often achieved through post-
transcriptional knockdown, which may provide enough of a window for the target lncRNA 
to perform a function thus resulting in a false negative, although some groups have been 
successful using this technique (Stojic et al. 2016).  Targeted knockdowns of lncRNA using 
a CRISPR/Cas9 system also has its own obstacles not encountered when targeting protein-
coding genes. For example, CRISPR/Cas9 is often used to introduce a frame-shift mutation 
early in the coding sequence of protein-coding gene, thus achieving an effective complete 
knockdown of the target protein. However, given that lncRNAs do not code for any 
proteins, they cannot acquire frameshift mutations, by definition. Further complicating the 
use of CRISPR/Cas9 is the fact that many of the strongly induced lncRNAs are antisense 
to induced protein-coding genes, as is the case with lnc_8460, lnc_15011, and lnc_15014, 
highlighted in Chapter 3, among others. Targeted genomic mutations of these lncRNAs 
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have the potential to also disrupt the sense transcript and thus could lead to false attribution 
of function.  
 
5.3 Chapter 4: Regulation of chromatin accessibility and histone modifications by 
activated CAR in male mouse liver 
5.3.1 Chapter 4 summary 
In chapter 4, I characterize the dynamic changes in mouse liver epigenome associated with 
CAR activation. First, I report, in male and female mice, CAR-responsive genes cluster 
into topologically associating domains (TADs). Responsive genes are found with other 
responsive genes that are regulated in the same direction. Next, we discovered several 
thousand DNase-I hypersensitivity sites that open or close (∆DHS) following TCPOBOP 
exposure, via DNase-seq, which cluster in TADs with induced or repressed genes, 
indicating they play a functional role in regulating those genes. Interestingly, we also report 
evidence of DHS opening or closing after 3 h TCPOBOP exposure preceding any 
associated gene expression as ~30% of ∆DHS 3 h that are found within a TAD without a 
gene regulated at 3 h but with at least 1 regulated gene at 27 h. Next, genome wide analysis 
in male liver of the activating chromatin marks H3K4me1 (K4me1), H3K4me3 (K4me3), 
and H3K27ac as well as the repressive chromatin mark H3K27me3 (K27me3) was 
performed via ChIP-seq. We used a combination of data from DNase-seq and ChIP-seq to 
analyze the various classes of DNA regulatory elements, including active promoter regions 
(DHS, K4me3, K27ac) and active enhancer regions (DHS, K4me1, K27ac). We identified 
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several dynamically activated enhancer regions that acquire a ∆DHS and ∆K27ac. These 
dynamically activated enhancers map to several known CAR-target genes including 
Cyp2b10, Cyp3all, and interestingly, novel lncRNA genes including lnc_5998. 
 
5.3.2 Chapter 4 discussion and future directions 
5.3.2.1 ∆DHS precedes gene expression 
We report a striking result that ∆DHS at 3 h are seen before any associated change in gene 
expression is measured within the same TAD region, but after 27 h, one or more gene 
within those TADs become dysregulated. One hypothesis for this observation is gene 
expression changes are dependent on the initial establishment of enhancer regions. A test 
of this hypothesis is to see if the same observation can be made with the ~1,000 ∆DHS at 
27 h in male and female liver that do not have any associated regulated gene within the 
same TAD region by performing RNA-seq on mouse liver exposed to TCPOBOP for 52 h 
(48 h + 3h) or 75 h (72 h + 3 h). This experiment would provide additional data related to 
Chapter 3 and can be used to see if striking sex-biases occur with long term TCPOBOP 
exposures. 
 
5.3.2.1 Better mapping through chromatin capture based assays 
In Chapter 4, we were limited to mapping genomic regions of interest to putative gene 
targets by linear distances within the same TAD region. While this is a reasonable approach 
based on the data currently available, a more accurate view of enhancer-gene regulatory 
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networks can be achieved through chromatin capture technologies such as 3C, 4C, or Hi-
C. By utilizing these more advanced techniques, we can better understand how CAR target 
genes are regulated in mouse liver and which genomic locations we identified in Chapter 
4 are functional in the cell. 
 
5.3.2.1 Additional chromatin marks may be relevant to CAR-dependent regulation of 
gene expression 
Chromatin marks analyzed in Chapter 4 were chosen based on their common presence 
around DNA regulatory elements of interest, such as enhancer and promoter regions. 
However, there are many histone modifications found in the genome and each could 
potentially be used by the cell to signal different critical regions. For example, H3K9me3 
is a mark of heterochromatin and is found in dense, transcriptionally silent regions of the 
genome. This mark may, however, be important for establishing the sex-bias activation of 
the HCC tumor promotion pathway observed in Chapter 3. Other marks that may be 
relevant to CAR activation are H3K36me2 and H3K36me3, which mark regions of the 
genome actively transcribed. These two marks may be relevant in determining if a lncRNA 
is actively targeted for transcription by the cell or if the transcription of the lncRNA is a 






Appendix 1 – List of supplemental tales related to Chapter 3. 
 
Supplemental files are available upon request by email to djw@bu.edu 
 
 
Table S3.1 - Primer sequences used for qPCR analysis. 
 
 
Table S2 – Genes showing significant differential expression at |fold change| >1.5 and 
FDR < 0.001, based on RNA-seq and EdgeR analysis of liver nuclear RNA after 3 h or 27 
h of TCPOBOP treatment in male or female mice, or after 3 h of PCN treatment in male 
mice, when compared to time-matched and sex-matched vehicle controls (1% DMSO in 
corn oil). Data shown are normalized differential expression ratios, calculated as 
treatment/vehicle, corresponding fold change (FC) values, normalized read counts (FPKM; 
fragments per kilobase of region of interest per million mapped reads) for vehicle and 
treatment, and FDR (adjusted p-values) for each of the five comparisons. Collapsed exon 
regions were considered for counting regions using FeatureCounts (Liao, 2014, 
Bioinformatics).    Also shown are the mouse genomic coordinates (genome release mm9) 
(Mapping Location(s)), NCBI accession number, official gene symbol, and Gene Ontology 
(GO) terms for each RefSeq gene.   The RefSeq Gene Notes column indicates which mouse 
TAD the gene is located in (TADs numbered sequentially from 1 to approx. 3660, based 
on their location in the mouse genome), which strand the gene is transcribed from, 
overlapping genes and isoforms, etc.    TFS number: Total Flag Sum, a numeric identifier 
used to denote in which of the 5 TCPOBOP or PCN exposure data sets the RefSeq gene 
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shows significant regulation. Each of the 5 digits to the right of the decimal place indicates 
one of the 5 data sets, with a value of 1 indicating up regulation and a value of 2 indicating 
down regulation.  Examples: TFS value that indicates up regulation in Male 3h TCPOBOP 
only = x.10000; TFS for Male 27h TCPOBOP only = x.01000; TFS for Female 3h 
TCPOBOP only = x.00100; TFS for Female 27h TCPOBOP only = x.00010; and TFs for 
PCN only = x.00001. In addition, TFS values for up regulation in Male 3h TCPOBOP and 
in Male 27 h TCPOBOP but not any of the 3 other treatments = x.11000, down regulation 
in Female 3h TCPOBOP and Male 3h PCN = x.00202, etc. 
 
Table S3 – Shown are differential expression data for the 530 liver-expressed lncRNA 
genes that show significant differential expression at |fold change|>4 and FDR < 0.05, 
based on RNA-seq and EdgeR analysis of liver nuclear RNA after 3 h or 27 h of TCPOBOP 
treatment in male or female mice, or after 3 h of PCN treatment in male mice, when 
compared to time-matched and sex-matched vehicle controls (1% DMSO in corn oil). TFS 
values (column A) are explained in Table S2. Here, the TFS values are based on thresholds 
of |fold change| > 2 and FDR <0.05. Other details are as described in Table S2.  LncRNA 
genes are numbered sequentially from 1 to 15,558 based on their genomic location. The 
LncRNA Gene ID column further indicates whether the lncRNA is intergenic (‘inter’), 
intragenic (‘intra’), or antisense (‘as’) relative to the nearest protein coding gene.   The 
LncRNA Notes column indicates which mouse TAD the gene is located in (TADs 
numbered sequentially from TAD1 to TAD3617, based on their location in the mouse 
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genome), which strand the gene is transcribed from, numbers of exons and RNA isoforms, 
the length of the longest open reading frame (ORF), and any overlapping genes. LncRNAs 
included in Fig. 6, Fig. 7 or in Supplemental Fig. S4 are shown in BOLD. For muti-exonic 
lncRNAs, column J indicates whether the lncRNA is in the same TAD as a co-expressed 
or opposite expressed RefSeq target gene (as listed in Table S6), or is not, in which case it 
is designated Distal. 
 
Table S4 - Summary of comprehensive output from KEGG Pathway analysis using 
DAVID, based on individual KEGG output data shown in Tables S4A-S4E. RefSeq genes 
dysregulated with a |fold-change| > 1.5 and an adjusted p-value (FDR) < 0.001 were used 
for analysis. Full output from DAVID was filtered based on FDR (Benjamini-Hochberg) 
< 0.05 and pathways were annotated based on broad association with cell cycle or 
metabolic pathways, as shown in the last column. Shown in red text are pathways populated 
by genes are other than drug and lipid metabolizing enzymes. 
 
Table S5 - Comprehensive output from IPA Upstream regulator analysis. Raw output was 
filtered to remove 'chemical' and 'biological drug' molecular types, as well as reduntant 
terms. Upstream regulators with a minimum of 5 downstream gene targets with an 





Table S6 - Genomic distance between TCPOBOP or PCN responsive multi-exonic 
lncRNA (|FC|>2; FDR<0.05) and the nearest responsive RefSeq gene (|FC|>1.5; 
FDR<0.001) in each data set. Responsive transcripts (lncRNA and RefSeq) were defined 
for each experiment separately and gene body-to-gene body distances were determined 
using BEDTools. Only those lncRNA-RefSeq gene pairs that are in the same TAD are 
presented. lncRNA-RefSeq gene pairs that show the opposte response to TCPOBOP or 
PCN treatment and highlighted. These may represent cases where the lncRNA exerts 




Appendix 2 – List of supplemental tales related to Chapter 4. 
 
Supplemental files are available upon request by email to djw@bu.edu 
 
 
Supplemental Table S4.1- ∆DHS and static DHS mapped to genes. Merged list of 
DHS were generated based on the the MACS2 peaks called in each sequenced replicated 
(see Methods) and assigned a unique name (Peak Number, column D). Genomic position 
of DHS is listed in columns A-C and mouse liver TAD DHS is found in is listed in 
column E. Columns F-J: TFS score for each DHS in each TCPOBOP-exposed group. 3 h 
male- 1.1= ∆DHS that opens, 1.2=∆DHS that closes; 27 h male- 2.01=∆DHS that opens, 
2.02=∆DHS that closes; 3 h female- 4.001=∆DHS that opens, 4.002=∆DHS that closes; 
27 h female- 8.0001=∆DHS that opens, 8.0002 = ∆DHS that closes. Column J is the total 
TFS score (sum of columns F-J). Nearest gene within the same TAD to each DHS is 
listed in column N with the linear genomic distance listed in column P. Columns R-AK, 
results from RNA-seq, as reported in Chapter 3, in males and females at 3 h and 27 h. 
RNA-seq results include FPKM (fragments per kilobase per million reads) in vehicle-
treated and TCPOBOP-treated animals, ratio, and adjusted pvalue (FDR). Corresponding 
TFS for the gene is listed in columns V, AA, AF, AK. 3 h male- 1.1= up regulated, 
1.2=down regulated; 27 h male- 2.01=up regulated, 2.02=down regulated; 3 h female- 





Supplemental Table S4.2- Results from ChIP-seq analysis of K27ac, K4me1, and 
K4me3. Merged lists of peaks for each individual histone mark was generated based on 
the MACS2 peaks called for each biological replicated sequenced (see Methods). Overlap 
of merged MACS2 peaks for each mark with diffReps regions discovered for each mark 
was determined using BEDtools. For each mark, merged peaks that overlapped diffReps 
regions discovered at 3 h or 27 h were annotated. 1.1=peak overlaps with diffReps region 
discovered at 3 h and is more abundant in TCPOBOP-treated samples. 1.2=peak overlaps 
with diffReps region at 27 h and is more abundant in vehicle-treated samples. 1.3=peak 
does not overlap with diffReps region but is MACS2 peak in both vehicle- and 
TCPOBOP-treated samples.  2.01=peak overlaps with diffReps region discovered at 27 h 
and is more abundant in TCPOBOP-treated samples. 2.02=peak overlaps with diffReps 
region at 27 h and is more abundant in vehicle-treated samples. 2.03=peak does not 
overlap with diffReps region but is MACS2 peak in both vehicle- and TCPOBOP-treated 
samples. A. Results from K27ac. B. Results from K4me1. C. Results from K4me3. D. 
DHS were mapped to the nearest annotated K27ac, K4me1, and K4me3 peak. Distance 
from the DHS to the given mark are found in columns H and J (K27ac at 3 h, K27ac at 27 
h), N (K4me1), and R (K4me3). 
 
Supplemental Table S4.3- Enhancer class definitions. DHS were mapped to the nearst 
K27ac peak found at 3 h or 27 h, as described in Supplemental Table S4.2. DHS were 
then classified based on the overlap of DHS and K27ac. DHS and K27ac were considered 
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overlapping if found within 1 kb of one another (see Methods). Dyamic active enhancers 
are defined as a ∆DHS that overlaps with a ∆K27ac peak while a stable active region is 
defined by a static DHS that overlaps with a static K27ac peak. Dyanamic active 
enhancers at 3 h are flagged as '1' in column U while stable active regions are flagged as 
'1' in column V. Dyanamic active enhancers at 27 h are flagged as '1' in column W while 
stable active regions are flagged as '1' in column X. 
 
Supplemental Table S4.4 - DHS with K4me3 cluster definitions. ∆DHS were 
clustered based on the K4me3 signal in a 2 kb window (+/- 1 kb) centered on the DHS 
midpoint using k-means clustering in deepTools. Two clusters were used for 3 h ∆DHS 
and three clusters were used for 27 h ∆DHS. 3 h cluster definitions (column M): cluster 
1- promoter like, cluster 2- enhancer like; 27 h cluster definitions (column N): cluster 1- 
promoter like, cluster 2- promoter like, cluster 3- enhancer-like. DHS definitions and 
further details about gene mapping found in Supplemental Table 4.1. DHS marked as 
#N/A are static DHS at the given time point and was therefore not used for K4me3 
clustering. 
 
Supplemental Table S4.5-Genes and DHS per TAD. Up and down regulated genes 
were counted for each mouse liver TAD in male or female mice treated with TCPOBOP 
for 3 h or 27 h (columns B-I). ∆DHS that open and close were counted for each mouse 
liver TAD in male or female mice treated with TCPOBOP for 3 h or 27 h (columns J-Q).  
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